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1. PUBLIC HEALTH STATEMENT 
This Statement was prepared to give you information about disulfoton and to emphasize the 
human health effects that may result from exposure to it. The Environmental Protection 
Agency (EPA) has identified 1,408 hazardous waste sites as the most serious in the nation. 
These sites make up the National Priorities List (NPL) and are the sites targeted for long-term 
federal clean-up activities. Disulfoton has been found in at least 7 of the sites on the NPL. 
However, the number of NPL sites evaluated for disulfoton is not known. As EPA evaluates 
more sites, the number of sites at which disulfoton is found may increase. This information 
is important because exposure to disulfoton may cause harmful health effects and because 
these sites are potential or actual sources of human exposure to disulfoton. 
When a substance is released from a large area, such as an industrial plant, or from a 
container, such as a drum or bottle, it enters the environment. This release does not always 
lead to exposure. You can be exposed to a substance only when you come in contact with it. 
You may be exposed by breathing, eating, or drinking substances containing the substance or 
by skin contact with it. 
If you are exposed to substances such as disulfoton, many factors will determine whether 
harmful health effects will occur and what the type and severity of those health effects will 
be. These factors include the dose (how much), the duration (how long), the route or 
pathway by which you are exposed (breathing, eating, drinking, or skin contact), the other 
chemicals to which you are exposed, and your individual characteristics such as age, gender, 
nutritional status, family traits, life-style, and state of health. 
1.1 WHAT IS DISULFOTON? 
Disulfoton is a manufactured substance used as a pesticide to control a variety of harmful 
pests that attack many field and vegetable crops. Disulfoton does not occur naturally. The 
common trade names for disulfoton are Di-syston, Disystox, Frumin AL, and Solvirex. Pure 
disulfoton is a colorless oil with no identifiable odor and taste. The technical product is dark 
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yellowish, and has an aromatic odor. It does not easily dissolve in water or evaporate to air. 
It is most likely to be present in hazardous waste sites with other wastes, either in drums or 
mixed with soil. Disulfoton is used to protect small grains, sorghum, corn, and other field 
crops; some vegetables, fruit, and nut crops; and ornamental and potted plants against certain 
insects. Although it is used primarily in agriculture, small quantities are used on home and 
garden plants. Small quantities also are used for other purposes, such as mosquito control in 
swamps. The use of disulfoton has decreased in recent years. Chapters 3 and 4 of this 
profile provide more information on the physical properties and uses of disulfoton. 
1.2 WHAT HAPPENS TO DISULFOTON WHEN IT ENTERS THE ENVIRONMENT? 
Disulfoton enters the environment principally when it is applied as a spray or as granules on 
field crops, vegetables, potted plants, and home gardens. Disulfoton also can enter the 
environment when it accidentally spills or leaks during storage and transport. Disulfoton may 
also enter the environment from hazardous waste sites. Environmental contamination by 
disulfoton mainly affects soil and water. Natural chemical reactions and bacterial attack 
remove disulfoton from soil and water. Such reactions form some by-products that are more 
toxic than disulfoton. Fish accumulate disulfoton in their bodies. The levels of disulfoton in 
fish can be hundreds of times higher than the level in water. Disulfoton binds moderately 
well to soil and typically does not travel deep into soil with rainwater. Disulfoton has been 
detected infrequently in groundwater from agricultural soil in California and Virginia. The 
estimated amount of time required for the concentration of disulfoton in river water to 
decrease to half of its initial level (half-life) is 7 days. The estimated half-life in soil ranges 
from 3.5 to 290 days, depending on the nature of the soil and climatic conditions. Chapter 5 
provides more information about what happens to disulfoton in the environment. 
1.3 HOW MIGHT I BE EXPOSED TO DISULFOTON? 
You may be exposed to disulfoton by breathing contaminated air, drinking contaminated 
water, and eating contaminated food. Disulfoton is rarely detected in air. In 1980, a low 
level of disulfoton was detected in 1 of 123 air samples collected from 10 locations in the 
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United States. The average concentration at this site was 0.1 nanogram (ng) in 1 cubic meter 
of air (1 ng = 1/1,000,000,000th [one billionth] of a gram). Disulfoton has not been detected 
in drinking water. Low levels of disulfoton (0.05-1.0 milligram in a kilogram [mg/kg] of 
food) (1 mg = l/1,000 [one thousandth] of one gram) are sometimes found in some grains, 
fruits, and vegetables treated with this pesticide. Because the levels in food are higher than 
levels in air and water, you are more likely to be exposed to disulfoton by eating 
contaminated food. The Food and Drug Administration (FDA) estimated that the average 
intake of disulfoton in food per day for a 14- to 16-year-old male in the United States from 
1986 to 1991 was 0.2 ng/kg (nanograms per kilogram) of body weight. The FDA estimate 
for disulfoton intake from foods is 0.07% or less than l/l,000th of the Food and Agriculture 
Organization/World Health Organization (FAO/WHO) acceptable daily intake (ADI) value of 
300 ng/kg. The FAO/WHO AD1 value is the maximum amount of a chemical which if 
ingested over a person’s lifetime appears to be without appreciable health risk. Workers in 
industries that manufacture and formulate disulfoton are at a higher risk of exposure. 
Workers who spray the pesticide in fields and some farm workers who enter the fields 
following spraying also are at a higher risk of exposure than the general population. Among 
the general population, people who frequently use the pesticide in their homes and gardens 
are potentially at higher risk. People who live near hazardous waste sites that contain 
disulfoton also are potentially at a higher risk of exposure. Children playing at or near these 
hazardous waste sites may be exposed by touching and eating soil that contains disulfoton. 
More information about disulfoton exposure can be found in Chapter 5 of this profile. 
1.4 HOW CAN DISULFOTON ENTER AND LEAVE MY BODY? 
Disulfoton can easily enter your body when you breathe it in, swallow it, or have skin contact 
with it. The amount of disulfoton that enters your body depends on the amount in air, food, 
and water, and the length of time you are exposed to it. In an oily mixture, disulfoton may 
enter the body through the skin, lungs, or stomach more easily than it would in a water 
mixture. After disulfoton enters your body, the blood carries it to your organs and tissues. 
Disulfoton generally does not build up in your organs and tissues, but is initially changed to 
more harmful substances, which quickly break down to harmless by-products. The harmful 
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breakdown products inhibit important enzymes (cholinesterases) in the nervous system, and 
this action can cause neurological effects. The harmless breakdown products do not have any 
known effects on the body. Studies in animals show that disulfoton and/or the breakdown 
products completely leave the body through the urine, feces, and exhaled air in about 10 days 
or less. More information on how disulfoton moves in the body can be found in Chapter 2. 
1.5 HOW CAN DISULFOTON AFFECT MY HEALTH? 
In people, disulfoton mainly causes harmful effects to the nervous system. The harmful 
breakdown products of disulfoton inhibit cholinesterase activity in the nervous system, which 
results in neurological effects. Depending on the amount of disulfoton that enters the body, 
neurological effects, such as inhibited cholinesterase activity, narrowing of the pupils, 
vomiting, diarrhea, drooling, difficulty in breathing, tremors, convulsions, and even death may 
occur. These effects can occur if you breathe in, swallow, or have skin contact with 
disulfoton. Exposure to small amounts of disulfoton can sometimes inhibit cholinesterase 
activity without causing obvious neurological effects. If you take in disulfoton from food or 
water for long periods, you may also become nearsighted. You are less likely to die from 
skin contact with disulfoton than from swallowing it, but you may become weak and tired 
after skin contact. 
Breathing in, swallowing, or having skin contact with high levels of disulfoton can cause 
similar neurological effects in animals. The neurological effects of disulfoton are the most 
common effects. Animals that swallowed disulfoton for long periods became nearsighted, and 
the structures of their eyes were further damaged. Results of animal studies suggest that 
female rats and mice are more sensitive to disulfoton than male rats and mice. 
We do not know whether disulfoton causes reproductive or birth defects, or cancer in people. 
However, some studies suggest that disulfoton may cause reproductive effects in animals. 
Some animals that swallowed disulfoton during pregnancy had newborns with underdeveloped 
bones, damaged livers and kidneys, and underdeveloped testes. Animals that swallowed 
disulfoton for long periods did not develop cancer. Chapter 2 provides more information on 
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the harmful effects of disulfoton. Disulfoton has not been classified for carcinogenic effects 
by the Department of Health and Human Services (DHHS), the International Agency for 
Research on Cancer (IARC), or the EPA. 
1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN
      EXPOSED TO DISULFOTON? 
Disulfoton and its breakdown products can be measured in the blood, urine, feces, liver, 
kidney, or body fat of exposed people. In cases of occupational or accidental exposure to 
disulfoton, the breakdown products are often measured in the urine. The breakdown products 
are relatively specific for disulfoton and a few other similar organophosphate pesticides and 
can be detected in urine for up to one week after people were last exposed. Because 
disulfoton inhibits cholinesterase in blood and in blood cells, inhibition of this enzyme 
activity may also suggest exposure to disulfoton. Cholinesterase activity in blood and in 
blood cells may remain inhibited for as long as l-2 weeks after the last exposure. Because 
other organophosphate pesticides also inhibit cholinesterase activity in blood and blood cells, 
this test is not specific for disulfoton. The measurement of cholinesterase in blood and blood 
cells and the amount of disulfoton breakdown products in the urine cannot always predict 
how much disulfoton you were exposed to. Your doctor can send samples of your blood or 
urine to special laboratories that perform these tests. Chapters 2 and 6 provide more 
information about medical tests. 
1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO
      PROTECT HUMAN HEALTH? 
The National Institute for Occupational Safety and Health (NIOSH) recommends an exposure 
limit of 0.1 mg disulfoton/ m3 of air for a 10-hour workday within a 40-hour workweek. 
EPA recommends that no more than 10 parts of disulfoton per billion parts (ppb) of water be 
present in drinking water that children drink for periods of up to 10 days. Disulfoton in 
drinking water should not exceed 3 ppb for children or 9 ppb for adults if they drink the 
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water for longer periods, and should not exceed 0.3 ppb for adults who will drink the water
 
during an average lifetime. EPA has designated disulfoton as a hazardous substance, but it
 
does not intend to cancel or restrict registration of pesticide products containing disulfoton.
 
Federal regulations limit the amount of disulfoton that factories can release into waste water.
 
EPA requires industries to report releases or spills of 1 pound or more.
 
For more information on recommendations by the federal government, please see Chapter 7.
 
1.8 WHERE CAN I GET MORE INFORMATION? 
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department or: 
Agency for Toxic Substances and Disease Registry 
Division of Toxicology 
1600 Clifton Road NE, Mailstop E-29 
Atlanta, Georgia 30333 
(404) 639-6000 
This agency can also provide you with information on the location of occupational and 
environmental health clinics. These clinics specialize in the recognition, evaluation, and 
treatment of illness resulting from exposure to hazardous substances. 
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2.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective of the toxicology of disulfoton. It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public 
health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of 
exposure-inhalation, oral, and dermal; and then by health effect-death, systemic, immunological, 
neurological, reproductive, developmental, genotoxic, and carcinogenic effects. These data are 
discussed in terms of three exposure periods-acute (14 days or less), intermediate (15-364 days), and 
chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the 
studies. LOAELs have been classified into “less serious” or “serious” effects. “Serious” effects are 
those that evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute 
respiratory distress or death). “Less serious” effects are those that are not expected to cause significant 
dysfunction or death, or those whose significance to the organism is not entirely clear. ATSDR 
acknowledges that a considerable amount of judgment may be required in establishing whether an end 
point should be classified as a NOAEL, “less serious” LOAEL, or “serious” LOAEL, and that in some 
cases, there will be insufficient data to decide whether the effect is indicative of significant 
dysfunction. However, the Agency has established guidelines and policies that are used to classify 
these end points. ATSDR believes that there is sufficient merit in this approach to warrant an attempt 
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at distinguishing between “less serious” and “serious” effects. The distinction between “less serious” 
effects and “serious” effects is considered to be important because it helps the users of the profiles to 
identify levels of exposure at which major health effects start to appear. LOAELs or NOAELs should 
also help in determining whether or not the effects vary with dose and/or duration, and place into 
perspective the possible significance of these effects to human health. 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user’s perspective. Public health officials and others concerned 
with appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which 
no adverse effects (NOAELs) have been observed. Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike. 
Estimates of exposure levels posing minimal risk to humans (Minimal Risk Levels or MRLs) have 
been made for disulfoton. An MRL is defined as an estimate of daily human exposure to a substance 
that is likely to be without an appreciable risk of adverse effects (noncarcinogenic) over a specified 
duration of exposure. MRLs are derived when reliable and sufficient data exist to identify the target 
organ(s) of effect or the most sensitive health effect(s) for a specific duration within a given route of 
exposure. MRLs are based on noncancerous health effects only and do not consider carcinogenic 
effects. MRLs can be derived for acute, intermediate, and chronic duration exposures for inhalation 
and oral routes. Appropriate methodology does not exist to develop MRLs for dermal exposure. 
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques. Furthermore, ATSDR acknowledges additional 
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs. As an 
example, acute inhalation MRLs may not be protective for health effects that are delayed in 
development or are acquired following repeated acute insults, such as hypersensitivity reactions, 
asthma, or chronic bronchitis. As these kinds of health effects data become available and methods to 
assess levels of significant human exposure improve, these MRLs will be revised. 
A User’s Guide has been provided at the end of this profile (see APPENDIX A). This guide should aid 
in the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
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2.2.1 Inhalation Exposure 
2.2.1.1 Death 
No studies were located regarding the lethal effects in humans after inhalation exposure to disulfoton. 
In an acute inhalation study, l-hour exposure of male Sprague-Dawley rats to 202.2 mg/ m3 disulfoton 
resulted in 60% mortality, while no deaths occurred in male rats exposed to ≤195.1 mg/ m3 (Doull 
1957). In Holtzman rats, a l-hour exposure resulted in death of 3 of 6 males at 180.1 mg/ m3 and 2 of 
6 females at 87.6 mg/ m3 (DuBois 1971). No deaths occurred in males at 101.3 mg/ m3 or in females 
at 75.1 mg/ m3. LC50 values reported for Wistar rats were 290 mg/ m3 in males and 63 mg/ m3 for 
females exposed for 1 hour and 60 mg/ m3 for males and 15 mg/ m3 for females exposed for 4 hours 
(Thyssen 1978). When the rats were exposed to disulfoton 4 hours/day for 5 days, a concentration of 
9.8 mg/ m3 resulted in death of 9 of 10 females within l-8 days after exposure. No males died, and 
no deaths occurred in either sex at ≤l.8 mg/ m3. In a 3-week study, 5 of 10 females exposed 
intermittently to 3.7 mg/ m3 died after 3-12 exposures, while 3 of 20 females exposed intermittently to 
3.1 mg/ m3 intermittently died after 8-15 exposures (Thyssen 1980). No deaths occurred in the male 
rats in the 3-week study. Based on these data, strain differences in the lethal concentrations of 
disulfoton appear to exist in rats, and female rats are definitely more susceptible to the lethality of 
disulfoton than male rats. A l-hour exposure of female mice to 53.4 mg/ m3 (lowest exposure 
concentration) resulted in 10% mortality, and 58.2 mg/ m3 resulted in 70% mortality (Doull 1957). 
Male mice were not studied; therefore, data are insufficient to make comparisons of the inhalation 
lethality of disulfoton between male and female mice, and between rats and mice. The lethality of 
disulfoton appears to be related to the cholinergic effects, since such effects as tremors or convulsions 
were usually noted in the animals that died (see Section 2.2.1.5). The LC50 values in rats and the 
LOAEL values resulting in mortality in rats and mice are recorded in Table 2-l and plotted in 
Figure 2- 1. 
2.2.1.2 Systemic Effects 
No studies were located regarding respiratory, cardiovascular, gastrointestinal, hematological, 
musculoskeletal, hepatic, renal, endocrine, dermal, ocular, or body weight effects in humans after 
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Studies on these end points in animals exposed by inhalation to disulfoton are discussed below. The 
highest NOAEL values and all LOAEL values from each reliable study for these end points in animals 
in each duration category are recorded in Table 2-l and plotted in Figure 2-l. 
Respiratory Effects. In two separate experiments in which male and female rats were exposed 
intermittently for 3 weeks to 0.1, 0.5, or 3.7 mg/ m3 in the first experiment, and to 0.02 mg/ m3 (males 
and females) or 3.1 mg/ m3 (females only) in the second experiment, inflammatory changes were found 
throughout the respiratory tract at 0.5, 3.1, and 3.7 mg/ m3 (Thyssen 1980). These inflammatory 
changes were considered to be related to reactive bone marrow changes (see Section 2.2.1.3), which 
were minimal in male rats and definite in females in the first experiment. Deaths occurred in the 
female rats exposed to 3.1 or 3.7 mg/ m3, and mottled, distended, and discolored lungs were found 
upon necropsy of the rats that died. Increased incidences of inflammation of the nasal turbinates were 
found in male rats, but not female rats, exposed to 1.4 mg/ m3 intermittently for 13 weeks (Shiotsuka 
1989). These lesions were not found at 0.16 mg/ m3. 
Cardiovascular Effects. No treatment-related microscopic lesions were found in the hearts of rats 
exposed intermittently to 3.7 mg/ m3 for 3 weeks (Thyssen 1980) or to 1.4 mg/ m3 for 13 weeks 
(Shiotsuka 1989). 
Gastrointestinal Effects. In the female rats that died during intermittent exposure to 3.7 mg/ m3 
for 3 weeks, bloated gastrointestinal tracts and ulcer-like foci in the glandular mucosa were found 
upon necropsy (Thyssen 1980). Otherwise, no treatment-related histological effects in the 
gastrointestinal tract of the surviving females or in males exposed to ≤3.7 mg/ m3 were found. 
Likewise, no gastrointestinal tract lesions were found in male or female rats exposed intermittently to 
≤1.4 mg/ m3 for 13 weeks (Shiotsuka 1989). 
Hematological Effects. No effects on formed elements of the blood were found upon 
hematological examination in rats exposed intermittently to ≤3.7 mg/ m3 for 3 weeks (Thyssen 1980). 
However, in a second experiment in which female rats were similarly exposed to 3.1 mg/ m3, a 
relatively low percentage of lymphocytes and high percentages of polymorphonuclear leukocytes in the 
differential leukocyte counts were found. These effects were regarded as a first sign of a response to 
the inflammation in the respiratory tract and bone marrow changes observed in these rats (see 
19 DISULFOTON 
2. HEALTH EFFECTS 
Section 2.2.1.3). No hematological effects were observed in rats exposed intermittently to 
0.02-0.5 mg/ m3 for 3 weeks (Thyssen 1980) or to 1.4 mg/ m3 for 13 weeks (Shiotsuka 1989). 
Musculoskeletal Effects. No gross or histological lesions were found in bones or skeletal muscle 
of rats exposed intermittently to ≤1.4 mg/ m3 for 13 weeks (Shiotsuka 1989). 
Hepatic Effects. Clinical chemistry tests and histological examination of livers revealed no hepatic 
effects in rats exposed intermittently to ≤3.7 mg/ m3 for 3 weeks (Thyssen 1980) or to ≤1.4 mg/ m3 for 
13 weeks (Shiotsuka 1989). 
Renal Effects. Clinical chemistry, urinalysis, and histological examination of kidneys revealed no 
renal effects in rats exposed intermittently to ≤3.7 mg/ m3 for 3 weeks (Thyssen 1980) or to 
≤1.4 mg/ m3 for 13 weeks (Shiotsuka 1989). 
Endocrine Effects. No histological lesions were found in the thyroid or adrenal glands of rats 
exposed interrnittently to ≤3.7 mg/ m3 for 3 weeks, but females exposed to 3.1 and 3.7 mg/ m3 in two 
separate experiments had significantly increased absolute and relative adrenal weights (Thyssen 1980). 
Since the increase in adrenal weights was consistently observed in both experiments, it was considered 
to be related to disulfoton exposure. No histological effects or effects on the weight of the adrenal 
gland and no histological effects on the thyroids, parathyroids, pituitary, or pancreas were observed in 
rats exposed intermittently to ≤1.4 mg/ m3 for 13 weeks (Shiotsuka 1989). 
Dermal Effects. No gross or histological lesions were found in the skin of rats exposed 
intermittently to 1.4 mg/ m3 for 13 weeks (Shiotsuka 1989). 
Ocular Effects. No histological or ophthalmological evidence of ocular effects were found in rats 
exposed intermittently to ≤3.7 mg/ m3 for 3 weeks (Thyssen 1980) or to ≤1.4 mg/ m3 for 13 weeks 
(Shiotsuka 1989). 
Body Weight Effects. Female rats exposed intermittently to 3.7 mg/ m3, but not 3.1 mg/ m3, for 
3 weeks had 12% and 11% lower body weights than controls during weeks 1 and 2, respectively, but 
only 5% lower body weight during week 3 (Thyssen 1980). Males similarly exposed to 3.7 mg/ m3 
had lower body weights than controls, but the difference was never >10%. No effects on body weight 
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were found in the rats exposed intermittently to 0.5 mg/ m3 (Thyssen 1980) or 0.7 mg/ m3 (Shiotsuka 
1988) for 3 weeks, or 1.4 mg/ m3 for 13 weeks (Shiotsuka 1989). 
2.2.1.3 Immunological and Lymphoreticular Effects 
No studies were located regarding immunological and lymphoreticular effects in humans after 
inhalation exposure to disulfoton. 
In two separate experiments in which male and female Wistar rats were exposed intermittently for 
3 weeks to 0.1, 0.5, or 3.7 mg/ m3 in the first experiment, and to 0.02 mg/ m3 (males and females) or 
3.1 mg/ m3 (females only) in the second experiment, inflammatory changes were found throughout the 
respiratory tract at 0.5, 3.1, and 3.7 mg/ m3 (Thyssen 1980). These inflammatory changes were 
considered to be related to reactive bone marrow changes. The reactive bone marrow changes were 
not specifically described in the study, but were regarded as minimal in male rats and definite in 
female rats in the first experiment. In the second experiment, but not in the first, female rats exposed 
to 3.1 mg/ m3 had a relatively low percentage of lymphocytes and high percentages of 
polymorphonuclear leukocytes in the differential leukocyte counts. These effects were regarded as a 
first sign of a response to the inflammation in the respiratory tract and bone marrow changes observed 
in these rats. The female rats exposed to 3.1 mg/ m3 also had decreased absolute and relative spleen 
weight, but histological examination of the spleen and bronchial lymph nodes revealed no treatmentrelated 
effects in males or females exposed to ≤3.7 mg/ m3. In addition, histological examination of 
bone marrow, cervical lymph nodes, mesenteric lymph nodes, spleen, and thymus of Fischer 344 rats 
exposed intermittently to ≤1.4 mg/ m3 for 13 weeks revealed no effects (Shiotsuka 1989). The highest 
NOAEL values and the LOAEL values for immunological and lymphoreticular effects in rats are 
recorded in Table 2-l and plotted in Figure 2-l. 
2.2.1.4 Neurological Effects 
Exposure to disulfoton can result in inhibition of cholinesterase activity in blood and at nerve synapses 
of muscles, secretory organs, and nervous tissue such as the brain and spinal cord (Murphy 1986). 
The accumulation of acetylcholine at these sites (specifically, the nerve synapses and ganglia in these 
organs) results in central nervous system, nicotinic, and muscarinic effects. Clinical signs and 
symptoms of neurotoxicity are usually observed in humans and animals that have been acutely 
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exposed to disulfoton or other organophosphate insecticides. Central nervous system signs and 
symptoms include anxiety, restlessness, depression of respiratory and circulatory centers, ataxia, 
convulsions, and coma. Nicotinic signs of disulfoton toxicity include muscle weakness, muscle 
tremors and fasciculations, and involuntary twitching. Muscle weakness that affects the respiratory 
muscles may contribute to dyspnea and cyanosis. Tachycardia may result from stimulation of 
sympathetic ganglia in cardiac tissue and may, therefore, mask the bradycardia due to the muscarinic 
action on the heart. Nicotinic action at the sympathetic ganglion may also result in pallor, high blood 
pressure, and hyperglycemia. Muscarinic signs of disulfoton toxicity include miosis, increased 
salivation, sweating, urination and defecation, vomiting and nausea, bronchoconstriction, increased 
bronchial secretions, and bradycardia that can progress to heart block. 
Inhibition of the two principal human cholinesterases, acetylcholinesterase and pseudocholinesterase, 
may not always result in visible neurological effects (Sundlof et al. 1984). Acetylcholinesterase, also 
referred to as true cholinesterase, red blood cell cholinesterase, or erythrocyte cholinesterase is found 
in erythrocytes, lymphocytes, and at nerve synapses (Goldfrank et al. 1990). Inhibition of erythrocyte 
or lymphocyte acetylcholinesterase is theoretically a reflection of the degree of synaptic cholinesterase 
inhibition in nervous tissue, and therefore a more accurate indicator than pseudocholinesterase activity 
of inhibited nervous tissue acetylcholinesterase (Fitzgerald and Costa 1993; Sundlof et al. 1984). 
Pseudocholinesterase (also referred to as cholinesterase, butyrylcholinesterase, serum cholinesterase, or 
plasma cholinesterase) is found in the plasma, serum, pancreas, brain, and liver and is an indicator of 
exposure to a cholinesterase inhibitor. 
Pseudocholinesterase and lymphocyte acetylcholinesterase activities are depressed before erythrocyte 
cholinesterase, suggesting that these cholinesterases are more sensitive than acetylcholinesterase 
(Fitzgerald and Costa 1993; Iyaniwura 1991; Sundlof et al. 1984). However, erythrocyte 
cholinesterase recovers more slowly (90-120 days) than pseudocholinesterase or lymphocyte 
acetylcholinesterase (days to weeks), and is therefore a better indicator after exposure ceases. 
Depression in pseudocholinesterase activity only indicates possible exposure to organophosphate(s), 
whereas depression in erythrocyte and lymphocyte cholinesterases also indicates a neurological effect, 
since they reflect inhibition of brain acetylcholinesterase activity. Recently, it was shown that the 
inhibition of lymphocyte acetylcholinesterase activity more closely paralleled the inhibition of brain 
acetylcholinesterase than did erythrocyte acetylcholinesterase activity (Fitzgerald and Costa 1993). In 
this profile, inhibition in lymphocyte or erythrocyte acetylcholinesterase activity and not 
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pseudocholinesterase activity is considered as an adverse neurological effect. Based on an evaluation 
by Kaloyanova and El Batawi (1991), ATSDR considers a 60% or greater acetylcholinesterase 
inhibition as a serious effect and less than 60%, but greater than 20%, acetylcholinesterase inhibition 
as a less serious effect. 
Nervous system effects may occur in humans after occupational exposure to disulfoton (Wolfe et al. 
1978). In this study, mean disulfoton concentrations of 0.460-0.633 mg/ m3 caused a 22.8% 
depression in erythrocyte cholinesterase activity in workers at a pesticide-fertilizer mixing operation. 
The workers were exposed to disulfoton for 9 weeks, and there were no reports of adverse clinical 
signs due to disulfoton exposure. The study was limited in that baseline blood cholinesterase activities 
were obtained 2 weeks after the initial exposure and were compared with cholinesterase activities at 
9 weeks. Therefore, the actual depression in cholinesterase activity over a 9-week period was 
probably >22.8%. In addition, these workers were also dermally exposed to disulfoton (see 
Section 2.2.3.4); therefore, the 22.8% depression in cholinesterase activity was probably due to both 
inhalation and dermal exposure. Despite these limitations, the study concluded that because this 
depression in cholinesterase activity was only associated with dry mixing operations, the wet mixing 
operations are less hazardous to workers. 
Neurological effects, such as muscle twitching, ataxia, and increased salivation, urination, defecation, 
and lacrimation were observed in male Sprague-Dawley rats exposed to ≥65.1 mg/ m3 and in female 
Carworth Farms mice exposed to ≥53.4 mg/ m3 for 1 hour (Doull 1957). Female rats and male mice 
were not included in this study. However, the greater susceptibility of female rats to the cholinergic 
effects of disulfoton was demonstrated in several experiments in an acute inhalation study using Wistar 
rats (Thyssen 1978). In the LC50 determinations in this study, sluggishness, failure to groom, and 
typical signs of cholinesterase inhibition (not otherwise described) were observed in male rats exposed 
to ≥133 mg/ m3 and in females exposed to ≥27 mg/ m3 for 1 hour. These signs of toxicity were 
observed at lower exposure levels when rats were exposed for 4 hours (in males exposed to 
≥64 mg/ m3 and in females exposed to ≥3.4 mg/ m3). These effects were transient, lasting for about 
24 hours after exposure. In an experiment designed to examine cholinesterase activity in rats exposed 
to 0.5, 1.8, or 9.8 mg/ m3 for 4 hours/day for 5 days, erythrocyte cholinesterase activity was depressed 
by 30-32% of controls in males exposed to 9.8 mg/ m3 and by 17-26% in females at both 1.8 and 
9.8 mg/ m3. In addition, all rats were reported to display unspecified behavioral disorders at 
≥1.8 mg/ m3 and unspecified signs of cholinergic toxicity at 9.8 mg/ m3. No inhibition of erythrocyte 
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cholinesterase activity and no signs of cholinergic toxicity were observed at 0.5 mg/ m3. Based on this 
NOAEL of 0.5 mg/ m3, an acute-duration inhalation MRL of 0.006 mg/ m3 was calculated as described 
in footnote “b” in Table 2-l. No significant decrease in the activity of brain, serum, or submaxillary 
gland cholinesterase was found in female rats exposed to 0.14-0.7 mg/ m3 disulfoton for 1 hour/day for 
5-10 days (DuBois and Kinoshita 1971). No clinical signs of disulfoton toxicity or other details were 
reported. 
Signs of cholinergic toxicity and depressions in cholinesterase activities were also observed in rats 
exposed to disulfoton for intermediate durations. In Wistar rats exposed intermittently to 0.1, 0.5, or 
3.7 mg/ m3 for 3 weeks, exposure to 0.1 mg/ m3 resulted in brief periods of lethargy after exposure 
ended during the last week; exposure to 0.5 mg/ m3 resulted in lethargy and failure to groom in males 
during the last week and in females during the second and last week; and exposure to 3.7 mg/ m3 
resulted in muscle tremors, convulsion, increased salivation, and dyspnea in males starting at the end 
of the first week and in females during the first week (Thyssen 1980). Erythrocyte cholinesterase 
activity was inhibited in males by 24-28% and in females by 27-32% at 3.7 mg/ m3. Brain 
cholinesterase activity was inhibited in males by 48% at 3.7 mg/ m3 and in females by 30% at 
0.5 mg/ m3 and 58% at 3.7 mg/ m3. In a second 3-week experiment to determine a no-effect level for 
cholinesterase inhibition in Wistar male and female rats, no clinical signs of neurological effects and 
no effects on plasma, erythrocyte, or brain cholinesterase were observed at 0.02 mg/ m3 (Thyssen 
1980). Female rats exposed to 3.1 mg/ m3 had muscle tremors, convulsion, increased salivation, and 
dyspnea, confirming the results in the first experiment. Male rats were not exposed to 3.1 mg/ m3 in 
the second experiment. Based on the NOAEL of 0.02 mg/ m3, an intermediate-duration inhalation 
MRL of 2x10-4 mg/ m3 was calculated as described in footnote “c” in Table 2-l. In Fischer rats 
exposed intermittently to 1.4 mg/ m3 for 13 weeks, erythrocyte cholinesterase activity was inhibited by 
22-28% in males and 26-34% in females, and brain cholinesterase activity was inhibited by 29% in 
males and 28% in females (Shiotsuka 1989). Cholinesterase activities were not affected at 
≤0.16 mg/ m3, and no effects on brain weight or histological evidence of lesions in the brain, optic 
nerve, sciatic nerve, or spinal cord were found at any exposure level. In a similar study in Fischer 344 
rats exposed to lower concentrations for 3 weeks, no significant differences in brain cholinesterase 
activities were found at 0.006-0.7 mg/ m3 (Shiotsuka 1988). Erythrocyte cholinesterase activity was 
statistically consistently decreased at 0.7 mg/ m3, but the decreases were never greater than 17% of 
control levels. The highest NOAEL values and all reliable LOAEL values for neurological effects in 
rats and mice for each duration category are recorded in Table 2- 1 and plotted in Figure 2- 1. 
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2.2.1.5 Reproductive Effects 
No studies were located regarding reproductive effects in humans after inhalation exposure to 
disulfoton. 
In rats exposed intermittently to 0.02-3.7 mg/ m3 for 3 weeks, measurements of the testes and ovary 
weights and histological examination of the testes and ovaries revealed no compound-related effects 
(Thyssen 1980). Similarly, no effects on testis or ovary weight and no compound-related histological 
lesions in epididymides, prostate, seminal vesicles, testicles, cervix, mammary glands, ovaries, or 
uterus were found in rats exposed intermittently to ≤1.4 mg/ m3 for 13 weeks (Shiotsuka 1989). 
Reproductive studies in animals given disulfoton by the oral route have demonstrated that disulfoton 
produces effects on reproductive parameters (see Section 2.2.2.5); therefore, the above inhalation 
concentration levels cannot be considered NOAEL values for reproductive effects because these 
inhalation studies did not examine reproductive performance or outcomes. 
2.2.1.6 Developmental Effects 
No studies were located regarding developmental effects in humans or animals after inhalation 
exposure to disulfoton. 
2.2.1.7 Genotoxic Effects 
No studies were located regarding genotoxic effects in humans or animals after inhalation exposure to 
disulfoton. 
Genotoxicity studies are discussed in Section 2.4. 
2.2.1.8 Cancer 
No studies were located regarding cancer in humans after inhalation exposure to disulfoton. 
In a 13-week study in rats exposed intermittently to ≤1.4 mg/ m3, the author reported that 
comprehensive histological examination of organs and tissues revealed no treatment-related neoplastic 
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lesions (Shiotsuka 1989). However, chronic-duration inhalation studies, which would be more 
appropriate to assess possible carcinogenicity, were not located for disulfoton. 
2.2.2 Oral Exposure 
2.2.2.1 Death 
Only one study was located involving death in humans after ingestion of disulfoton (Hattori et al. 
1982). In this case report, a 30-year-old man was found dead after consuming an unknown amount of 
disulfoton. He was believed to have been dead for at least 24 hours. Autopsy and histopathological 
examination revealed miosis, bubbling saliva from the mouth, pulmonary edema and hemorrhage, 
swelling of the glomemlus, and congestion of most organs, which suggested that the man had ingested 
an organophosphate. Analysis of urine and blood samples confirmed that disulfoton was the toxicant 
responsible for the death. 
The dose of disulfoton associated with death following acute oral exposure in animals depends on the 
sex, species, and the duration of the exposure. As seen from Table 2-2 and Figure 2-2, female rats 
and mice were generally more sensitive than male rats and mice, and rats generally appeared to be 
more sensitive than mice, to disulfoton given orally. LD50 values ranged from 1.9 to 3.2 mg/kg in 
female rats, 6.2-12.5 mg/kg in male rats (Bombinski and DuBois 1958; Crawford and Anderson 1974; 
Gaines 1969; Mihail 1978; Pawar and Fawade 1978), 2.7-8.2 mg/kg in female mice, and 
5.8-19.3 mg/kg in male mice (Mihail 1978; Pawar and Fawade 1978; Stevens et al. 1972a). In one 
LD50 determination in rats, deaths occurred within 6 minutes to 2 days in males and 4 minutes to 
3 days in females (Gaines 1969). Oral LD50 values of 10 mg/kg in rats of unspecified sex (Schafer 
1972), of 8.9-10.8 mg/kg in male guinea pigs (Bombinski and DuBois 1958; Crawford and Anderson 
1973), and of 12.7 mg/kg in female guinea pigs (Crawford and Anderson 1973) have also been 
reported. A dose of 18 mg/kg was determined to be the minimum dose at which mortality occurred in 
wild deer mice of unspecified sex given disulfoton by gavage (Schafer and Bowles 1985). 
Deaths occurred on the day of treatment in 4 of 6 female rats at a dose of 2.5 mg/kg and in 1 of 
9 female rats at a dose of 1.5 mg/kg, but no deaths occurred in male rats given ≤5.2 mg/kg (Sheets 
1993a). However, in another study using the same strain of rats (Sprague-Dawley), 1 of 5 male rats 
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same dose for 3 consecutive days (Schwab et al. 1981). In the same study, 1 of 8 rats died after 
receiving either 2.5 or 3.5 mgfkgfday for 6 days. When groups of mice were given 50% of the 
derived LD50 (9.6 mg/kg) for 3, 5, and 10 days, mortality was 2 of 8, 2 of 8, and 9 of 20, respectively 
(Stevens et al. 1972b). The results suggest that even at half the acute LD50 dose, almost half of the 
mice given disulfoton for 10 days died. 
In intermediate-duration studies, 1 of 12 female rats given 1.3 1 mg/kg/day disulfoton in the diet was 
found dead on day 48 due to cholinergic effects (tremor, muscle fasciculation) (Sheets 1993b). In 
addition, 4 of 71 male rats died when given a diet providing 2.5 mg/kg/day for 30 days (Robinson et 
al. 1978), and 5 of 25 female mice died when given a diet providing 26 mg/kg/day disulfoton for 
4 weeks (Clark et al. 1971). The reason that mice could tolerate a higher dose in the diet for 4 weeks 
compared with single dose LD50 values is probably related to the method of administration (i.e., 
continuous intermittent exposure during feeding versus a single bolus dose by gavage). 
In a 2-year dietary study, female rats in the high dose group (1.02 mg/kg/day) had a 40% mortality 
rate during the last week of the study compared with 12% in controls (Hayes 1985). While the 
mortality rate in the control group was unusually low, the 40% mortality rate in the high dose female 
rats was also increased when compared with historical controls, in which the mortality rate ranged 
from 18 to 34%. No increase in the mortality rate of male rats was observed. Furthermore, no 
increase in the mortality was reported for mice exposed to 2.13 mg/kg/day (males) or 2.53 mg/kg/day 
(females) disulfoton in the diet for 23 months (Hayes 1983). These results support the conclusion that 
rats are more sensitive than mice and that female rats are more sensitive than male rats to the lethal 
effects of disulfoton. 
The causes of death in these studies were not specifically mentioned, but disulfoton is a cholinesterase 
inhibitor, and animals exposed to disulfoton typically exhibit cholinergic signs of toxicity (see 
Section 2.2.2.4). 
The LD50 values and the doses associated with death in each species and duration category are 
recorded in Table 2-2 and plotted in Figure 2-2. 
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2.2.2.2 Systemic Effects 
Studies regarding the systemic effects that have been observed in humans and animals after oral 
exposure to disulfoton are discussed below. The highest NOAEL values and all LOAEL values from 
each reliable study for each systemic effect in each species and duration category are recorded in 
Table 2-2 and plotted in Figure 2-2. 
Respiratory Effects. Intra-alveolar bleeding, edema of the lungs, and blood in the bronchus were 
observed at autopsy in a man who had been dead for at least 24 hours after ingesting an unknown 
quantity of disulfoton (Hattori et al. 1982). This was the only information found regarding respiratory 
effects in humans after oral exposure to disulfoton. 
Breathing difficulties were observed in rats given a single gavage dose of 1.0 mg/kg and in mice given 
5.0 mg/kg disulfoton (Mihail 1978). Rats given 0.5 mg/kg and mice given 2.5 mg/kg did not display 
breathing disorders. 
No histopathological lesions were found in the lungs of rats exposed to 0.34 mg/kg/day (males) or 
0.55 mg/kg/day (females) (Klotzsche 1972) or mice exposed to 0.63 mg/kg/day (males) or 
0.71 mg/kg/day (females) (Rivett et al. 1972) in the diet for 90 days, or in rats exposed to 
≤0.21 mg/kg/day (Carpy et al. 1975; Hayes 1985), in mice exposed to 2.13 mg/kg/day (males) or 
2.53 mg/kg/day (females) (Hayes 1983), or in dogs exposed to 0.14 mg/kg/day (Hoffman et al. 1975) 
in the diet for up to 2 years. In rats exposed to disulfoton in the diet for 2 years, granulomatous and 
suppurative inflammation of the lungs was found in the high dose groups (0.75 mg/kg/day in males 
and 1.02 mg/kg/day in females) (Hayes 1985). The lung inflammation was considered to be due to 
aspiration of the food particles, which in turn may have been associated with the debilitation observed 
in the high dose groups. 
Cardiovascular Effects. No studies were located regarding cardiovascular effects in humans after 
oral exposure to disulfoton. 
No histopathological lesions were found in the hearts of rats exposed to ≤0.55 mg/kg/day (Klotzsche 
1972) or mice exposed to ≤0.71 mg/kg/day (Rivett et al. 1972) in the diet for 90 days, or in rats 
exposed to 0.1 mg/kg/day (Carpy et al. 1975) or ≤1.02 mg/kg/day (Hayes 1985), in mice exposed to 
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≤2.53 mg/kg/day (Hayes 1983), or in dogs exposed to 0.14 mg/kg/day (Hoffman et al. 1975) in the 
diet for up to 2 years. 
Gastrointestinal Effects. No studies were located regarding gastrointestinal effects in humans 
after oral exposure to disulfoton. 
No histopathological lesions were found in the gastrointestinal tracts of rats exposed to 0.34 mg/kg/day 
(males) or 0.55 mg/kg/day (females) (Klotzsche 1972) or mice exposed to 0.63 mg/kg/day (males) or 
0.71 mg/kg/day (females) (Rivett et al. 1972) in the diet for 90 days, or in rats exposed to 
0.1 mg/kg/day (Carpy et al. 1975), in mice exposed to 2.13 mg/kg/day (males) or 2.53 mg/kg/day 
(females) (Hayes 1983), or in dogs exposed to 0.14 mg/kg/day (Hoffman et al. 1975) in the diet for up 
to 2 years. However, increased incidences of mucosal hyperplasia and chronic inflammation of the 
forestomach were observed in female rats given 1.02 mg/kg/day disulfoton in the diet for 2 years 
(Hayes 1985). The mucosal hyperplasia was usually diffuse but was sometimes more locally severe 
and accompanied by inflammation, fibrosis, and ulceration. The forestomach lesions were not 
observed in male rats at ≤0.75 mg/kg/day or in females at ≤0.21 mg/kg/day. 
Hematological Effects. No studies were located regarding hematological effects in humans after 
oral exposure to disulfoton. 
Limited information from animal studies suggests that intermediate- or chronic-duration exposure to 
disulfoton is not associated with hematological effects. No hematological effects were observed in rats 
fed ≤0.55 mg/kg/day of disulfoton (Klotzsche 1972) or in mice fed ≤0.71 mg/kg/day (Rivett et al. 
1972) for 90 days. In 2-year feeding studies, disulfoton did not cause any hematological effects in rats 
(Carpy et al. 1975; Hayes 1985), mice (Hayes 1983), or dogs (Hoffman et al. 1975). 
Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans 
after oral exposure to disulfoton. 
Degeneration of ciliary muscle cells was found in the eyes of dogs given disulfoton at doses 
≥0.63 mg/kg/day for 2 years (Ishikawa and Miyata 1980; Suzuki and Ishikawa 1974). The 
degenerative changes consisted of the presence of unique membranous structures, displacement of 
myofilaments, and lack of clearly defined organelles. The authors suggested that the microsomal 
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oxidation of disulfoton to an active metabolite that can destroy microsomes may account for the 
destructive changes in the ciliary muscle cells (Suzuki and Ishikawa 1974) or that cholinergic 
innervation of the iris-sphincter and ciliary muscle by disulfoton resulted in edema of the ciliary 
muscles (Ishikawa and Miyata 1980). The degeneration of these cells was believed to be the cause of 
myopia (see Ocular Effects below) in these dogs. 
Histological examination of the gastrocnemius muscle of rats given a single gavage dose of 
≤5.2 mg/kg (Sheets 1993a) or ≤1.31 mg/kg/day disulfoton in the diet for 13 weeks (Sheets 1993b) 
revealed no treatment-related lesions. No histopathological muscular or skeletal lesions were found in 
rats exposed to 0.34 mg/kg/day (males) or 0.55 mg/kg/day (females) (Klotzsche 1972) or mice 
exposed to 0.63 mg/kg/day (males) or 0.71 mg/kg/day (females) (Rivett et al. 1972) in the diet for 
90 days, or in rats exposed to ≤0.21 mg/kg/day (Carpy et al. 1975; Hayes 1985), in mice exposed to 
2.13 mg/kg/day (males) or 2.53 mg/kg/day (females) (Hayes 1983), or in dogs exposed to 
0.14 mg/kg/day (Hoffman et al. 1975) in the diet for up to 2 years. However, reduced skeletal muscle 
size and skeletal muscle atrophy were observed in female rats given 1.02 mg/kg/day disulfoton in the 
diet for 2 years (Hayes 1985). The skeletal muscle atrophy corresponded to the generalized 
debilitation in the high dose females. 
Hepatic Effects. No studies were located regarding hepatic effects in humans after oral exposure 
to disulfoton. 
In animals, the hepatic effects associated with oral exposure to disulfoton included alterations in liver 
microsomal enzyme activities, lipid peroxidation, and changes in liver weight. The ability of 
disulfoton to affect microsomal enzyme activities appears to depend upon the dose, the duration of 
dosing, and the time between dosing and enzyme assays. Microsomal enzyme induction is considered 
to be nonadverse unless the induction of enzymes can be linked to more serious liver effects. A single 
oral dose (9.6 mg/kg) of disulfoton caused a significant (p<0.05) decrease in in vitro mouse liver 
ethylmorphine N-demethylase and reduced nicotinamide adenine dinucleotide phosphate (NADPH) 
cytochrome c reductase activities, but no significant effect on NADPH oxidase, when assayed 1 hour 
after dosing (Stevens et al. 1973). However, a significant increase in liver ethylmorphine 
N-demethylase and NADPH oxidase activities, but no significant effect on NADPH cytochrome 
c reductase activity or cytochrome P-450 content, was observed in mice given 9.6 mg/kg/day 
disulfoton for 3 days and sacrificed 24 hours later for in vitro enzyme assays. When mice were 
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treated with 8 mg/kg/day for 5 days, the content of cytochrome P-450 was also significantly increased. 
Treatment of mice with 9.6 mg/kg/day disulfoton for 3, 5, or 10 days resulted in significant shortening 
of the hexobarbital sleeping time, compared with controls, and stimulated the in vitro side chain 
oxidation of hexobarbital and the hydroxylation of aniline (Stevens et al. 1972b). Significant increases 
in microsomal protein content and delta-aminolevulinic acid synthetase activity, and significant 
decreases in ethylmorphine N-demethylase, aminopyrine N-demethylase, and acetanilide hydroxylase 
activities were found in the livers from rats given 2 mg/kg or mice given 0.5 or 1.0 mg/kg/day 
disulfoton for l-4 days (Fawade and Pawar 1978, 1980, 1983). Disulfoton also caused an increase in 
NADPH-dependent and ascorbate-promoted lipid peroxidation and a decrease in electron transport 
elements. The reduction in electron transport elements was thought to be due to loss of integrity of 
the membranes and structural alterations in the membrane phospholipids, leading to increased lipid 
peroxidation. Disulfoton or its oxygenated metabolite may also have changed the conformation of 
heme protein, leading to enhanced lipid peroxidation (Fawade and Pawar 1978). 
In intermediate-duration studies, no effects on clinical chemistry indices of liver toxicity and no 
histopathological hepatic lesions were found in rats given 0.34 mg/kg/day (males) or 0.55 mg/kg/day 
(females) (Klotzsche 1972) or in mice given 0.63 mg/kg/day (males) or 0.71 mg/kg/day (females) 
(Rivett et al. 1972) in the diet for 90 days. However, a slight increase in liver weight was observed in 
female mice at 0.71 mg/kg/day (Rivett at al. 1972). 
Similarly, in chronic feeding studies, no clinical chemistry or histological evidence of liver toxicity 
was found in rats (Carpy et al. 1975; Hayes 1985), mice (Hayes 1983), or dogs (Hoffman et al. 1975). 
However, trends towards increased liver weights in male rats and decreased liver weights in female 
rats fed disulfoton for 1.5-2.0 years were observed (Carpy et al. 1975). The reason for these opposite 
trends in male and female rats is not clear. 
Renal Effects. The only information found regarding renal effects in humans after oral exposure 
to disulfoton was swelling of the glomerulus at autopsy in a man who had been dead for at least 
24 hours after ingesting an unknown quantity of disulfoton (Hattori et al. 1982). 
Few data were located regarding renal effects in animals after oral exposure to disulfoton, and the 
evidence for renal effects due to disulfoton ingestion is inconclusive. Urinalysis and histological 
examination revealed no renal effects in rats given ≤0.55 mg/kg/day disulfoton (Klotzsche 1972) or in 
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mice given ≤0.71 mg/kg/day disulfoton (Rivett et al. 1972) in the diet for 90 days, in rats given 
≤1.02 mg/kg/day in the diet for 1.5-2 years (Carpy et al. 1975; Hayes 1985), in mice given 
≤2.53 mg/kg/day in the diet for 23 months (Hayes 1983), or in dogs given 0.14 mg/kg/day in the diet 
for 2 years (Hoffman et al. 1975). Trends towards increased kidney weights in male rats and 
decreased kidney weights in female rats fed disulfoton for 1.5-2 years were observed (Carpy et al. 
1975). The reason for these opposite trends in male and female rats is not clear. In another study, 
absolute and relative kidney weights were significantly increased in females mice fed 2.53 mg/kg/day, 
but not in male mice fed 2.13 mg/kg/day, disulfoton for 23 months (Hayes 1983). The increased 
kidney weight was thought to be associated with an insignificant increase in the incidence of malignant 
lymphoma in the kidney. Since the kidney tumors were not believed to be the result of disulfoton 
treatment, the toxicological significance of the increased kidney weight is not clear. 
Endocrine Effects. No studies were located regarding endocrine effects in humans after oral 
exposure to disulfoton. 
Disulfoton exposure altered catecholamine levels in animals, and this hormonal imbalance may be 
associated with elevated acetylcholine levels (Brzezinski 1969, 1972, 1973; Brzezinski and Ludwicki 
1973; Brzezinski and Rusiecki 1970; Wysocka-Paruszewska 1970, 1971). In these studies, acute 
dosing with disulfoton caused increases in urinary and plasma noradrenaline and adrenaline levels, 
accompanied by decreases of adrenaline in the adrenal glands, in rats. In addition, the major urinary 
metabolite of catecholamine metabolism, 4-hydroxy-3-methoxymandelic acid (HMMA), was recovered 
in the urine from rats given acute doses of disulfoton (Wysocka-Paruszewska 1970, 1971). The 
maximum level of HMMA in the urine occurred 72 hours after exposure, which coincides with the 
time period for maximum urine catecholamine levels. There was a direct relationship between blood 
cholinesterase inhibition and catecholamine (adrenaline and noradrenaline) levels in the urine and 
blood (Brzezinski and Ludwicki 1973). Maximum inhibition of cholinesterase activity and maximum 
plasma catecholamine occurred during the first l-2 hours after exposure. However, catecholamine 
levels returned to normal more rapidly than cholinesterase activity. It was proposed that high levels of 
acetylcholine, which are normally associated with cholinesterase activity inhibition, caused a release of 
catecholamines from the stores in the adrenals. 
Elevated catecholamine concentrations in the urine were also observed in rats dosed with 
0.625 mg/kg/day of disulfoton every other day for 76 days (Brzezinski and Rusiecki 1970). Urinary 
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catecholamine levels plateaued between 16 and 36 days, followed by a gradual decline for the next 
40 days. However, these levels were still elevated at day 76. 
In 13-week dietary studies, measurement of organ weight and histological examination of adrenals, 
pancreas, pituitary, and thyroid revealed no effects in rats at doses ≤0.55 mg/kg/day (Klotzsche 1972) 
or mice at dose ≤0.1 mg/kg/day (Rivett et al. 1972) 
There was a trend towards increased pituitary weights in male rats and decreased pituitary weights in 
female rats fed disulfoton for 1.5-2.0 years (Carpy et al. 1975). The reason for the opposite trends in 
organ weights in males and females and the toxicological significance for these effects is not clear. 
Male rats given a high dose (0.75 mg/kg/day) of disulfoton in the diet for 2 years had a significantly 
increased incidence of pancreatic atrophy, seen as small focal areas of shrunken acinar cells (Hayes 
1985). No histopathological lesion in the pancreas were observed in females at doses 
≤1.02 mg/kg/day, and no histopathological lesions in the adrenal, pituitary, thyroid, or parathyroid 
were found in the male or female rats at any dose. In other chronic dietary studies, no organ weight 
changes or histopathological lesions in the adrenals, pancreas, thyroid, parathyroid, or pituitary were 
found in mice at doses ≤2.53 mg/kg/day (Hayes 1983) or dogs at doses ≤0.14 mg/kg/day (Hoffman et 
al. 1975). The Hoffman study also found no changes or histopathological lesions in parotid in dogs. 
Dermal Effects. No studies were located regarding dermal effects in humans after oral exposure to 
disulfoton. 
In animals, histological examination of skin revealed no lesions in rats exposed to 0.34 mg/kg/day 
(males) or 0.55 mg/kg/day (females) (Klotzsche 1972) in the diet for 90 days, or in rats exposed to 
0.1 mg/kg/day (Carpy et al. 1975) or in mice exposed to 2.13 mg/kg/day (males) or 2.53 mg/kg/day 
(females) (Hayes 1983) in the diet for up to 2 years. However, acanthosis, hyperkeratosis, ulceration 
of the skin, exudate formation, and epithelial inclusion cysts were increased in male rats exposed to 
0.75 mg/kg/day and female rats exposed to 1.02 mg/kg/day disulfoton in the diet for 2 years (Hayes 
1985). No increase in skin lesions was found in the male rats at 0.18 mg/kg/day or in female rats at 
0.21 mg/kg/day. 
Ocular Effects. The only information regarding ocular effects in humans comes from an 
epidemiological study in which a marked increase of myopia in young children was observed 
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(Ishikawa and Miyata 1980). The increase coincided with an increased use of disulfoton in 
combination with other organophosphates to treat food crops. As discussed below, disulfoton caused 
myopia in Beagle dogs, providing supportive evidence that disulfoton probably contributed to the 
development of myopia in the young children. 
Ocular effects such as myopia and astigmatism have been observed in dogs. Myopia and astigmatism 
occurred after 12 months in Beagle dogs given ≥0.63 mg/kg/day disulfoton for 2 years (Ishikawa and 
Miyata 1980; Suzuki and Ishikawa 1974). The myopia became progressively worse until cessation of 
dosing. As discussed above for musculoskeletal effects, histological examination of the ciliary muscle 
cells revealed degenerative changes that were considered to be the cause of the myopia. Cystic 
degeneration of the Harderian gland was observed in male rats exposed to 0.75 mg/kg/day and in 
female rats exposed to ≥0.21 mg/kg/day disulfoton in the diet for 2 years (Hayes 1985). In the same 
study, the incidence of cornea1 neovascularization was significantly increased in the high dose rats 
(0.75 mg/kg/day in males and 1.02 mg/kg/day in females), while no ocular lesions were found in the 
male rats at 0.18 mg/kg/day or in the female rats at 0.06 mg/kg/day. In other studies, 
ophthalmological and histological examination of eyes revealed no lesions in rats given a single 
gavage dose of 5.2 mg/kg (males) or 1.5 mg/kg (females) (Sheets 1993a); or in rats exposed to 
≤1.08 mg/kg/day (males) or ≤1.31 mg/kg/day (females) (Klotzsche 1972; Sheets 1993b) or mice 
exposed to 0.63 mg/kg/day (males) or 0.71 mg/kg/day (females) (Rivett et al. 1972) in the diet for 
90 days; or in rats exposed to 0.1 mg/kg/day (Carpy et al. 1975), in mice exposed to 2.13 mg/kg/day 
(males) or 2.53 mg/kg/day (females) (Hayes 1983), or in dogs exposed to 0.14 mg/kg/day (Hoffman et 
al. 1975) in the diet for up to 2 years. 
Body Weight Effects. Weight loss or decreased body weight gain is commonly observed in 
animals after acute exposure to disulfoton and is one of the typical signs of cholinergic toxicity of 
cholinesterase inhibitors (see Section 2.2.1.4). The weight loss or reduced weight gain usually occurs 
early in the dosing regimen, but the rate of weight gain recovers with repeated dosing as the animals 
become tolerant (Costa et al. 1984, 1986; Fitzgerald and Costa 1992, 1993; Schwab and Murphy 1981; 
Schwab et al. 1981). Many of the acute oral studies conducted in animals showing initial body weight 
loss were designed to study the phenomenon and mechanism of tolerance development (see 
Section 2.3.5). Rats treated with 2.0 or 2.5 mg/kg/day disulfoton by gavage for l-10 days initially 
exhibited a 20-50% reduction in weight gain (Costa et al. 1984, 1986; Schwab et al. 1981, 1983). In 
another study, rats exhibited an unspecified, but significant (p<0.01), decrease in body weight gain 
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within 3 days of a 9-day disulfoton feeding regimen that provided 1 mg/kg/day (Schwab and Murphy 
1981). In all of these studies, the effect on weight gain diminished with repeated dosing, suggesting 
that the rats became tolerant to disulfoton. In addition, a more severe weight loss (≈20%) was 
observed in rats given 3.5 mg/kg/day of disulfoton for 3 days than in rats that had previously received 
a 2.5 mg/kg/day dose for 6 days and then a 3.5 mg/kg/day dose for an additional 6 days (Schwab et 
al. 1981). Although changes in neurological effects are more commonly employed, these studies 
suggested that body weight changes can be used to monitor the development of tolerance in rats. 
Although the acute studies suggest that with repeated dosing body weight gain recovers after the initial 
decrease, the body weight remains lower than the control body weight, as demonstrated in 
intermediate-duration studies. Rats given 2.5 mg/kg/day disulfoton for 30 days gained 29% less in 
body weight gain than controls (Robinson et al. 1978). In a 62-day feeding study, significantly 
(p<0.01) lower body weights were seen in rats within 3 days at 1 mg/kg/day disulfoton (Schwab and 
Murphy 1981). Although the rats recovered some of the body weight, the body weights were still 
significantly depressed at all weighing times during the 62-day exposure. A 40% decrease in body 
weight gain was observed in rats given 1.25 mg/kg/day, but not 0.5 mg/kg/day, disulfoton in the diet 
for 141-178 days (Stavinoha et al. 1969). Weight changes were used as the major criterion for 
tolerance development rather than the less objective neurological signs of cholinergic poisoning. The 
time for tolerance development increased as the dose of disulfoton increased. In an extensive 
reproductive study, body weight gain was marginally depressed by 6-10% in F1 parental females and 
9-l 1% in F1 parental males receiving 0.09 mg/kg/day disulfoton in the diet during the premating 
period of 13 weeks (Hixson and Hathaway 1986). In other intermediate-duration dietary studies, no 
effects on body weight gain were observed in rats given ≤l.3 1 mg/kg/day (Christenson and Wahle 
1993; Klotzsche 1972; Sheets 1993b) or in mice given ≤0.71 mg/kg/day (Rivett et al. 1972). 
In rats given disulfoton in the diet for 2 years, body weight gain was decreased by ll-19% in females 
at 1.02 mg/kg/day, but not at 0.21 mg/kg/day, and in males at 0.75 mg/kg/day, but not at 
0.18 mg/kg/day (Hayes 1985). In other chronic-duration studies, no effects on body weight were 
observed in rats given 0.1 mg/kg/day in the diet (Carpy et al. 1975), in mice given ≤2.53 mg/kg/day in 
the diet (Hayes 1983), or in dogs given 0.14 mg/kg/day in the diet (Hoffman et al. 1975). 
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2.2.2.3 Immunological and Lymphoreticular Effects 
No studies were located regarding the immunological or lymphoreticular effects in humans after oral 
exposure to disulfoton. 
In 13-week feeding studies, histological examination of lymph nodes, spleen, and bone marrow of rats 
at doses ≤0.55 mg/kg/day (Klotzsche 1972) and of lymph nodes, spleen, and thymus of mice at 
≤0.71 mg/kg/day (Rivett et al. 1972) revealed no treatment-related lesions. In rats given the high 
concentration of disulfoton in the diet for 2 years, males (0.75 mg/kg/day) had a significantly 
increased incidence of plasma cell hyperplasia in the mandibular lymph nodes, and females 
(1.02 mg/kg/day) had a significantly increased incidence of splenic lymphoid follicle depletion (Hayes 
1985). The author suggested that plasma cell hyperplasia in the mandibular lymph nodes was 
probably a response to upper respiratory tract inflammation, which may have been due to aspiration of 
ingested food particles. Histological examination of the mesenteric lymph node or thymus revealed no 
treatment-related lesions in either sex at any dose. In other chronic dietary studies, no treatmentrelated 
lesions were found in the lymph nodes, spleen, thymus, or bone marrow of rats at 
≤0.1 mg/kg/day (Carpy et al. 1975), mice at ≤2.53 mg/kg/day (Hayes 1983), or dogs at 
≤0.14 mg/kg/day (Hoffman et al. 1975). 
Down-regulation of cholinergic muscarinic receptors in T-lymphocytes and significantly inhibited 
acetylcholinesterase activity in T-lymphocytes were found in rats given 2 mg/kg/day disulfoton by 
gavage for l-2 weeks (Fitzgerald and Costa 1993). The inhibition of T-lymphocyte 
acetylcholinesterase activity paralleled that in the brain. The immunological significance of these 
neurological effects (see Section 2.2.2.4) is not known. 
2.2.2.4 Neurological Effects 
Exposure to disulfoton can result in inhibition of acetylcholinesterase activity, with consequent 
accumulation of acetylcholine at nerve synapses and ganglia leading to central nervous system, 
nicotinic, and muscarinic effects (see Section 2.2.1.4 for more extensive discussion). 
In a human case-report study, a 30-year-old man was found dead after consuming an unknown amount 
of disulfoton (Hattori et al. 1982). Bubbling saliva in the oral cavity and constricted pupils were 
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evidence of muscarinic effects. Pulmonary edema and blood in the lungs and bronchus suggested that 
death was primarily due to respiratory failure brought on by disulfoton intoxication. Severe signs and 
symptoms of disulfoton toxicosis (miosis, salivation, masseteric spasms, and monoplegia) were 
observed in a man within 2-3 hours of consuming 34 heaping tablespoons of disulfoton (Yashiki et 
al. 1990). The coincidental depression in serum cholinesterase activity and the occurrence of severe 
clinical signs suggests that a very severe toxic dose of disulfoton was consumed, and death may have 
occurred were it not for the medical treatment. 
Disulfoton can interfere with neurotransmitter levels (e.g., acetylcholine, catecholamines) in the brain 
of affected animals (Brzezinski 1972; Costa et al. 1986). A single dose of disulfoton caused a lower 
noradrenaline level in the brain of rats compared with the controls, with the greatest decreases (about 
0.175 µg /mL and 0.1 µg /mL compared with 0.3 µg /rnL in control) at 15 and 120 minutes after dosing 
(Brzezinski 1972). Adrenaline levels in the brain, however, showed little difference from control 
levels, being slightly increased at 60 minutes and slightly decreased at 120 minutes. The rats exhibited 
typical cholinergic signs of disulfoton toxicosis (not otherwise specified). In other acute exposure 
studies, brain cholinesterase activity was significantly depressed when rats were given disulfoton for 
7-10 days, suggesting elevated brain acetylcholine levels (Costa and Murphy 1983a; Costa et al. 1986; 
Schwab and Murphy 1981; Su et al. 1971). 
Muscle twitching, clonic cramps, and increased salivation were observed in rats given a single gavage 
dose of 1.0 mg/kg and in mice given a single oral gavage dose of 5.0 mg/kg (Mihail 1978). Rats 
given 0.5 mg/kg and mice given 2.5 mg/kg did not develop these signs. However, in another study, 
rats given a single gavage dose of 0.5 mg/kg had tremors (Crawford and Anderson 1974). In an 
extensive neurotoxicity screening study, rats were given single gavage doses of disulfoton (0.24, 1.5, 
and 5.2 mg/kg in males; 0.24, 0.76, and 1.5 mg/kg for females) (Sheets 1993a). Clinical signs of 
cholinergic intoxication consisted of muscle fasciculation, tremors, ataxia, oral stain, urine stain, 
diarrhea, or decreased activity in the high dose males (5.2 mg/kg) and high dose females (1.5 mg/kg) 
and muscle fasciculation in the mid dose females (0.76 mg/kg). A battery of functional observational 
tests revealed effects in both males and female at the mid and high doses. At the mid dose and high 
dose, these effects included muscle fasciculation, ataxia, and minimal head or body movement during 
open field observation in both sexes and a lower incidence of vocalizations upon removal from the 
home cage in females. High dose males also had uncoordinated righting reflex. Results of motor and 
locomotor activity tests revealed a 55% and 51% reduced motor activity in high dose males and 
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females, respectively, and 64% and 62% reduced locomotor activity in high dose males and females, 
respectively. Erythrocyte cholinesterase activity was inhibited by 21% in high dose males, 75% in 
high dose females, and 53% in mid dose females. No treatment-related effects were observed for 
brain weight and extensive histopathological examination of the brain, spinal cord, peripheral nerves 
(sciatic, tibial, sural), optic nerves, or gasserian ganglion. 
Animals exposed to disulfoton develop typical signs of cholinergic toxicity associated with inhibition 
of brain acetylcholinesterase activity after a few oral doses (Costa et al. 1984; Schwab and Murphy 
1981; Schwab et al. 1981, 1983). However, with subsequent dosing, the severity of the overt 
cholinergic effects diminish, while cholinesterase remains inhibited. This phenomenon is known as 
tolerance (see Section 2.3.5). Male rats given 2.0 or 2.5 mg/kg/day of disulfoton for 1-14 days 
initially exhibited exophthalmia, excessive salivation, urination and defecation, diarrhea, fasciculations, 
generalized tremors, flaccidity, and malaise (Costa et al. 1984; Fitzgerald and Costa 1992, 1993; 
Schwab et al. 1981, 1983). Similar effects were observed in female rats after 3 days on a diet that 
provided 1 mg/kg/day disulfoton (Schwab and Murphy 1981). A diet that provided 0.38 mg/kg/day 
did not cause overt signs of toxicity, but brain acetylcholinesterase was inhibited by 30-35%. The 
severity of these signs diminished after an unspecified time with repeated dosing, but the signs did not 
completely disappear (Costa et al. 1984; Schwab and Murphy 1981; Schwab et al. 1981, 1983). When 
rats were given 3.5 mg/kg/day for 3-4 days, these clinical signs were more severe than those exhibited 
by rats pretreated with 2.5 mg/kg/day of disulfoton for 6 days and then given 3.5 mg/kg/day for 
6 more days (Schwab et al. 1981). Thus, the rats pretreated with 2.5 mg/kg/day for 6 days became 
tolerant to even higher doses of disulfoton. In the same study, heart, ileum, forebrain, and hindbrain 
cholinesterase activity was moderately but significantly depressed in rats given seven daily doses of 
2 mg/kg/day of disulfoton, followed by four daily doses of 3 mg/kg/day. Furthermore, a 50% 
reduction in pancreatic acetylcholinesterase activity was observed in rats given 2 mg/kg/day for 
10 days despite the disappearance of clinical cholinergic signs after a few doses (Costa et al. 1984). 
This depression in cholinesterase activity suggests that the mechanism associated with disulfoton 
toxicity was not impaired, despite the disappearance of overt neurological signs of toxicity following 
repeated doses of disulfoton. 
Disulfoton caused muscular tremors, unsteadiness, and ataxia in pregnant rabbits after exposure to 
1.5-3.0 mg/kg/day on days 6-18 of gestation (Tesh et al. 1982). Doses of 0.3 or 1.0 mg/kg/day 
disulfoton did not affect the pregnant rabbits. In a reproductive study, tremors were observed in high 
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dose (0.09 mg/kg/day) F0 female rats, but not the mid dose (0.03 mg/kg/day) F0 females, during the 
production of the F1 generation (Hixson and Hathaway 1986). Pregnant rats given disulfoton during 
gestation had significantly inhibited plasma and erythrocyte cholinesterase activity by 82-90% at 
1 mg/kg/day and by 41% at 0.3 mg/kg/day, but not at 0.1 mg/kg/day (Lamb and Hixson 1983). Basec 
on this NOAEL (0.1 mg/kg/day), an acute oral MRL of 0.001 mg/kg/day was calculated as described 
in footnote “b” in Table 2-2. 
An intermediate-duration extensive neurotoxicity screening study similar to the acute study described 
above was conducted in rats fed disulfoton in the diet that provided doses of 0.063, 0.270, or 
1.08 mg/kg/day for males and 0.71, 0.315 or 1.31 mg/kg/day for females (Sheets 1993b). Clinical 
signs of cholinergic intoxication consisted of muscle fasciculation, perianal stains, and increased 
reactivity in high dose males and females and increased incidence of urine stains in mid and high dose 
females. A battery of functional observational tests revealed effects in high dose males and mid and 
high dose females. The effects in high dose rats included muscle fasciculations, tremors, increased 
defecation, decreased forelimb grip strength, decreased movement, and increased urine stain. Muscle 
fasciculations and increased urine stain were also seen in mid dose females. Automated measures of 
motor and locomotor activity were reduced on each test occasion (weeks 4, 8, and 13) in the high dose 
males and females. Erythrocyte cholinesterase activity was inhibited by 95100% in high dose rats 
and 61-80% in mid dose rats. Brain cholinesterase activity was inhibited by 35% in mid dose males 
and 64% in mid dose females and by 75% in high dose males and 87% in high dose females. No 
treatment-related effects were observed for brain weight and extensive histopathological examination of 
the brain, spinal cord, peripheral nerves (sciatic, tibial, sural), optic nerves, or gasserian ganglion. 
In intermediate-duration studies, typical signs of cholinergic poisoning are generally seen only during 
the first few days, after which they diminish. However, cholinesterase activity usually remains 
inhibited during exposure. Characteristic signs (not otherwise specified) of anticholinesterase 
poisoning were observed in rats fed disulfoton for 30 days, and some of the rats recovered (Robinson 
et al. 1978). Brain, stomach, and diaphragm cholinesterase activity were severely depressed. In a 
62-day feeding study, rats developed severe cholinergic signs of disulfoton toxicity after 3 days on a 
diet providing 1 mg/kg/day disulfoton (Schwab and Murphy 1981). The severity of these signs 
decreased but never completely disappeared after 62 days. Brain and diaphragm cholinesterase activity 
was depressed at day 6 and remained depressed throughout the study. Sex and strain differences in 
rats may influence the ability of disulfoton to inhibit cholinesterase or to elevate acetylcholine levels. 
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Brain cholinesterase activity was significantly depressed to about the same extent in Holtzman rats and 
Charles River rats fed disulfoton for 141-178 days, but only the Charles River rats had elevated brain 
acetylcholine levels (Stavinoha et al. 1969). Cholinesterase activity of erythrocytes and the brain was 
inhibited to a greater extent or at lower doses in female rats than in male rats given disulfoton in the 
diet for intermediate durations (Christenson and Wahle 1993; Doull and Vaughn 1958; Hayes 1985; 
Klotzsche 1972; Ryan et al. 1970). In mice fed diets providing 0.63 mg/kg/day (males) or 
0.71 mg/kg/day (females), cholinesterase was inhibited in all tissues, especially in females, but the 
tissues were not specified (Rivett et al. 1972). In a chronic study in which dogs were given capsules 
containing disulfoton for 2 years, erythrocyte cholinesterase activity was inhibited by 80% after 
5 months of exposure to ≥0.5 mg/kg/day and remained depressed throughout the 2-year duration 
(Hikita et al. 1973). A 22-50% inhibition of erythrocyte cholinesterase activity and a 33-36% 
inhibition of plasma cholinesterase activity were found in dogs given diets containing disulfoton at a 
dose of 0.06 mg/kg/day for 40 weeks (Hoffman et al. 1975). 
Disulfoton has also been studied for behavioral effects. Rats fed ≥0.5 mg/kg/day disulfoton for 
90 days had significantly depressed brain acetylcholinesterase levels (59-74% below control), but the 
treated rats had shorter maze running times and made fewer mistakes than the controls (Clark and 
Pearson 1973). This unexpected result (improved learning) at reduced brain cholinesterase levels led 
the authors to question the “critical level of 60% reduction” for neurobehavioral effects. In another 
behavioral experiment, there was an unexplained increase in exploratory behavior in mice fed 
disulfoton for 12 weeks (Clark et al. 1971). Dietary exposure of rats and mice to 2.5 mg/kg/day 
disulfoton for 2 months resulted in an increase in the permeability of spinal cord and brain stem 
tissues in both species (Clark and Stavinoha 1971). The nature of this change in permeability was not 
further investigated. 
In a chronic-duration study, a decrease in relative and absolute brain weights was observed in male 
rats, but an increase in brain weights was observed in female rats fed disulfoton for 1.5-2.0 years 
(Carpy et al. 1975). The reason for and the toxicological significance of these opposite trends in 
males and females is not clear. In the same study, plasma, erythrocyte, and brain cholinesterase 
activity was significantly inhibited in both male and female rats. A dose of 0.1 mg/kg/day resulted in 
a 21% inhibition of brain cholinesterase activity in female rats. At 0.05 mg/kg/day, brain 
cholinesterase was inhibited by 11% in male rats. In another chronic dietary study in rats which 
provided doses of 0.05, 0.18, and 0.75 mg/kg/day in males and 0.06, 0.21, and 1.02 mg/kg/day in 
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females, erythrocyte cholinesterase activity was inhibited by ≤19% and 14-24% in low dose males and 
females respectively, 46-67% and 57-77% in mid dose males and females, respectively, and 71-82% 
and 75-86% in high dose males and females, respectively (Hayes 1985). Brain cholinesterase activity 
was inhibited by 15% and 21% in low dose males and females, respectively; 53% in both mid dose 
males and females; and 79% and 82% in high dose males and females, respectively. Relative brain 
weight was significantly increased in both high dose males and females. Histological examination 
revealed a dose-related increased incidence of optic nerve degeneration that was statistically significant 
in mid dose males and mid and high dose females. No treatment-related lesions were found in the 
brain, sciatic nerve, or spinal cord. Based on the LOAEL of 0.06 mg/kg/day for erythrocyte and brain 
cholinesterase inhibition in female rats, a chronic oral MRL of 6x10-5 mg/kg/day was calculated as 
described in footnote “d” in Table 2-2. Significant depression of erythrocyte, plasma, and brain 
cholinesterase activity was also found in mice fed disulfoton for 23 months at doses of 2.13 mg/kg/day 
(males) and 2.53 mg/kg/day (females) (Hayes 1983). Beagle dogs did not exhibit profound changes in 
general appearance or behavior when fed disulfoton (0.03 or 0.14 mg/kg/day) for 2 years (Hoffman et 
al. 1975). However, significant depression of plasma and erythrocyte and brain cholinesterase activity 
occurred at 0.14, but not at 0.03 mg/kg/day. No histological lesions were found in the brain. Necrosis 
and atrophy of the optic nerve and retina was observed in dogs given disulfoton (0.5-1.5 mg/kg/day) 
for 2 years (Uga et al. 1977). The authors regarded the pathological changes in the retina as mild; 
however, the nerve fibers in the optic nerve were reduced in number. 
The highest NOAEL values and all LOAEL values for neurological effects in all reliable studies in 
each species and duration category are recorded in Table 2-2 and plotted in Figure 2-2. 
2.2.2.5 Reproductive Effects 
No studies were located regarding reproductive effects in humans after oral exposure to disulfoton. 
In a dominant lethal test, treatment of male mice with a single oral dose of 5 mg/kg disulfoton had no 
effect on male fertility (Herbold 1980). In a three-generation reproductive study, exposure of male and 
female rats to disulfoton in the diet at 0.5 mg/kg/day resulted a “slight” reduction of litter sizes in the 
third generation (Taylor 1965a). This study was limited by data reporting deficiencies such as lack of 
statistical analysis, incomplete necropsy report, and insufficient histopathological data. A more 
extensive multigeneration study was conducted in male and female rats exposed to disulfoton in the 
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diet that provided doses of 0.009, 0.03, and 0.09 mg/kg/day (Hixson and Hathaway 1986). At 
0.09 mg/kg/day, decreased reproductive performance occurred, evidenced by a decreased percentage of 
females placed for mating and decreased percentage of sperm-positive F0 and F1 parental females. In 
addition, decreased maternal weight of F0 and F1 dams during gestation and lactation, decreased litter 
counts, viability index, and lactation index, and increased dead births and percentage of dead births 
occurred in both generations at 0.09 mg/kg/day. A decrease in F2b litter counts and litter weights 
occurred at 0.03 mg/kg/day. Gross and histological examination of the ovary, vagina, uterus, testes, 
epididymis, seminal vesicles, and prostate of the F0 and F1 parents revealed no treatment-related 
lesions. In an intermediate-duration study, exposure of male and female rats to diets providing 
0.5 mg/kg/day disulfoton for 60 days prior to mating and/or during mating resulted in the failure of 
two of five females to become pregnant (Ryan et al. 1970). Histological examination of reproductive 
organs of males (testes, epididymides, seminal vesicles, prostate glands) and females (ovaries, uteri, 
mammary glands) did not reveal any treatment-related lesions in rats fed 0.34 mg/kg/day (males) or 
0.55 mg/kg/day (females) (Klotzsche 1972) or in mice fed 0.63 mg/kg/day (males) or 0.71 mg/kg/day 
(females) (Rivett et al. 1972) for 90 days, or in rats fed 0.1 mg/kg/day (Carpy et al. 1975), in mice fed 
2.13 mg/kg/day (males) or 2.53 mg/kg/day (females) (Hayes 1983), or in dogs fed 0.14 mg/kg/day 
(Hoffman et al. 1975) for up to 2 years. However, uterine cystic hyperplasia was observed in female 
rats given disulfoton in the diet at 1.02 mg/kg/day, but not at 0.21 mg/kg/day, for 2 years (Hayes 
1985). Histological examination of the cervix, mammary glands, ovaries, prostate gland, seminal 
vesicles, and testes revealed no effects in the rats at any dose level. In the studies that did not assess 
reproductive function, the dose levels that were not associated with histopathological lesions in 
reproductive organs cannot be considered as NOAEL values. 
The reliable NOAEL value for reproductive performance and the LOAEL values for reproductive 
effects in each species and duration category are recorded in Table 2-2 and plotted in Figure 2-2. 
2.2.2.6 Developmental Effects 
No studies were located regarding development effects in humans after oral exposure to disulfoton. 
Pregnant rats given disulfoton on days 6-15 of gestation had decreased plasma and erythrocyte 
cholinesterase activity at ≥0.3 mg/kg/day (Lamb and Hixson 1983). Fetotoxic effects included 
increased incidences of incomplete ossified parietal bones and stemebrae at 1.0 mg/kg/day, but not at 
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0.3 mg/kg/day. This was considered as evidence of growth retardation due to maternal toxicity rather 
than specific fetotoxic effects. There was no evidence of soft tissue, external, or skeletal 
malformations. Pregnant rabbits given high doses of disulfoton (1.5-3.0 mg/kg/day) died or exhibited 
cholinergic signs of disulfoton toxicity (Tesh et al. 1982). Generally, there were no adverse effects on 
fetal survival, growth, or development. Because of the high mortality of the dams, the initial high 
dose (3.0 mg/kg/day) was reduced to 2.0 mg/kg/day and finally to 1.5 mg/kg/day. In animals that 
received doses in the range of 1.5-3.0 mg/kg or a combination of doses, no fetotoxic effects were 
observed in the offspring. Thus, 1.5 mg/kg/day is considered the NOAEL for developmental effects in 
this study. In an intermediate-duration study, exposure of male and female rats to diets providing 
0.5 mg/kg/day disulfoton for 60 days prior to mating and/or during mating resulted in a 32.1% 
depression in fetal brain cholinesterase activity (Ryan et al. 1970). In a three-generation study in rats, 
cloudy swelling and fatty infiltration of the liver, mild nephropathy (females), and juvenile hypoplasia 
of the testes were observed in F3b litters (Taylor 1965a). These litters also had significantly depressed 
erythrocyte cholinesterase activities. In another multigeneration study in rats, brain cholinesterase 
activity was inhibited by 24% and 32% in male and female F1a pups, respectively, at 0.03 mg/kg/day 
and by 50% and 59% in male and female F1a pups, respectively, at 0.09 mg/kg/day (Hixson and 
Hathaway 1986). No inhibition of brain cholinesterase was found in the F1a pups at 0.009 mg/kg/day, 
and no grossly observable developmental abnormalities were found in any pups in the F1 or F2 
generation. Based on this NOAEL of 0.009 mg/kg/day for brain cholinesterase inhibition in pups, an 
intermediate oral MRL of 9x10-5 mg/kg/day was calculated as described in footnote “c” in Table 2-2. 
The highest NOAEL values and all LOAEL values for developmental effects in each reliable study in 
each species and duration category are recorded in Table 2-2 and plotted in Figure 2-2. 
2.2.2.7 Genotoxic Effects 
No studies were located regarding genotoxic effects in humans after oral exposure to disulfoton. 
Disulfoton was negative in a dominant lethal test in male mice treated orally with a single dose of 
5 mg/kg (Herbold 1980) and in an erythrocyte micronucleus test in mice dosed with 6 or 
12 mg/kg/day for 2 days (Herbold 1981). Disulfoton also did not induce micronuclei in erythrocytes 
of mice dosed with 2, 4, or 8 mg/kg disulfoton (EPA 1984a; Sandhu et al. 1985), but whether 
disulfoton was administered by the oral or intraperitoneal route was not clear. Other genotoxicity 
studies are discussed in Section 2.4. 
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2.2.2.8 Cancer 
No studies were located regarding cancer in humans after oral exposure to disulfoton. 
No histological evidence of a carcinogenic effect was observed in rats fed ≤0.1 mg/kg/day disulfoton
 
for 1.5-2.0 years (Carpy et al. 1975), in rats fed ≤1.02 mg/kg/day disulfoton for 2 years (Hayes 1985),
 
or in mice fed ≤2.53 mg/kg/day disulfoton for 23 months (Hayes 1983). The study by Carpy et al.
 
(1975) was limited by insufficient necropsy and histological data and by dosing manipulations. In
 
addition, there was no evidence of carcinogenicity in Beagle dogs fed disulfoton
 
(0.02-0.14 mg/kg/day) for 2 years (Hoffman et al. 1975).
 
2.2.3 Dermal Exposure 
2.2.3.1 Death 
No studies were located regarding death in humans after dermal exposure to disulfoton. 
Dermal LD50 values suggest that, irrespective of strain, female rats are more sensitive than male rats 
when disulfoton is administered dermally. The dermal LD50 for disulfoton was determined to be 
15.9 and 3.6 mg/kg in male and female Wistar rats, respectively (Mihail 1978). In Sherman rats, the 
dermal LD50 was determined to be 15 and 6 mg/kg in males and females, respectively (Gaines 1969). 
In male Sprague-Dawley rats, the dermal LD50 was determined to be 20 mg/kg (DuBois 1957). A 
dermal LD50 value of 0.285 mL/kg (187 mg/kg) was reported for rats given a liquid formulation 
containing 65.7% disulfoton (Weil et al. 1971). When a granular formulation containing 10% 
disulfoton was applied at a dose of 1,280 mg/kg, one of four rats died. The difference in dermal LD50 
values is probably related to the different formulations of disulfoton. In a range-finding study, 2 of 
2 rabbits died after 1 or 2 applications of 10 mg/kg/day disulfoton was applied to the shorn, unabraded 
skin and left for 6 hours (Flucke 1986). None of the rabbits similarly treated with 0.4 or 
2.0 mg/kg/day for 5 days died. In a 3-week experiment, similar treatment of rabbits 5 days/week 
resulted in death of 5 of 5 females after l-6 treatments and of 5 of 5 males after 3-10 treatments with 
6.5 mg/kg/day. None of the rabbits treated with ≤1.6 mg/kg/day for 3 weeks died. The rabbits that 
died in these experiments exhibited persistent cholinergic signs of intoxication (muscle spasms, 
dyspnea, salivation) before death. 
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The LD50 values in rats and the LOAEL values for death of rabbits after dermal exposure to 
disulfoton are recorded in Table 2-3. 
2.2.3.2 Systemic Effects 
No studies were located regarding musculoskeletal or ocular effects in humans or animals after dermal 
exposure to disulfoton. The highest NOAEL values and all LOAEL values from each reliable study 
for systemic end points in animals are recorded in Table 2-3. 
Respiratory Effects. No studies were located regarding respiratory effects in humans after dermal 
exposure to disulfoton. 
In rats exposed to disulfoton applied to clipped dorsal skin at doses of 2.5-20 mg/kg, breathing 
difficulties were noted (Mihail 1978), but it was not clear at which doses this effect was seen. In a 
3-week study, in which disulfoton was applied to the shorn, unabraded skin of rabbits and left for 
6 hours, 5 days/week, necropsy of the rabbits that died within 2 weeks during treatment (100%) with 
the high dose of 6.5 mg/kg/day revealed distended, pale, mottled, and fluid-containing lungs (Flucke 
1986). The organs and tissues of the high dose rabbits were not examined histologically, but gross 
and histological examination of the lungs of rabbits similarly treated with ≤1.6 mg/kg/day for 3 weeks 
revealed no treatment-related lesions. 
Cardiovascular Effects. No studies were located regarding cardiovascular effects in humans after 
dermal exposure to disulfoton. 
Acute dermal exposure to unspecified doses of organophosphorus insecticides, including disulfoton, 
was reported to cause protein degeneration and significant circulatory disruptions in heart muscles of 
rats, cats, and rabbits (Kundiev and Rappoport 1967). This study is limited by reporting deficiencies 
regarding incidences, and by uncertainty about whether the effects were observed in all species and 
whether disulfoton was among the insecticides causing these effects. In a 3-week study in which 
disulfoton was applied to the shorn, unabraded skin of rabbits and left for 6 hours, 5 days/week, gross 
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Gastrointestinal Effects. No studies were located regarding gastrointestinal effects in humans 
after dermal exposure to disulfoton. 
In a 3-week study in which disulfoton was applied to the shorn, unabraded skin of rabbits and left for 
6 hours, 5 days/week, necropsy of the rabbits that died within 2 weeks during treatment (100%) with 
the high dose of 6.5 mg/kg/day revealed marked intussusception of the ileum of one female (Flucke 
1986). The gastrointestinal tract of the high dose rabbits or of rabbits similarly treated with 
≤1.6 mg/kg/day for 3 weeks were not examined histologically. 
Hematological Effects. No studies were located regarding hematological effects in humans after 
dermal exposure to disulfoton. No hematological effects in rabbits were found at ≤1.6 mg/kg/day in a 
3-week study in which disulfoton was applied to the shorn, unabraded skin and left for 6 hours, 
5 days/week (Flucke 1986). 
Hepatic Effects. No studies were located regarding hepatic effects in humans after dermal 
exposure to disulfoton. 
Acute dermal exposure to unspecified doses of organophosphorus insecticides, including disulfoton, 
was reported to cause protein degeneration and significant circulatory disruptions in the livers of rats, 
cats, and rabbits (Kundiev and Rappoport 1967). This study is limited by reporting deficiencies 
regarding incidences, and by uncertainties about whether the effects were observed in all species and 
whether disulfoton was among the insecticides causing these effects. In a 3-week study in which 
disulfoton was applied to the shorn, unabraded skin of rabbits and left for 6 hours, 5 days/week, 100% 
of the rabbits died within 2 weeks during treatment. Necropsy of the rabbits treated with the high 
dose of 6.5 mg/kg/day revealed a lobular pattern in the liver (Flucke 1986). The organs and tissues of 
the high dose rabbits were not examined histologically, but clinical chemistry results and gross and 
histological examination of the liver of rabbits similarly treated with ≤1.6 mg/kg/day for 3 weeks 
revealed no treatment-related hepatic effects. Slight increases in the absolute and relative liver weights 
were found in male rabbits at 1.6 mg/kg/day, but the absence of clinical chemistry and histological 
effects indicates that the liver weight change was not toxicologically significant. 
Renal Effects. No studies were located regarding renal effects in humans after dermal exposure to 
disulfoton. 
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Acute dermal exposure to unspecified doses of organophosphorus insecticides, including disulfoton, 
was reported to cause protein degeneration and significant circulatory disruptions in the kidneys of 
rats, cats, and rabbits (Kundiev and Rappoport 1967). This study is limited by reporting deficiencies 
regarding incidences, and uncertainties about whether the effects were observed in all species and 
whether disulfoton was among the insecticides causing these effects. In a 3-week study in which 
disulfoton was applied to the shorn, unabraded skin of rabbits and left for 6 hours, 5 days/week, 100% 
of the rabbits died within 2 weeks during treatment. Necropsy of the rabbits treated with the high 
dose of 6.5 mg/kg/day revealed pale kidneys, with reddened renal pelvis and indistinct structure 
(Flucke 1986). The organs and tissues of the high dose rabbits were not examined histologically, but 
clinical chemistry and urinalysis results and gross and histological examination of the kidney of rabbits 
similarly treated with ≤1.6 mg/kg/day for 3 weeks revealed no treatment-related renal effects. 
Endocrine Effects. No studies were located regarding endocrine effects in humans after dermal 
exposure to disulfoton. 
In a 3-week study in which disulfoton was applied to the shorn, unabraded skin of rabbits and left for 
6 hours, 5 days/week, gross and histological examination of the adrenal and thyroid glands revealed no 
treatment-related lesions at ≤1.6 mg/kg/day (Flucke 1986). 
Dermal Effects. No studies were located regarding dermal effects in humans after dermal exposure 
to disulfoton. 
Acute dermal exposure to unspecified doses of organophosphorus insecticides, including disulfoton, 
was reported to cause microscopic changes in the blood vessels and fibrous structures in the skin of 
rats, cats, and rabbits (Kundiev and Rappoport 1967). Collagen and elastin fibers in the skin and the 
blood vessels in the skin appeared to have been affected. These effects were thought to have further 
increased the absorption of the insecticides by the skin. This study is limited by reporting deficiencies 
regarding incidences, and questions about whether the effects were observed in all species and whether 
disulfoton was among the insecticides causing these effects. In a 3-week study in which disulfoton 
was applied to the shorn, unabraded skin of rabbits and left for 6 hours, 5 days/week, the treated areas 
of the skin were observed daily for signs of inflammation (redness and swelling) (Flucke 1986). In 
the rabbits that died within 2 weeks during treatment with the high dose of 6.5 mg/kg/day (100%) and 
in the rabbits treated with ≤1.6 mg/kg/day for 3 weeks, no indication of local irritation was found. 
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The skin of the high dose rabbits was not examined histologically, but histological examination of the 
skin of rabbits treated with ≤1.6 mg/kg/day for 3 weeks revealed no treatment-related lesions. 
Body Weight Effects. No studies were located regarding body weight effects in humans after 
dermal exposure to disulfoton. 
In a 3-week study in which disulfoton was applied to the shorn, unabraded skin of rabbits and left for 
6 hours, 5 days/week, little or no feed intake and distinct weight loss occurred up to the time of death 
in the rabbits that died within 2 weeks during treatment. Necropsy of the rabbits treated with the high 
dose of 6.5 mg/kg/day (100%) (Flucke 1986). No effects on body weight were found in rabbits 
similarly treated with ≤1.6 mg/kg/day for 3 weeks. 
2.2.3.3 Immunological and Lymphoreticular Effects 
No studies were located regarding immunological and lymphoreticular effects in humans after dermal 
exposure to disulfoton. 
In a 3-week study in which disulfoton was applied to the shorn, unabraded skin of rabbits and left for 
6 hours, 5 days/week, 100% of the rabbits died within 2 weeks during treatment. Necropsy of the 
rabbits treated with the high dose of 6.5 mg/kg/day revealed small and pale spleens in some cases 
(Flucke 1986). The organs and tissues of the high dose rabbits were not examined histologically, but 
gross and histological examination of the spleens of rabbits similarly treated with ≤1.6 mg/kg/day for 
3 weeks revealed no treatment-related lesions. The NOAEL value and the LOAEL value for effects 
on the spleen in rabbits are recorded in Table 2-3. 
2.2.3.4 Neurological Effects 
Exposure to disulfoton can result in inhibition of acetylcholinesterase activity, with consequent 
accumulation of acetylcholine at nerve synapses and ganglia leading to central nervous system, 
nicotinic, and muscarinic effects (see Section 2.2.1.4 for more extensive discussion). 
A farmer who had worn disulfoton~ontaminated gloves for several days developed signs of disulfoton 
toxicity (weakness, fatigue, and cyanosis) and had to be hospitalized (Savage et al. 1971). Because a 
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considerable amount (not otherwise specified) of disulfoton was detected in the serum and because 
blood cholinesterase activity was severely depressed, it can be assumed that the patient had absorbed a 
considerable amount of disulfoton through the skin. The patient recovered following treatment for the 
toxicosis. Severe neurological signs and symptoms were not reported by workers exposed to 
disulfoton during wet or dry mix operations at mean doses of 0.013-0.23 mg/kg/day for 9 weeks at a 
pesticide-fertilizer mixing plant (Wolfe et al. 1978). However, erythrocyte cholinesterase activity was 
depressed by 22.8% from week 2-9 of the study in workers involved in dry mix operations 
(0.23 mg/kg/day). No depression in blood cholinesterase activity was observed in workers involved 
with wet mix operations (0.013 mg/kg/day). These workers were also exposed to disulfoton by the 
inhalation route (see Section 2.2.1.4). Therefore, the depression in erythrocyte cholinesterase activity 
may be due to both absorption of disulfoton through the respiratory tract and through the skin. No 
significant reductions in plasma or erythrocyte cholinesterase activities occurred in three employees at 
a pesticide formulating plant exposed to disulfoton (unspecified doses) for 25 weeks (Brokopp et al. 
1981). Similarly, no reductions in cholinesterase activity were found for eight employees exposed for 
shorter periods. 
Disulfoton caused muscle twitching and clonic cramps in male and female rats after acute dermal 
exposure to doses 2.5-20 mg/kg (Mihail 1978), but it was not clear at which doses these signs were 
observed. These neurological effects persisted for an unspecified time after disulfoton was removed 
from the skin. Disulfoton also caused depression in skin cholinesterase activity in rats, cats, and 
rabbits given acute unspecified dermal doses (Kundiev and Rappoport 1967). This study is limited by 
reporting deficiencies regarding incidences and uncertainty about whether the effects were observed in 
all species. In a range-finding study, 2 of 2 rabbits died after 1 or 2 applications of 10 mg/kg/day 
disulfoton were applied to the shorn, unabraded skin and left for 6 hours (Flucke 1986). The rabbits 
exhibited cholinergic signs of intoxication (not otherwise specified) before death. None of the rabbits 
similarly treated with 0.4 or 2.0 mg/kg/day for 5 days showed cholinergic signs or died. In a 3-week 
experiment, similar treatment of rabbits 5 days/week resulted in death of 5 of 5 females after 
l-6 treatments and of 5 of 5 males after 3-10 treatments with 6.5 mg/kg/day. Persistent cholinergic 
signs (muscle spasm, dyspnea, salivation) were observed in the high dose females after 1 or 
2 treatments and in high dose males after 2 treatments. No clinical signs of cholinergic intoxication 
were seen in the rabbits treated with 0.4 or 1.6 mg/kg/day, but erythrocyte cholinesterase activity was 
inhibited by 21-33% in the female rabbits treated with 1.6 mg/kg/day. The highest NOAEL values 
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and the LOAEL values for neurological effects in rabbits for the acute and intermediate duration are 
recorded in Table 2-3. 
2.2.3.5 Reproductive Effects 
No studies were located regarding reproductive effects in humans after dermal exposure to disulfoton. 
In a 3-week study, in which disulfoton was applied to the shorn, unabraded skin of rabbits and left for 
6 hours, 5 days/week, gross and histological examination of the testes, epididymides, ovaries, and 
uterus revealed no treatment-related lesions at ≤1.6 mg/kg/day (Flucke 1986). Slight increases in the 
absolute and relative testes weights were found in male rabbits at 1.6 mg/kg/day, but the absence of 
histological effects indicates that the testes weight change was not toxicologically significant. 
Reproductive function was not evaluated. 
No studies were located regarding the following effects in humans or animals after dermal exposure to 
disulfoton: 
2.2.3.6 Developmental Effects 
2.2.3.7 Genotoxic Effects 
Genotoxicity studies are discussed in Section 2.4. 
2.2.3.8 Cancer 
2.3 TOXICOKINETICS 
The toxicokinetics of disulfoton in humans and animals depends on its physicochemical characteristics 
and its metabolism. The lipophilicity of disulfoton indicates that the insecticide should be easily 
absorbed by oral, inhalation, and dermal routes. No bioavailability data were located for inhalation 
and dermal exposure. However, disulfoton is almost completely absorbed from the gastrointestinal 
tract within 2 days after oral exposure. Animal studies suggest that disulfoton is widely distributed 
primarily to the liver and in smaller quantities to the kidney, fat, skin, muscle, brain, and other organs. 
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Disulfoton and/or its metabolites are excreted mainly in the urine of humans and animals, with minor 
amounts excreted in the feces and expired air. 
Disulfoton causes neurological effects in humans and animals. The mechanism of action on the 
nervous system depends on the metabolism of disulfoton to active metabolites. The liver is the major 
site of metabolic oxidation of disulfoton to disulfoton sulfoxide, disulfoton sulfone, demeton 
S-sulfoxide and demeton S-sulfone, which inhibit acetylcholinesterase in nervous tissue. These four 
active metabolites are more potent inhibitors of acetylcholinesterase than disulfoton. Cytochrome 
P-450 monooxygenase and flavin adenine dinucleotide monooxygenase are involved in this metabolic 
activation. The active metabolites ultimately undergo nonenzymatic and/or enzymatic hydrolysis to 
more polar metabolites that are not toxic and are excreted in the urine. 
The inhibition of acetylcholinesterase increases the amount of acetylcholine at nerve synapses, which 
causes an overstimulation of cholinergic nerves and effector organs. Depending on the dose and its 
duration, the resulting cholinergic effects are usually reversible within several days to 2 weeks after 
disulfoton exposure has been discontinued. Prolonged exposure to disulfoton results in diminished 
cholinergic signs, and affected animals develop tolerance. The down-regulation of cholinergic 
receptors due to accumulation of acetylcholine may be associated with disulfoton-induced tolerance. 
2.3.1 Absorption 
2.3.1.1 Inhalation Exposure 
No studies were located regarding absorption in humans or animals after inhalation exposure to 
disulfoton. 
2.3.1.2 Oral Exposure 
Disulfoton and/or its metabolites have been detected in the blood and urine of humans who consumed 
unknown amounts of disulfoton solution (Hattori et al. 1982; Yashiki et al. 1990). In one case, the 
concentration of disulfoton and the sum of its metabolites in the blood were 0.093 nmol/g (25.4 ng/g) 
and 4.92 nmol/g, respectively, at ≈2 hours after ingestion (Yashiki et al. 1990). The 4.92 nmol/g 
blood concentration corresponded to 1.35 µg disulfoton/g. Gastrointestinal absorption was not yet 
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complete, since 3.3 mg of disulfoton were recovered from the stomach contents, which was also 
collected at ≈2 hours after the ingestion. The concentration of metabolites in the urine was not 
quantitated. While these data indicate disulfoton is absorbed from the gastrointestinal tract of humans, 
the data are not sufficient to estimate the extent or rate of absorption. 
Male rats given a single acute dose (1.2 mg/kg) of [14C]-disulfoton eliminated an average of 84.3%, 
6.1%, and 9.2% of the dose in the urine, feces, and expired air, respectively, in the 10 days following 
exposure (Puhl and Fredrickson 1975). Female rats given 0.2 mg/kg eliminated 78.9%, 7.8%, and 
9.2% of the administered radioactivity in the urine, feces, and expired air, respectively, in the same 
time period. The data indicate that at least 88-91% of the administered dose was absorbed over the 
lo-day period. Absorption rates were not determined; however, 50% of the administered dose was 
recovered in the urine during the first 4-6 hours after exposure in males and the first 30-32 hours 
after exposure in females. Although it was not possible to quantitatively determine the absorption rate 
in female rats, the data from the male rats suggest that absorption was almost complete within 
12-24 hours of dosing in males. As seen in Section 2.2, female rats are more sensitive to the toxic 
effects of disulfoton than male rats; therefore, the females were given a lower dose. Nevertheless, it 
took longer for females to excrete 50% of the dose than males. Whether this sex difference is due to 
differences in absorption, metabolism, retention, excretion, or a combination of factors is not known. 
In another study, rats received [14C]-disulfoton at a single oral dose of 0.2 mg/kg or 1.0 mg/kg or 
repeated oral doses 0.2 mg/kg/day for 14 days (Lee et al. 1985). In the rats given a single dose of 
0.2 mg/kg, the respective percentages of administered radioactivity 72 hours later in females and males 
were: urine, 97.1% and 96.9%; feces, 1.1% and 1.4%; tissues, 0.1% in both sexes; carcass, 0.7% in 
both sexes; and cage rinses, 1.0% and 0.9%. In the rats given a single dose of 1.0 mg/kg, the 
respective percentages of administered radioactivity for females and males were: urine, 97.5% and 
96.9%; feces, 1.7% and 1.9%; tissues, 0.1% and 0%; carcass, 0.5% and 0.4%; and cage rinse, 0.2% 
and 0.8%. In the rats given 14 daily doses of 0.2 mg/kg/day, the respective percentages in females 
and males were: urine, 97.1% and 98%; feces, 0.5% and 0.7%; tissues, 0.1% and 0.3%; carcass, 0.9% 
and 0.5%; and cage rinse, 1.4% and 0.5%. Based on the percentages of administered radioactivity in 
the urine, ≥97% of the administered dose was absorbed from the gastrointestinal tract within 72 hours. 
At least 90% of the administered dose was excreted in the urine in the first 24 hours, indicating rapid 
absorption. In a preliminary experiment, in which rats were given a single oral dose of 0.2 mg/kg 
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radioactive disulfoton, urinary excretion was essentially complete within 48 hours, with 61-72% 
excreted in urine of females and 31-48% excreted in the urine of males in the first 4 hours. 
Gastrointestinal absorption of disulfoton was extensive following oral exposure of rats and guinea pigs, 
as evidenced by the small differences in the oral LD50 values versus the intraperitoneal LD50 values 
(Bombinski and DuBois 1958). However, the intraperitoneal LD50 values were slightly lower than the 
oral LD50 values, suggesting that gastrointestinal absorption is <100%. 
2.3.1.3 Dermal Exposure 
No studies were located regarding absorption in humans or animals after dermal exposure to 
disulfoton. However, data on lethality, other signs of toxicity, and acetylcholinesterase inhibition in 
animals after dermal exposure (see Section 2.2.3) suggest that disulfoton can be absorbed from the 
skin. 
2.3.2 Distribution 
2.3.2.1 Inhalation Exposure 
No studies were located regarding distribution in humans or animals after inhalation exposure to 
disulfoton. 
2.3.2.2 Oral Exposure 
No studies were located regarding distribution in humans after oral exposure to disulfoton. 
Analysis of tissues and blood for radioactivity at various time intervals after rats were dosed with 
[14C]-disulfoton (1.2 mg/kg for males, 0.2 mg/kg for females) showed that peak levels occurred 
6 hours after dosing (Puhl and Fredrickson 1975). The highest levels were found in the liver (peak 
was 3.6 mg/kg for males, 2.3 mg/kg for females). Peak levels in other tissues (kidney, plasma, fat, 
whole blood, skin, muscle, and brain in descending order) also generally occurred at 6 hours. At 
10 days after dosing, the levels of radioactivity in all tissues decreased; however, low levels were 
found in the heart at this sampling time. In Beagle dogs dosed with 0.5-l.5 mg/kg/day disulfoton in 
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capsules for 2 years, disulfoton was detected in the kidney (0.06 ppm), urine (0.06 ppm), liver 
(0.02 ppm), serum (0.04 ppm), brain and spinal cord (0.01-0.02 ppm) (Hikita et al. 1973). Disulfoton 
and its metabolites (unidentified) were also detected in small intestine, pancreas, bile, fatty tissue, 
thymus, spleen, erythrocytes, extraocular muscle, and muscles of the extremities and torso. 
2.3.2.3 Dermal Exposure 
No studies were located regarding distribution in humans or animals after dermal exposure to 
disulfoton. 
2.3.3 Metabolism 
Three different pathways are associated with the metabolism of disulfoton: (1) oxidation of the 
thioether sulfur to produce sulfoxides and sulfones; (2) oxidation of the thiono sulfur to produce the 
oxygen analogs; and (3) hydrolysis of the P-S-C linkage to produce the corresponding 
phosphorothionate or phosphate (WHO 1976) (see Figure 2-3). These pathways have been elucidated 
from data obtained in humans exposed to disulfoton and from in vivo and in vitro metabolism studies 
in rats and mice. 
The oxygen analog of disulfoton sulfoxide (demeton S-sulfoxide) and the oxygen analog of disulfoton 
sulfone (demeton S-sulfone) were identified in the urine from an 87-year-old man who accidentally 
drank an unknown amount of diluted disulfoton (Yashiki et al. 1990). Disulfoton sulfone and demeton 
S-sulfone were the only metabolites of disulfoton detected in the blood of this patient. The authors 
did not report whether they detected the products of disulfoton and/or sulfoxide/sulfone hydrolysis, 
diethyl phosphate (DEP), diethyl thiophosphate (DETP), and diethyl dithiophosphate (DEDPT) in the 
urine. From this case report, there is evidence of oxidation of the thioether and thiono sulfur, which 
produces sulfoxides or sulfones and oxygen analogs of disulfoton, respectively. Workers exposed 
mainly to disulfoton at a pesticide formulating plant had excreted the metabolites DEP, DETP, 
DEDPT, and diethyl phosphorothiolate (DEPTh) in urine after dermal and possibly inhalation exposure 
to disulfoton (Brokopp et al. 1981). 
Studies in rats and mice indicate that the same pathways operate in humans and rodents. Unidentified 
urinary metabolites in mice injected intraperitoneally with 32ρ-disulfoton were described as hydrolysis 
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products (March et al. 1957). The metabolites, disulfoton sulfoxide, disulfoton sulfone, demeton 
S-sulfoxide, and demeton S-sulfone were also identified as products of in vitro hepatic disulfoton 
metabolism. Disulfoton sulfoxide (11.3%), disulfoton sulfone (2.4%), demeton S-sulfoxide (26.7%), 
and demeton S-sulfone (59.6%) were also identified in the livers of rats 30 minutes after 
intraperitoneal injection with disulfoton (Bull 1965). Disulfoton sulfone was the only one of these 
metabolites not recovered from the liver 120 minutes after exposure. DEP and DETP, formed from 
the hydrolysis of disulfoton and/or its oxidation products, were identified as the major urinary 
metabolites in rats dosed orally or intraperitoneally in several studies (Bull 1965; Puhl and Fredrickson 
1975; Wolfe et al. 1978). The minor urinary metabolites included disulfoton sulfoxide, demeton 
S-sulfoxide, and demeton S-sulfone (Puhl and Fredrickson 1975). Although disulfoton sulfone was not 
detected in the urine in this study, it can be assumed that, subsequent to its formation, it was quickly 
oxidized to demeton S-sulfone or quickly hydrolyzed to DETP. Furthermore, in another study, 
disulfoton sulfone was found in the urine of rats after oral exposure to disulfoton (Lee et al. 1985). 
These findings are consistent with the pathways in Figure 2-3, whereby disulfoton metabolism 
proceeds via the sequential oxidation of thioether sulfur and/or oxidative desulfuration followed by 
hydrolysis of the ester. The data also suggest that a greater percentage of disulfoton sulfoxide is 
oxidized to demeton S-sulfoxide, rather than disulfoton sulfone, to form demeton S-sulfone (Bull 
1965). The relative importance of each of the pathways, however, cannot be deduced from relative 
percentages of metabolites formed because the final urinary metabolites are common products of 
several of the intermediate metabolites (see Figure 2-3). In addition, after a single dose of 0.2 mg/kg 
[14C]-disulfoton, disulfoton sulfone, demeton S-sulfone, and demeton S-sulfoxide were found in urine 
of males, while only demeton S-sulfone was apparent in the urine of females (Lee et al. 1985). 
However, after dosing with 0.2 mg/kg/day for 14 days, the pattern in males and females was reversed. 
This reversed pattern after repeated dosing was more likely due to metabolic rate differences than to a 
difference in pathway, since disulfoton sulfone and demeton S-sulfoxide are precursors to the demeton 
S-sulfone. 
The studies described above support the accepted theory (Eto 1974) that most thioether 
organophosphate insecticides, such as disulfoton, first undergo metabolic oxidation to sulfoxides, 
sulfones, and their respective oxygen analogs as part of the metabolic activation pathway. These 
active metabolites bind to ubiquitous cholinesterase and cause signs of disulfoton toxicity. In the 
detoxification pathway, these oxidation products and/or disulfoton subsequently undergo hydrolysis to 
more polar metabolites that are eliminated in the urine. Cytochrome P-450 monooxygenase and flavin 
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adenine dinucleotide (FAD) monooxygenase are thought to be involved in the metabolic activation 
pathways. 
Generally, organophosphates serve as substrates for the hepatic cytochrome P-450 mixed-function 
oxidase (MFO) system. The components of the MFO system include cytochrome P-450, the terminal 
oxidase, and NADPH, and NADPH-dependent cytochrome c reductase (Stevens and Green 1974). 
Generally, anticholinesterase insecticides such as disulfoton bind to oxidized cytochrome P-450 to 
form a disulfoton:cytochrome P-450 complex, which usually produces some form of a Type I spectra 
(Stevens et al. 1973). An electron is then transferred from cytochrome c reductase to cytochrome 
P-450 (Gillette et al. 1972), thereby reducing the disulfoton:cytochrome P-450 complex. Molecular 
oxygen then binds to this complex to form a disulfoton:reduced cytochrome P-450:02 complex (Gigon 
et al. 1969). A second electron from NADPH or reduced nicotinamide adenine dinucleotide (NADH) 
then reduces this complex to form an active oxygen intermediate that decomposes with the formation 
of the product and oxidized cytochrome P-450 (Hildebrandt and Estabrook 1971). 
Flavin monooxygenase specifically oxidizes sulfides to (R)-(+)-sulfoxide enantiomers, while 
cytochrome P-450-dependent oxidations yield predominantly sulfoxides in the (S)-(-) configuration 
(Light et al. 1982; Waxman et al. 1982). Disulfoton has three sulfur atoms that can be oxidized: the 
thiophosphoryl or thiono, the thiol, and the thioether. It has been proposed that flavin monooxygenase 
I cannot catalyze P=S to P=O conversions (Hajjar and Hodgson 1980). The flavin monooxygenase 
enzymes metabolize thioether-containing organophosphates to sulfoxides only; that is, there is no 
evidence for the formation of any other products such as disulfoton sulfones in the presence of only 
FAD monooxygenase (Hajjar and Hodgson 1980). Sequential oxidations by both monooxygenases 
(FAD-dependent and cytochrome P-450) may be required to form sulfones (Tynes and Hodgson 1985). 
Disulfoton interacted with cytochrome P-450 to markedly inhibit the metabolism of p-nitroanisole and 
parathion, both of which have rather high affinities for cytochrome P-450. These findings underscore 
the fact that cytochrome P-450 and flavin monooxygenase both have the potential to participate in the 
oxidation of the disulfoton. 
FAD-dependent monooxygenase, purified from pig liver microsomes oxidized disulfoton (Hajjar and 
Hodgson 1982). The product of this reaction was disulfoton sulfoxide. However, disulfoton sulfoxide 
was not a substrate for this enzyme, as disulfoton sulfone was not detected. Structure-activity 
relationships suggest that substitution by oxygen of either the thiono or thiol sulfur atoms decreases 
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the activity of FAD-dependent monooxygenase and thus the rate of sulfoxidation. In addition, changes 
in the thioether sulfur have a similar effect. Structural changes on the thioether moiety may increase 
steric hindrance of the sulfur atom, affect enzyme-substrate binding, and decrease the rate of 
sulfoxidation. Thus, disulfoton sulfones were not formed, and further oxidation of the sulfoxides to 
sulfones did not involve FAD-dependent monooxygenase, but rather another oxidase or nonenzymatic 
reaction. Sulfoxidation was not inhibited by n-octylamine, a known inhibitor of cytochrome P-450­
dependent oxygenation (Hajjar and Hodgson 1982). This finding further suggests that FAD-dependent 
monooxygenase may play a greater role than cytochrome P-450 monooxygenase in the oxygenation of 
thioether organophosphates. Compared to most other thioether compounds, it was concluded that 
disulfoton is among the best known flavin monooxygenase substrates (Poulsen 1981). Compared to 
most other organophosphate insecticides (parathion, diazinon, ethion, phorate, azinophosmethyl, methyl 
parathion, and ronnel), disulfoton was more rapidly metabolized in the hepatic microsomal oxidative 
system involving NADPH from rats, guinea pigs, and monkeys (Rao and McKinley 1969). 
The metabolism of disulfoton appears to be similar among similar species. For example, liver 
homogenates from rats, guinea pigs, and monkeys were generally more active in metabolizing 
disulfoton than liver homogenates from chickens (Rao and McKinley 1969). In addition, pig liver 
flavin monooxygenase was more saturable by disulfoton than the mouse liver enzyme (Tynes and 
Hodgson 1985). Flavin monooxygenase in pig liver also had a higher affinity (lower Km) than the 
mouse enzyme towards disulfoton (Smyser et al. 1985). Rat liver and lung microsomes have lower 
flavin monooxygenase activity towards disulfoton than liver or lung microsomes from the mouse or 
the rabbit (Tynes and Hodgson 1985). However, flavin monooxygenase activity was greater in rabbit 
and mouse lungs than in their respective livers. This disparity between lung and liver tissues was not 
observed in rats. 
2.3.4 Excretion 
2.3.4.1 Inhalation Exposure 
No studies were located regarding the rate or extent of excretion in humans or animals after inhalation 
exposure to disulfoton. 
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2.3.4.2 Oral Exposure 
No studies were located regarding the rate or extent of excretion in humans after oral exposure to 
disulfoton. 
Male rats given a single acute dose (1.2 mg/kg) of [14C]-disulfoton eliminated an average of 84.3%, 
6.1%, and 9.2% of the dose in the urine, feces, and expired air, respectively, in the 10 days following 
exposure (Puhl and Fredrickson 1975). Female rats given 0.2 mg/kg eliminated 78.9%, 7.8%, and 
9.2% of the administered radioactivity in the urine, feces, and expired air, respectively, in the same 
time period. Male rats excreted 50% of the administered dose in the urine during the first 4-6 hours 
after exposure, while females required 30-32 hours to excrete 50% of the dose in the urine. The 
female rats were given a lower dose than the males because female rats are more sensitive than male 
rats to the toxic effects of disulfoton (see Section 2.2). Nevertheless, it took longer for females to 
excrete 50% of the dose. Whether this sex difference is due to differences in absorption, metabolism, 
retention, excretion, or a combination of factors is not known. 
In another study, rats received [14C]-disulfoton at a single oral dose of 0.2 mg/kg or 1.0 mg/kg or 
repeated oral doses of 0.2 mg/kg/day for 14 days (Lee et al. 1985). In the rats given a single dose of 
0.2 mg/kg, the respective percentages of administered radioactivity 72 hours later in females and males 
were 97.1% and 96.9% in urine and 1.1% and 1.4% in feces. In the rats given a single dose of 
1.0 mg/kg, the respective percentages of administered radioactivity for females and males were 97.5% 
and 96.9% post-dosing in urine and 1.7% and 1.9% in feces. In the rats given 14 daily doses of 
0.2 mg/kg/day, the respective percentages in females and males were 97.1% and 98% in urine and 
0.5% and 0.7% in feces. Thus, the primary route of excretion in all dose groups was via the urine (at 
least 97% in each group), and excretion was essentially complete within 72 hours post-dosing, with at 
least 90% excreted in the first 24 hours. In a preliminary experiment in which rats were given a 
single oral dose of 0.2 mg/kg radioactive disulfoton, urinary excretion was essentially complete within 
48 hours, with 61-72% excreted in urine of females and 3148% excreted in the urine of males in the 
first 4 hours. Analysis of expired gases at 24-hour intervals for 144 hours post-dosing in the 
preliminary experiment indicated that only 0.5% and 0.2% of the radioactivity in females and males, 
respectively, was present in the expired air. 
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2.3.4.3 Dermal Exposure 
No studies were located regarding the rate or extent of excretion in humans or animals after dermal 
exposure to disulfoton. 
2.3.4.4 Other Routes of Exposure 
No studies were located regarding excretion in humans after other routes of exposure to disulfoton. 
White rats given a single dose of radiolabeled disulfoton intraperitoneally eliminated the metabolites 
phosphoric acid (4.1%), DEP (61.2%), and DETP (24.8%) in urine as a percentage of excretory 
metabolites lo-12 hours after exposure (Bull 1965). Approximately 24 and 48 hours after exposure 
14.1% and 28.6%, respectively, of the administered dose was excreted in the urine. Excretion rates for 
disulfoton and its metabolites were not determined. Mice eliminated 30-60% of the radiolabeled 
intraperitoneal dose of disulfoton in the urine and 2-3% in the feces within 96 hours of exposure 
(March et al. 1957). 
2.3.5 Mechanisms of Action 
Disulfoton is readily absorbed from the gastrointestinal tract (Hattori et al. 1982; Lee et al. 1985; Puhl 
and Fredrickson 1975; Yashiki et al. 1990). Although information regarding the rate and extent of 
absorption of disulfoton after inhalation and dermal exposure was not located, the lipophilic nature of 
disulfoton suggests that it is probably absorbed by passive diffusion by these routes as well. 
Although there are no known intermediary proteins or other mechanisms associated with distribution 
of disulfoton to effector organs or to organs where the compound is likely to be metabolized, binding 
studies with other organophosphates suggest that serum albumin may be an important protein involved 
with distribution to effector organs (Braeckman et al. 1983). Available data suggest that more 
disulfoton is distributed initially to the liver than to any other organ (Puhl and Fredrickson 1975). The 
detection of disulfoton metabolites in the liver of rats is consistent with this observation (Bull 1965). 
The active metabolites of disulfoton are known to depress the activity of serum, erythrocyte, and brain 
cholinesterase (see Section 2.2.2.4). 
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Metabolism of disulfoton in humans and animals appears to be qualitatively and quantitatively similar 
(Brokopp et al. 1981; Bull 1965; Puhl and Fredrickson 1975; Yashiki et al. 1990). The intermediary 
products of disulfoton metabolism, rather than disulfoton itself, are responsible for the signs of toxicity 
observed in humans and animals exposed to the pesticide. These metabolites (disulfoton sulfoxide, 
disulfoton sulfone) and the oxygen analogs (demeton S-sulfoxide and demeton S-sulfone) are oxidation 
products of disulfoton and are formed primarily in the liver (Bull 1965; March et al. 1957). In an oral 
study in rats, the metabolites, disulfoton sulfoxide, disulfoton sulfone, demeton S-sulfoxide, and 
demeton S-sulfone resulted in mortality and signs of toxicity at lower doses than did disulfoton 
(Crawford and Anderson 1974). 
No information was located regarding the mechanism of excretion of disulfoton and/or its metabolites. 
Because disulfoton and its active metabolites are relatively lipophilic, excretion by passive diffusion is 
the probable mechanism. 
The acute toxic effects of organophosphate insecticides are due primarily to accumulation of 
acetylcholine at muscarinic and nicotinic cholinergic receptors (Costa et al. 1982b). The accumulation 
of this substrate is due to the inhibition of cholinesterase activity by the active metabolites of the 
organophosphate (Murphy et al. 1984). In many instances, humans and animals exhibit signs of 
toxicity resembling excessive stimulation of cholinergic nerves. Atropine, a cholinergic blocking 
agent, has been used to demonstrate that excessive acetylcholine accumulation is related to the 
mechanism of toxicity (Bombinski and DuBois 1958). Cholinesterase enzyme kinetics provide further 
evidence supporting the proposed mechanism. Studies indicate that the enzyme-acetylcholine complex 
and the enzyme-organophosphate complex usually are formed at the same rate (Murphy et al. 1984). 
However, the enzyme-acetylcholine complex is hydrolyzed at a much faster rate than the enzyme-
organophosphate complex; the enzyme is therefore regenerated faster in the forrner case. 
Dephosphorylation of the enzyme is a slow reaction, and, therefore rate-limiting. 
Signs of disulfoton toxicity, such as muscle tremors, fasciculations, lacrimation, and salivation, in 
animals are generally observed after a few daily doses, but begin to diminish in severity as exposure to 
disulfoton continues (Bombinski and DuBois 1958). This phenomenon is known as tolerance. 
Tolerance appears to be a reproducible phenomenon that does not depend on the organophosphate 
insecticide used, the route of administration, or the animal species (Costa et al. 1982b). Several 
possible mechanisms have been proposed to explain this phenomenon. 
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Evidence suggests that tolerance involves the cholinergic system and not the opiate system (Costa and 
Murphy 1986). Tolerance to chronic treatment with disulfoton was once thought to be due to 
refractoriness of the cholinergic receptor to acetylcholine (Brodeur and DuBois 1964). More recently, 
tolerance has been associated more specifically with alterations of cholinergic receptor density, rather 
than with changes in binding affinity (Costa et al. 1981, 1982a, 1990; McDonald et al. 1988). 
Radiolabeled ligands, such as [3H] quinuclidinyl benzilate ([3H] QNB), which are muscarinic 
antagonists that can bind to recognition sites on muscarinic receptors, were used in these studies to 
demonstrate that disulfoton caused a reduced number of receptor binding sites in central and peripheral 
nerve tissue. However, the binding affinity was not changed in disulfoton-tolerant animals. 
Furthermore, the alteration in cholinergic muscarinic receptors was not due to direct binding of 
disulfoton and/or its metabolites to the receptor, but due to an adaptive mechanism to overstimulation 
by endogenous acetylcholine (Costa et al. 1981). Disulfoton also caused modulation of Ml and 
M2 muscarinic receptor subtypes in the brain of disulfoton-tolerant rats (Fitzgerald and Costa 1992). 
However, recovery of M2 muscarinic receptor binding after termination of exposure was slower 
compared to the Ml subtype, particularly in the hippocampus. Alteration of muscarinic binding sites 
in lymphocytes was also demonstrated (Costa et al. 1990; Fitzgerald and Costa 1993). The rate of 
recovery of cholinesterase is much slower than the rate of recovery of [3H] QNB binding in 
disulfoton- tolerant animals (Costa et al. 1981). McDonald et al. (1988) hypothesized that the 
decrease in muscarinic receptor densities in the hippocampus, cortex, and striatum of the brain was the 
reason for memory loss in animals that became tolerant to disulfoton after repeated intraperitoneal 
dosing (see Section 2.4). The data from earlier intraperitoneal behavioral studies are not consistent 
with this finding (Costa and Murphy 1982). However, these two studies measured different 
neurobehavioral end points in different species. In addition, this memory loss has not been reported in 
humans. While cholinergic muscarinic signs diminish in severity in disulfoton-tolerant animals, 
nicotinic cholinergic signs may persist (McPhillips 1969a). It was proposed that nicotinic receptors 
were stable, while muscarinic receptors were labile to acetylcholine accumulation in disulfoton-tolerant 
animals (Costa et al. 1982a). However, a decrease in nicotinic acetylcholine receptors in the brain was 
subsequently found after repeated administration of disulfoton in rats (Costa and Murphy 1983a). 
As supporting evidence for this mechanism (i.e., reduced density of muscarinic receptor binding sites), 
subsensitivity to other cholinergic agonists was demonstrated in disulfoton-tolerant animals. The 
mechanism for the subsensitivity to cholinergic agonists is probably related to changes in agonist 
binding as well as loss of surface receptor labeling by hydrophilic ligands such as 
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N-methylscopolamine (Costa et al. 1982b; Schwab et al. 1983). Animals made tolerant to disulfoton 
were resistant to the lethal or adverse effects of cholinergic agonists, such as carbachol (Brodeur and 
DuBois 1964; Costa et al. 1981; Schwab and Murphy 1981) and oxotremorine (Costa et al. 1982b; 
McPhillips 1969a), which are not hydrolyzed by acetylcholinesterase. Tissues from animals tolerant to 
disulfoton such as the ilea (Foley and McPhillips 1973; McPhillips 1969b; McPhillips and Dar 1967) 
and the atria (Perrine and McPhillips 1970; Schwab et al. 1983), were resistant to the effects of 
carbachol and/or oxotremorine. Because the uterus and vas deferens have a relatively sparse 
parasympathetic innervation compared to the ileum and do not receive a steady flow of impulses via 
this system, these tissues were not as subsensitive to carbachol as the ileum (Foley and McPhillips 
1973). Thus, acetylcholine accumulation may be a prerequisite for tolerance development. 
Other hypotheses have been tested in attempts to explain the mechanism of tolerance. Tolerance may 
be associated with interference of acetylcholine synthesis at the presynaptic junction (Costa et al. 
1982b). However, no difference in the uptake of choline occurred in the hippocampus from 
disulfoton-tolerant mice compared with controls, suggesting that the availability of choline was not 
limiting. Noncholinergic mechanisms may also be involved in the development of tolerance. In one 
study, the atria from disulfoton-tolerant rats were subsensitive to carbachol and oxotremorine, but there 
was no alteration in binding of [3H] QNB when compared with the controls (Schwab et al. 1983). 
This finding is inconsistent with the “altered receptor” hypothesis that suggests tolerance is associated 
with a decrease in radioligand binding and a concomitant subsensitivity to cholinergic agonists. The 
authors proposed that in addition to receptor loss, other mechanisms distal to [3H] QNB binding sites 
or removed from the receptor complex may contribute to the subsensitivity of the atria and other 
tissues to cholinergic agonist. These and other related mechanisms remain to be studied. 
2.4 RELEVANCE TO PUBLIC HEALTH 
The lipophilic properties of disulfoton suggest that the compound is likely to be absorbed readily by 
the lungs, gastrointestinal tract, and the skin. Toxicokinetic data in humans and animals show that 
disulfoton is readily and extensively absorbed by the gastrointestinal tract. Disulfoton and/or its 
metabolites are distributed rapidly to tissues such as the liver, kidney, brain, and adipose tissue. 
Although the compound is relatively lipophilic, its accumulation in these organs does not appear to be 
appreciable. Fifty to ninety percent of the dose administered to rats was eliminated in the urine within 
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4-32 hours. Disulfoton is rapidly metabolized to its oxygen analogs, which are in turn rapidly 
detoxified to water soluble nontoxic metabolites that are eliminated via the urine. 
The most significant and sensitive effects resulting from acute, intermediate, or chronic exposure to 
disulfoton by the inhalation, oral, or dermal route are neurological. The neurological effects are the 
result of inhibition of acetylcholinesterase by active metabolites of disulfoton at nerve synapses; 
subsequent accumulation of acetylcholine results in overstimulation of the distal neuron, and more 
specifically, in cholinergic effects. Examples of cholinergic effects include salivation, miosis, muscle 
tremors, and urinary and fecal incontinence. Convulsions, coma, and death have been associated with 
severe disulfoton intoxication. Studies in chickens indicated that disulfoton does not cause delayed 
neurotoxicity. Body weight loss is also a common finding in animals and is associated with 
cholinesterase inhibition. In addition, disulfoton may alter catecholamine levels in body tissues. The 
effects on catecholamine levels appear to be related to the accumulation of acetylcholine. Optic nerve 
atrophy and necrosis have also been associated with chronic oral exposure to disulfoton in dogs. 
The inhibition of erythrocyte acetylcholinesterase is a very sensitive biomarker of this 
acetylcholinesterase inhibition at the nerve synapses, and, therefore, can be regarded as a sensitive 
effect as well. Some of these effects have been observed in occupationally exposed individuals and in 
a man who accidentally ingested disulfoton. Results from several animal studies support these 
findings. The cholinergic effects are usually associated with acute exposure to disulfoton. Prolonged 
exposure to disulfoton (5-10 days) generally results in a decrease in the severity of the cholinergic 
toxicity, while cholinesterase remains inhibited. This phenomenon, known as tolerance, has been 
observed in animals exposed to disulfoton for prolonged periods. A number of studies have 
investigated the mechanism of tolerance development. 
Hepatic effects have not been observed in humans, but mild hepatic effects were observed in animals 
after oral exposure to disulfoton. These hepatic effects include alterations in liver microsomal enzyme 
activities and lipid peroxidation. No concurrent histopathological changes in the liver were observed. 
Although hepatic effects should be of little concern to exposed humans, caution is advised with 
concomitant use of prescription or nonprescription drugs that share a common metabolic pathway with 
disulfoton. Results from oral studies suggest that disulfoton may cause myopia in animals and 
possibly humans. In one chronic dietary study in rats, effects on eyes (degeneration of the Harderian 
gland and cornea1 neovascularization), lungs (inflammation), stomach (mucosal hyperplasia and 
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inflammation of the forestomach), skeletal muscle (atrophy due to debilitation), pancreas (atrophy), ant 
spleen and lymph nodes were seen in some rats, mostly at the highest doses, but the most sensitive 
effects were associated with cholinesterase inhibition. Other than the cholinergic effects, none of the 
effects were seen in mice or dogs given chronic oral doses, and their relevance to humans are 
unknown. Other effects observed in rats exposed to disulfoton by the inhalation route include 
inflammation of the nasal turbinates and bone marrow changes, which were related to decreased 
lymphocytes and inflammatory changes in the lungs. 
No data were located regarding reproductive or developmental effects in humans. However, disulfoton 
has caused lower pregnancy rates and reduced litter sizes in animals after oral exposure for 
intermediate durations. Fetotoxic effects, such as increased incidences of incomplete ossification of 
parietal bones and stemebrae, have been reported in the fetuses of rat dams exposed orally during 
gestation. In addition, depression of fetal brain and erythrocyte cholinesterase, fatty infiltration of the 
liver, mild nephropathy, and juvenile hypoplasia of the testes occurred in litters of rats exposed orally 
in multiple-generation reproductive studies. Although placental transfer of disulfoton and/or its active 
metabolites appears to occur, no data were located regarding transfer via the dam’s milk. 
Disulfoton has been tested for genotoxicity in a variety of assays with mostly negative results; 
however, the few positive results indicate genotoxic potential. Carcinogenicity was not observed in 
Beagle dogs, rats, or mice fed disulfoton for 2 years. 
Employees at hazardous waste sites, employees at pesticide mixing and formulating plants, and farm 
workers are more likely to be exposed to disulfoton than individuals in other occupations. Neurotoxic 
effects have been observed in occupationally exposed persons. However, no human data were located 
to identify susceptible subpopulations. Animal data suggest that female animals and young animals 
are more susceptible to disulfoton toxicosis. Based on the results from animal studies, women and 
children could also be more susceptible than men to toxic effects of disulfoton. 
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Minimal Risk Levels for Disulfoton 
Inhalation MRLs 
•	 An MRL of 0.006 mg/ m3 has been derived for acute-duration inhalation exposure (14 days or
  less) to disulfoton. 
The MRL is based on a NOAEL of 0.5 mg/ m3 for decreased acetylcholinesterase activity in rats 
exposed to disulfoton 4 hours/day for 5 days in a study by Thyssen (1978). The NOAEL was adjusted 
for intermittent exposure, converted to a human equivalent concentration, and divided by an 
uncertainty factor of 30 (3 for extrapolation from animals to humans and 10 for human variability). 
Inhibition of erythrocyte cholinesterase activity and unspecified behavioral disorders were observed at 
1.8 mg/ m3, and unspecified signs of cholinergic toxicity were observed at 9.8 mg/ m3. Similar effects 
were observed in rats or mice exposed to higher concentrations for shorter durations (Doull 1957; 
Thyssen 1978). The NOAEL value of 0.5 mg/ m3 is supported by another study, in which no 
significant decrease in the activity of brain, serum, or submaxillary gland cholinesterase was found in 
rats exposed to 0.14-0.7 mg/ m3 for 1 hour/day for 5-10 days (DuBois and Kinoshita 1971). Mild 
depression of erythrocyte cholinesterase activity was reported in workers exposed by the inhalation and 
dermal routes (Wolfe et al. 1978). 
•	 An MRL of 2x10-4 mg/ m3 has been derived for intermediate-duration inhalation exposure
 (15-364 days) to disulfoton. 
The intermediate MRL is based on a NOAEL of 0.02 mg/ m3 for decreased acetylcholinesterase 
activity in rats exposed to disulfoton 6 hours/day, 5 days/week for 3 weeks in a study by Thyssen 
(1980). The NOAEL was adjusted for intermittent exposure, converted to a human equivalent 
concentration, and divided by an uncertainty factor of 30 (3 for extrapolation from animals to humans 
and 10 for human variability). In the Thyssen (1980) study, 2 separate 3-week experiments were 
conducted. In the first experiment, rats exposed to 0.1, 0.5, or 3.7 mg/ m3 showed concentrationrelated 
increased severity of cholinesterase inhibition and cholinergic signs of toxicity, with the lowest 
exposure level of 0.1 mg/ m3 associated with lethargy during the last week of exposure. At 0.5 mg/ m3, 
lethargy and failure to groom were observed during the second and third weeks; and at 3.7 mg/ m3, 
muscle tremors, convulsions, inhibition of brain cholinesterase, and death were observed. Because a 
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NOAEL could not be established in the first experiment, the second experiment used an exposure level 
of 0.02 mg/m3, which resulted in no inhibition of cholinesterase activity or signs of cholinergic 
toxicity, and an exposure level of 3.1 mg/ m3 to confirm the effects seen at 3.7 mg/ m3 in the first 
experiment. In a 13-week inhalation study, inhibition of erythrocyte and brain cholinesterase activity 
was observed in rats exposed to 1.4 mg/ m3, but not 0.16 mg/ m3, disulfoton 6 hours/day, 5 days/week 
(Shiotsuka 1989). Other effects of intermediate-inhalation exposure of rats to disulfoton include 
inflammatory changes in the respiratory tract associated with bone marrow changes at 20.5 mg/ m3 and 
decreased percentages of lymphocytes with increased polymorphonuclear leukocytes at 3.1 mg/ m3, 
increased absolute and relative adrenal weight at 3.1 and 3.7 mg/ m3 (Thyssen 1980), and increased 
incidence of inflammation of the nasal turbinates at 1.4 mg/ m3 (Shiotsuka 1989). 
An MRL has not been derived for chronic-duration inhalation exposure to disulfoton because no 
chronic-duration inhalation studies were located. 
Oral MRLs 
•	 An MRL of 0.001 mg/kg/day has been derived for acute-duration oral exposure (14 days or less) 
to disulfoton. 
The MRL was based on a NOAEL of 0.1 mg/kg/day for decreased cholinesterase activity in rats 
treated with disulfoton by gavage on gestation days 6-15 (Lamb and Hixson 1983). Erythrocyte and 
plasma cholinesterase activities were significantly inhibited at 0.3 mg/kg/day. Numerous acute oral 
studies in rats and mice have found significantly depressed brain or other tissue cholinesterase 
activities (Costa and Murphy 1983a; Costa et al. 1984, 1986; Schwab and Murphy 1981; Schwab et al. 
1981, 1983; Su et al. 1971). Most of these studies used higher doses than those in the Lamb and 
Hixson (1983) study. However, a 50% inhibition of brain cholinesterase activity was found in rats 
exposed to disulfoton in the diet at 0.26 mg/kg/day for 1 week (Su et al. 1971), which supports the 
LOAEL of 0.3 mg/kg/day in the Lamb and Hixson (1983) study. In an extensive acute oral 
neurotoxicity study in rats, a NOAEL of 0.24 mg/kg for erythrocyte cholinesterase activity was found 
(Sheets 1993a); however this NOAEL value is essentially the same as the LOAEL values of 
0.26 mg/kg/day in the Su et al. (1971) study and 0.3 mg/kg/day in the Lamb and Hixson (1983) study. 
Other effects of disulfoton in acute oral studies include depression of body weight gain (Schwab and 
Murphy 1981; Schwab et al. 1981, 1983), interference with catecholamine levels in body tissues 
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(Brzezinski 1969; Brzezinski and Ludwicki 1973; Brzezinski and Rusiecki 1970; Wysocka-
Paruszewska 1970, 1971, 1972), and lipid peroxidation in the liver (Fawade and Pawar 1978, 1980, 
1983). None of these effects occurred at doses lower than the acute oral NOAEL of 0.1 mg/kg/day for 
neurological effects. Furthermore, the NOAEL is an order of magnitude lower than the dose 
(1 mg/kg/day) associated with delayed ossification in fetal rats (Lamb and Hixson 1983). 
•	 An MRL of 9x10-5 mg/kg/day has been derived for intermediate-duration oral exposure 
(15-364 days) to disulfoton. 
The MRL was based on a NOAEL of 0.009 mg/kg/day for decreased brain cholinesterase activity in 
F1a pups in a multigeneration feeding study in rats by Hixson and Hathaway (1986). At the LOAEL 
of 0.03 mg/kg/day, the brain cholinesterase activity was inhibited 24-32% in the F1a pups and litter 
counts and litter weights were decreased in F2b litters. At 0.09 mg/kg/day, effects included tremors in 
the F0 females during the production of the F1 generation, decreased reproductive performance, 
decreased maternal F0 and F1 weight during gestation and lactation, decreased litter counts and 
viability and lactation indices, and increased dead births and percentage dead births. Numerous 
intermediate-duration oral studies in rats, mice, and dogs have found significantly depressed brain or 
other tissue cholinesterase activities (Clark and Pearson 1973; Doull and Vaughn 1958; Hayes 1985; 
Hoffman et al. 1975; Klotzsche 1972; Rivett et al. 1972; Robinson et al. 1978; Ryan et al. 1970; 
Schwab and Murphy 1981; Sheets 1993b; Stavinoha et al. 1969; Vaughn et al. 1958). All of these 
studies reported cholinesterase inhibition at higher doses than those in the Hixson and Hathaway 
(1986) study. In addition, other intermediate-duration oral developmental and reproductive studies in 
animals reported depression of brain or erythrocyte cholinesterase activity in the offspring of rats and 
reduced litter sizes or failure to produce litters at doses ≥0.1 mg/kg/day (Ryan et al. 1970; Taylor 
1965a). In addition, cloudy swelling or fatty livers, mild nephropathy, and juvenile hypoplasia of the 
testes occurred in F3 litters (Taylor 1965a). 
•	 An MRL of 6x10-5mg/kg/day has been derived for chronic-duration oral exposure (≥365 days) 
to disulfoton. 
The MRL is based on a LOAEL of 0.06 mg/kg/day for acetylcholinesterase inhibition in rats exposed 
to disulfoton in the diet for 2 years in a study by Hayes (1985) using an uncertainty factor of 
1,000 (10 for use of a LOAEL, 10 for extrapolation from animals to human, and 10 for human 
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variability). The chronic-duration oral studies have found inhibition of brain, erythrocyte, and plasma 
cholinesterase in rats given ≥0.06 mg/kg/day, but not ≤0.05 mg/kg/day, disulfoton in the diet for 
1.5-2 years (Carpy et al. 1975; Hayes 1985) and in mice given 2.13 mg/kg/day (males) and 
2.53 mg/kg/day (females), but not ≤0.5 mg/kg/day, disulfoton for 23 months (Hayes 1983). Dogs 
treated with 0.5 mg/kg/day disulfoton in capsules (Uga et al. 1977) and rats given ≥0.18 mg/kg/day in 
the diet (Hayes 1985) for 2 years had optic nerve degeneration. Systemic effects of disulfoton in 
chronic oral studies were ocular effects (degeneration of ciliary muscles cells, myopia, and 
astigmatism) in dogs at 0.63 mg/kg/day (Ishikawa and Miyata 1980) and cystic degeneration of the 
Harderian gland at 0.21 mg/kg/day and cornea1 neovascularization at 0.75 mg/kg/day in rats (Hayes 
1985). In addition, rats given disulfoton in the diet for 2 years had granulomatous and suppurative 
inflammation of the lungs, pancreatic atrophy, dermal lesions, decreased body weight gain, and plasma 
cell hyperplasia in the mandibular lymph nodes at ≥0.75 mg/kg/day, and mucosal hyperplasia and 
chronic inflammation of the forestomach and splenic lymphoid follicle depletion at 1.02 mg/kg/day. 
In a a-year feeding study in dogs, erythrocyte and plasma cholinesterase activities were significantly 
inhibited at a time-weighted-average dose of 0.14 mg/kg/day, but not at 0.03 mg/kg/day (Hoffman et 
al. 1975). Although NOABL values of 0.03 mg/kg/day in dogs (Hoffman et al. 1975) and of 
0.05 mg/kg/day in rats (Carpy et al. 1975; Hayes 1985) were found, the NOAEL values would result 
in MRLs higher than the intermediate-duration oral MRL. Thus, the chronic-duration oral MRL of 
6x10-5 mg/kg/day was based on the LOAEL value of 0.06 mg/kg/day in female rats in the study by 
Hayes (1985), using an uncertainty factor of 1,000. 
The chronic-duration oral MRL for disulfoton is 6x10-5  mg/kg/day, and the EPA chronic oral RfD is 
4x10-5  mg/kg/day (IRIS 1994). Both of these values are based on the same study (Hayes 1985) and 
the identical end point. Even though the MRL and the RfD are essentially the same, they have minor 
differences due to the manner in which the exposure doses were calculated. The LOAEL of 
0.04 mg/kg/day used by EPA was calculated by multiplying the analytical dietary concentration of 
0.8 ppm (nominal concentration of 1 ppm) by the reference rat food consumption factor of 0.05. 
However, Hayes (1985) provided an equivalent dose of 0.08 mg/kg/day for the nominal concentration 
of 1 ppm, based on actual food consumption and body weight data. The LOAEL of 0.06 mg/kg/day 
used in deriving the chronic oral MRL was obtained by multiplying the 0.08 mg/kg/day dose, 
corresponding to the nominal concentration of 1 ppm, by the analytical concentration of 0.8 ppm. 
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Death. No studies were located regarding death in humans after inhalation or dermal exposure to 
disulfoton. One case report of human death after acute oral exposure to disulfoton was found (Hattori 
et al. 1982). Because an unknown amount was ingested, the lethal dose was not determined. Autopsy 
results suggested that death may have been due to asphyxia resulting from respiratory failure. 
Pulmonary edema is associated with disulfoton-induced overstimulation of secretory glands and 
bronchial secretions in the respiratory tract. 
High mortality was found at 202.2 mg/ m3 in male Sprague-Dawley rats (Doull 1957), at 180.1 mg/ m3 
in male Holtzman rats and 87.6 mg/ m3 in female Holtzman rats (DuBois 1971), and at 53.4 mg/ m3 in 
female mice (Doull 1957) after l-hour exposures; and in female Wistar rats, but not males, at 
intermittent exposures ≥3.1 mg/ m3 for 3-15 exposures (Thyssen 1980). LC50 values reported for 
Wistar rats were 290 mg/ m3 in males and 63 mg/ m3 for females exposed for 1 hour, and 60 mg/ m3 for 
males and 15 mg/ m3 for females exposed for 4 hours (Thyssen 1978). Thus, strain-, sex-, and species-
related differences in the inhalation lethality of disulfoton exist. Acute oral LD50 values for rats and 
mice also suggest that female rats and mice are more sensitive to disulfoton (1.9-8.2 mg/kg) than male 
rats and mice (5.8-19.3 mg/kg) (Bombinski and DuBois 1958; Crawford and Anderson 1974; Gaines 
1969; Mihail 1978; Pawar and Fawade 1978; Stevens et al. 1972a) and that rats are generally more 
sensitive than mice to disulfoton. However, female guinea pigs appear to be less sensitive than male 
guinea pigs (LD50 of 12.7 mg/kg for females and 8.9 mg/kg for males) (Crawford and Anderson 1973). 
Acute dermal LD50 studies (Gaines 1969; Mihail 1978), and acute intraperitoneal LD50 studies 
(Bombinski and DuBois 1958) also indicate that female rats are more sensitive than male rats and that 
young animals are more sensitive than adult animals. The acute dermal LD50 in rats ranges from 
3.6 to 187 mg/kg, depending on the formulation (Weil et al. 1971). Acute dermal exposure resulted in 
deaths in rabbits at doses of 6.5-10 mg/kg/day (Flucke 1986). In most of these studies, the cause of 
death was not reported, but may have been due to the cholinergic effects and hypoxia resulting from 
bronchoconstriction, excessive respiratory secretions, and erratic, slowed heart rate. 
Although the dose levels of disulfoton that would cause death in humans are not known, disulfoton 
levels in the workplace, in the ambient environment, in drinking water, or at hazardous waste sites are 
probably not high enough to cause death. 
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Systemic Effects. 
Respiratory Effects. Information on respiratory effects due to exposure to disulfoton is very limited. 
Exposure to disulfoton causes overstimulation of the muscarinic cholinergic receptors in the respiratory 
tract (Murphy 1986). This usually results in excessive bronchial secretions, bronchoconstriction, and 
eventually respiratory failure. Pulmonary edema and hemoptysis were recognized as probable causes 
of death in a man who ingested an unknown amount of disulfoton (Hattori et al. 1982). Studies 
regarding inhalation exposure were concerned primarily with lethality or cholinesterase inhibition. 
However, in intermediate-duration inhalation studies in rats, inflammation of the nasal turbinates at 
1.4 mg/ m3 (Shiotsuka 1989) and inflammatory changes throughout the respiratory tracts, possibly 
related to bone marrow changes, at 0.5 mg/ m3 (Thyssen 1980) were observed. Breathing difficulties 
were observed in rats given a single gavage dose of 1.0 mg/kg, mice given a single gavage dose of 
5.0 mg/kg, and rats given single dermal applications of disulfoton (Mihail 1978). In a chronic dietary 
study in rats, granulotamous and suppurative inflammation of the lungs occurred at the highest dietary 
concentration, but may have been due to aspiration of food particles, since the high dose rats showed 
considerable debilitation (Hayes 1885). However, no histopathological lesions were found in the lungs 
of rats (Klotzsche 1972) or mice (Rivett et al. 1972) exposed to disulfoton in the diet for intermediate 
durations, or in mice (Hayes 1983) or dogs (Hoffman et al. 1975) exposed in the diet for up to 
2 years. The likelihood that respiratory effects would occur in humans exposed to disulfoton in the 
ambient environment or at hazardous waste sites is negligible. 
Cardiovascular Effects. Exposure to disulfoton may cause acetylcholine-mediated overstimulation of 
muscarinic receptors in the heart, which can result in bradycardia progressing to fatal heart block 
(Murphy 1986). However, no studies were located regarding cardiovascular effects in humans after 
inhalation, oral, or dermal exposure to disulfoton. No histopathological lesions were found in the 
hearts of rats exposed by the inhalation route for intermediate durations (Shiotsuka 1989; Thyssen 
1980), in rats (Klotzsche 1972) or mice (Rivett et al. 1972) exposed in the diet for intermediate 
durations, in rats (Carpy et al. 1975; Hayes 1985), mice (Hayes 1983), or dogs (Hoffman et al. 1975) 
exposed in the diet for chronic durations, or in rabbits exposed dermally for intermediate duration 
(Flucke 1986). However, acute dermal exposure to unspecified doses of organophosphorus 
insecticides, including disulfoton, reportedly caused protein degeneration and significant circulatory 
disruptions in heart muscles of rats, cats, and rabbits (Kundiev and Rappoport 1967). As discussed in 
Section 2.2.3, this study is limited by reporting deficiencies. No changes in blood pressure or heart 
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rate were found in rats injected intraperitoneally with disulfoton for ≤30 days (McPhillips and Dar 
1967; Perrine and McPhillips 1970). This information is too limited, however, to allow any analysis 
of the likelihood of cardiovascular effects occurring in humans exposed to disulfoton in any scenario. 
Gastrointestinal Effects. No studies were located regarding gastrointestinal effects in humans after 
exposure to disulfoton. Necropsy of rats that died after intermittent inhalation exposure to 3.7 mg/ m3 
for 3 weeks revealed bloated gastrointestinal tracts and ulcer-like foci in the glandular mucosa of the 
forestomach (Thyssen 1980). Mucosal hyperplasia and chronic inflammation of the forestomach was 
found in rats given 1.04 mg/kg/day disulfoton in the diet for 2 years (Hayes 1985). However, no 
histopathological lesions were found in the gastrointestinal tracts of rats exposed intermittently by 
inhalation to 3.1 mg/ m3 for 3 weeks (Thyssen 1980) or 1.4 mg/ m3 for 13 weeks (Shiotsuka 1989), in 
rats exposed to 0.55 mg/kg/day (Klotzsche 1972) or mice exposed to 0.71 mg/kg/day (Rivett et al. 
1972) in the diet for 90 days, in rats exposed to ≤0.75 mg/kg/day (Carpy et al. 1975; Hayes 1985), 
mice exposed to 2.53 mg/kg/day (Hayes 1983), or dogs exposed to 0.14 mg/kg/day (Hoffman et al. 
1975) in the diet for 2 years, or in rabbits treated dermally with 1.6 mg/kg/day for 3 weeks (Flucke 
1986). The likelihood that gastrointestinal effects would occur in humans exposed to disulfoton in the 
ambient environment or at hazardous waste sites is negligible. 
Hematological Effects. No studies were located regarding hematological effects in humans after 
exposure to disulfoton. Rats exposed intermittently for 3 weeks to 3.1 mg/ m3, but not 3.7 mg/ m3, had 
decreased percentages of lymphocytes and increased percentages of polymorphonuclear leukocytes, 
which represented an early response to the bone marrow changes (see Immunological and 
Lymphoreticular Effects below) (Thyssen 1980). No hematological effects were found in rats exposed 
by inhalation to lower concentrations for 13 weeks (Shiotsuka 1989); in 90-day dietary studies in rats 
(Klotzsche 1972) and mice (Rivett et al. 1972); in the 2-year dietary studies in rats (Carpy et al. 1975; 
Hayes 1985), mice (Hayes (1983), or dogs (Hoffman et al. 1975); or in the 3-week dermal study in 
rabbits (Flucke 1986). The results of the animal studies indicate that the potential for hematological 
effects is not a concern for humans exposed to disulfoton. 
Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans after 
exposure to disulfoton. Disulfoton injected intraperitoneally in rats for 10 days had no effect on the 
contractile mechanism of smooth muscle of the ileum (McPhillips 1969b). No histopathological 
muscular or skeletal lesions were found in rats dosed once by gavage with disulfoton (Sheets 1993a), 
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rats (Klotzsche 1972) or mice (Rivett et al. 1972) exposed to disulfoton in the diet for 90 days, or in 
rats (Carpy et al. 1975), mice (Hayes 1983), or dogs (Hoffman et al. 1975) exposed in the diet for up 
to 2 years. However, female rats exposed to the highest dietary concentrations of disulfoton for 
2 years had skeletal muscle atrophy, which was probably related to the general debilitation of these 
rats (Hayes 1985). Degenerative changes in the ciliary muscle cells of the eye were observed in dogs 
exposed orally to disulfoton for 2 years (Ishikawa and Miyata 1980; Suzuki and Ishikawa 1974). 
These histopathological changes in the muscle were thought to be associated with myopia, also 
observed in the dogs (see Ocular Effects below). Since high incidences of myopia found in children 
corresponded with an increased use of disulfoton in combination with other organophosphates to treat 
food crops (Ishikawa and Miyata 1980), the possibility that degeneration of ciliary muscle cells occurs 
in humans exposed to disulfoton cannot be ruled out. 
Hepatic Effects. No studies were located regarding hepatic effects in humans after exposure to 
disulfoton. No hepatic effects were found in rats exposed by inhalation (Shiotsuka 1989; Thyssen 
1980) or dermally (Flucke 1986) to disulfoton for intermediate durations. However, acute dermal 
exposure to unspecified doses of organophosphorus insecticides, including disulfoton, reportedly 
caused protein degeneration and significant circulatory disruptions in the liver of rats, cats, and rabbits 
(Kundiev and Rappoport 1967). As discussed in Section 2.2.3, this study is limited by reporting 
deficiencies. Acute oral exposure of animals to disulfoton has resulted in alterations in hepatic 
microsomal enzymes (Fawade and Pawar 1978, 1980, 1983; Stevens et al. 1972b, 1973). Although 
inhibition or induction of hepatic microsomal enzymes by disulfoton in the absence of liver pathology 
is not an adverse effect, animal studies have demonstrated that disulfoton-pretreated animals are more 
susceptible to the toxic effects of several drugs and anesthetics (see Section 2.6). In addition, lipid 
peroxidation was also observed in animals after oral exposure to disulfoton (Fawade and Pawar 1978). 
Fatty infiltration of the liver was observed in F3b offspring in a three-generation oral study (Taylor 
1965a). Although no histopathological changes were observed, increased liver weights were observed 
in female mice exposed orally for intermediate durations (Rivett et al. 1972) and in male rats exposed 
orally for chronic durations (Carpy et al. 1975). The increased liver weight may be associated with 
liver enzyme induction. However, an unexplained decrease in liver weights was observed in female 
rats (Carpy et al. 1975). Clinical chemistry and histological examination revealed no hepatic effects in 
rats (Carpy et al. 1975; Hayes 1985), dogs (Hoffman et al. 1975), or mice (Hayes 1983) exposed to 
disulfoton in the diet for up to 2 years. In an intraperitoneal study, injection of rats, but not mice, 
rabbits, or guinea pigs, resulted in a dose-related increase in serum β-glucuronidase activity at 
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≥2 mg/kg, but no histopathological lesions in the liver (Kikuchi et al. 1981). In another intraperitoneal 
study, injection of rats with 1 mg/kg/day for 10 days resulted in cytoplasmic RNA in much smaller 
clumps in the periportal and centrilobular areas of the liver than in control rats (Clark and Stavinoha 
1969). The results from these animal studies indicate that hepatic effects in humans exposed to 
disulfoton would be mild, if they occurred. 
Renal Effects. Glomerular swelling was among the postmortem changes observed in a man who died 
after he drank an unknown amount of disulfoton (Hattori et al. 1982). However, most organs were 
congested at autopsy, suggesting that the renal pathology was one of the sequelae of death. 
Inconclusive evidence that disulfoton causes renal effects was found in animals. In one study, kidney 
weights of male rats increased while kidney weights of female rats decreased during a 2-year feeding 
study (Carpy et al. 1975). The toxicological significance of these opposite trends is not clear. 
Urinalysis and histological examination of kidneys from animals exposed to disulfoton in the diet for 
intermediate (Klotzsche 1972; Rivett et al. 1972) and chronic durations (Carpy et al. 1975; Hayes 
1983, 1985; Hoffman et al. 1975), by inhalation for intermediate durations (Shiotsuka 1989; Thyssen 
1980), or dermally for intermediate duration (Flucke 1986) revealed no renal effects. However, acute 
dermal exposure to unspecified doses of organophosphorus insecticides, including disulfoton, 
reportedly caused protein degeneration and significant circulatory disruptions in the kidneys of rats, 
cats, and rabbits (Kundiev and Rappoport 1967). As discussed in Section 2.2.3, this study is limited 
by reporting deficiencies. These animal studies suggest that the potential for renal effects is not a 
concern for humans exposed to disulfoton. 
Endocrine Effects. No studies were located regarding endocrine effects in humans after exposure to 
disulfoton. No histopathological evidence of lesions in endocrine organs, such as adrenals, thyroids, 
pituitary, and pancreas, were found in animals exposed dermally (Flucke 1986) or by inhalation 
(Shiotsuka 1989; Thyssen 1980); however, female rats exposed to 3.1 and 3.7 mg/ m3 in two separate 
intermediate-duration inhalation experiments had significantly increased absolute and relative adrenal 
weights (Thyssen 1980). Since the increase in adrenal weights was consistently observed in both 
experiments, it was considered to be related to disulfoton exposure. Oral and intraperitoneal exposure 
of animals to disulfoton has also resulted in increased urinary or plasma levels of adrenaline or 
noradrenaline or their metabolites, accompanied by decreases in adrenaline in the adrenal glands 
(Brzezinski 1969, 1972, 1973; Brzezinski and Ludwicki 1973; Brzezinski and Rusiecki 1970; 
Wysocka-Pamszewska 1970, 1971), indicating interference with catecholamine levels in body tissues. 
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These effects may be related to elevated acetylcholine levels, which may cause a release of 
catecholamines from the stores in the adrenals. Various scenarios involving human exposure to 
disulfoton might result in an increase in the amount of adrenaline released from the adrenals. 
Histological examination of endocrine tissues in animals exposed orally to disulfoton for intermediate 
(Klotzsche 1972; Rivett et al. 1972) or chronic durations (Carpy et al. 1975; Hayes 1983, 1985; 
Hoffman et al. 1975) has generally shown no treatment-related lesions. However, male rats exposed 
chronically to the high dietary concentration had pancreatic atrophy (Hayes 1985). Increased pituitary 
weight in male rats and decreased pituitary weight in female rats were reported in another chronic 
feeding study (Carpy et al. 1975). The toxicological significance of these findings is unknown. 
Dermal Effects. No studies were located regarding dermal effects in humans after exposure to 
disulfoton. Dermal lesions consisting of acanthosis, hyperkeratosis, ulceration of the skin, exudate 
formation, and epithelial inclusion cysts were found in male and female rats exposed chronically to the 
high dietary concentration of disulfoton (Hayes 1985). However, in intermediate-duration studies, 
histological examination of skin revealed no lesions in rats exposed by inhalation (Shiotsuka 1989), in 
rabbits exposed dermally (Flucke 1986), or in rats (Klotzsche 1972) or mice (Rivett et al. 1972) 
exposed in the diet for 90 days. In a chronic-duration study in rats (Carpy et al. 1975), mice (Hayes 
1983), or dogs (Hoffman et al. 1975) exposed in the diet for up to 2 years, histological examination of 
the skin also revealed no lesions. Acute dermal exposure to unspecified doses of disulfoton appeared 
to have caused microscopic changes in the blood vessels and fibrous structures in the skin of rats, cats, 
and rabbits (Kundiev and Rappoport 1967). As discussed in Section 2.2.3, this study is limited by 
reporting deficiencies. Therefore, exposure to disulfoton in the workplace, in the environment, in 
drinking water or food, or at hazardous sites might cause dermal lesions in humans. 
Ocular Effects. An epidemiological study suggests that the increased use of disulfoton in combination 
with other organophosphates to treat food crops may have increased the incidence of myopia in 
children (Ishikawa and Miyata 1980). To determine whether the myopia was associated with 
disulfoton exposure specifically, dogs were given disulfoton orally for 2 years. Myopia, astigmatism, 
and associated degenerative changes in the ciliary muscle (see Musculoskeletal Effects above) were 
observed (Ishikawa and Miyata 1980; Suzuki and Ishikawa 1974). The dog studies support the 
evidence for disulfoton-induced myopia in humans. Although other factors may have contributed to 
the occurrence of myopia, histopathological changes in the ciliary muscle of the dogs suggest a strong 
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cause and effect relationship. Cystic degeneration of the Harderian gland and comeal 
neovascularization were observed in rats exposed chronically to disulfoton in the diet (Hayes 1985). 
However, in other studies, histological or ophthalmological examination of the eyes revealed no 
lesions in rats (Klotzsche 1972) or mice (Rivett et al. 1972) exposed in the diet for 90 days, or in rats 
(Carpy et al. 1975), mice (Hayes 1983), or dogs (Hoffman et al. 1975) exposed in the diet for up to 
2 years. The rats in the study by Carpy et al. (1975) received lower doses than the rats in the Hayes 
(1985) study. The possibility that myopia or other ocular effects may occur in humans exposed to 
disulfoton cannot be ruled out. 
Body Weight Effects. Weight loss or decreased body weight gain were commonly observed in 
animals exposed to disulfoton for acute and intermediate durations (Costa et al. 1984, 1986; Fitzgerald 
and Costa 1992, 1993; Robinson et al. 1978; Schwab and Murphy 1981; Schwab et al. 1981, 1983; 
Stavinoha et al. 1969; Thyssen 1980). This decrease in weight gain is consistent with disulfoton 
neurological toxicosis since cholinergic signs (e.g., nausea, emesis, or diarrhea) will reduce food 
ingestion, absorption, and assimilation. Like the other overt signs of disulfoton toxicosis (see 
Neurological Effects below), the weight loss is usually transient. In a chronic feeding study, an 
11-19s depression of body weight gain occurred in the rats exposed to the high concentration of 
disulfoton (Hayes 1985). The decrease in body weight gain was partially due to decreased food 
consumption, which was probably related to the general debilitation of the high dose rats. 
Intraperitoneal studies also have reported weight loss in animals injected with disulfoton (Costa and 
Murphy 1982; Costa et al. 1981; McDonald et al. 1988). Based on the results from animal studies, 
weight loss in humans following moderate to severe disulfoton exposure is possible. 
Immunological and Lymphoreticular Effects. No studies were located regarding 
immunological effects in humans after exposure to disulfoton. However, down-regulation of 
cholinergic muscarinic receptors in T-lymphocytes and significantly inhibited acetylcholinesterase 
activity in T-lymphocytes were found in rats given 2 mg/kg/day disulfoton orally for l-2 weeks 
(Fitzgerald and Costa 1993). The inhibition of T-lymphocyte acetylcholinesterase activity paralleled 
that in the brain. Similar results were found in rats injected intraperitoneally with 2 mg/kg/day 
disulfoton for 2 weeks (Costa et al. 1990). The immunological significance of these neurological 
effects (see Section 2.2.2.4) is not known. Inflammatory changes throughout the respiratory tract, 
associated with bone marrow changes and low percentages of lymphocytes and high percentages of 
polymorphonuclear leukocytes in the differential leukocyte counts, were observed in rats exposed to 
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disulfoton by inhalation for intermediate duration (Thyssen 1980). Female rats exposed by inhalation 
to a high concentration in this study also had decreased spleen weights (Thyssen 1980), and rats given 
the high concentration of disulfoton in the diet for 2 years had a significantly increased incidence of 
plasma cell hyperplasia in the mandibular lymph nodes (males) and a significantly increased incidence 
of splenic lymphoid follicle depletion (females) (Hayes 1985). The plasma cell hyperplasia in the 
mandibular lymph nodes was probably a response to upper respiratory tract inflammation, which may 
have been due to aspiration of ingested food particles. In other inhalation (Shiotsuka 1989), dietary 
(Carpy et al. 1975; Hayes 1983; Hoffman et al. 1975; Klotzsche 1972; Rivett et al. 1972), and dermal 
(Flucke 1986) studies in animals exposed to disulfoton, histological examination of spleen, thymus, 
lymph nodes,‘and bone marrow revealed no treatment-related lesions. The relevance of the various 
lymphoreticular and possible immunological effects to humans exposed to disulfoton is not clear. 
Neurological Effects. The neurological effects of disulfoton depend on its metabolism to active 
metabolites which, in turn, inhibit acetylcholinesterase activity at nerve synapses. Inhibition of 
acetylcholinesterase activity results in excessive accumulation of acetylcholine which, in turn, 
stimulates muscarinic cholinergic receptors located in various organ tissues. The response of these 
effector organs to overstimulation is recognized as a neurological effect, and the severity will depend 
on such factors as dose, sex, species, and age of the human or animal exposed. Despite mild 
depression of erythrocyte cholinesterase activity, neurological effects were not observed in pesticide-
fertilizer mixers after inhalation exposure to 0.46-0.633 mg/ m3 disulfoton and dermal exposure to 
0.23 mg/kg/day disulfoton (Wolfe et al. 1978). One case of accidental ingestion of disulfoton resulted 
in cholinergic signs including miosis, salivation, masseteric spasms, monoplegia, and depressed serum 
cholinesterase activity (Yashiki et al. 1990). Weakness, fatigue, and cyanosis were observed in a 
farmer who, for several days, had worn gloves that were soaked in disulfoton (Savage et al. 1971). 
Neurological effects observed in humans have also been demonstrated in animals after acute and 
intermediate oral exposure (Costa et al. 1984; Crawford and Anderson 1974; Mihail 1978; Schwab and 
Murphy 1981; Schwab et al. 1981, 1983; Sheets 1993a, 1993b), acute and intermediate inhalation 
exposure (Doull 1957; Shiotsuka 1989; Thyssen 1978, 1980), and acute dermal exposure (Flucke 1986; 
Mihail 1978) to disulfoton. Inhibition of brain acetylcholinesterase and other tissue 
acetylcholinesterase activities (Carpy et al. 1975; Christenson and Wahle 1993; Clark and Pearson 
1973; Doull and Vaughn 1958; Flucke 1986; Hayes 1983, 1985; Hikita et al. 1973; Hixson and 
Hathaway 1986; Hoffman et al. 1975; Klotzsche 1972; Robinson et al. 1970, 1978; Schwab and 
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Murphy 1981; Schwab et al. 1981; Sheets 1993a, 1993b; Shiotsuka 1989; Thyssen 1978, 1980) also
 
have been observed in animals in numerous studies regardless of the route, duration, or animal species.
 
Female animals appear to be more sensitive than males to the cholinergic effects of disulfoton.
 
Chronic oral exposure of animals to disulfoton has resulted in necrosis and atrophy of the optic nerve
 
and retina (Hayes 1983; Uga et al. 1977) and unexplained changes in brain weight (Carpy et al. 1975).
 
A 2-month dietary study in rats and mice found that disulfoton exposure increased the permeability of
 
spinal cord and brain stem tissues (Clark and Stavinoha 1971).
 
Limited evidence indicates that disulfoton does not cause organophosphate-induced delayed
 
neurotoxicity in chickens. This syndrome is caused by some phosphate, phosphonate, and
 
phosphoramidate esters, which are not usually used as insecticides (Ecobichon 1990). Axonal
 
degeneration followed by myelin degeneration in nerve fibers distal to the nerve cell body are common
 
histopathological findings in hens with organophosphate-induced delayed neurotoxicity. However, oral
 
doses of 0, 0.1, 0.6, or 1.5 mg/kg disulfoton for 30 days did not cause demyelination in White
 
Leghorn hens (Taylor 1965b). Furthermore, White Leghorn hens given two 30 mg/kg oral doses of
 
disulfoton 21 days apart displayed no signs of delayed neurotoxicity (Hixson 1983). While clinical
 
signs of cholinergic intoxication (loss of equilibrium, decreased activity, diarrhea, and locomotor
 
ataxia) were observed on the first treatment day, these signs disappeared within 5 days of treatment.
 
Histological examination of the sciatic nerve, spinal cord, and brain revealed no treatment-related
 
lesions. It should be noted that the disulfoton-treated hens in the Hixson (1983) study were also
 
treated with 0.5 mg/kg atropine intramuscularly 10 minutes prior to disulfoton and with 12.5 mg/kg
 
pralidoxime chloride (2-PAM) intramuscularly 30 minutes after disulfoton. These antidotes were given
 
to prevent lethality, but 2-PAM also reverses cholinesterase inhibition, and atropine blocks the
 
muscarinic and central nervous system toxicity (see Section 2.8.3). Therefore, the administration of
 




Numerous studies indicate that animals develop a tolerance to the cholinergic effects of disulfoton after
 
a few days of oral exposure (Costa et al. 1981; Fitzgerald and Costa 1992, 1993; Schwab and Murphy
 
1981; Schwab et al. 1981, 1983). Animals exposed to disulfoton initially developed cholinergic signs
 
of toxicity, but with subsequent dosing (5-10 days) these signs almost disappeared, even though
 
cholinesterase activity remained depressed. Inhibition of brain, erythrocyte, or other tissue
 
cholinesterase, and typical signs of cholinergic poisoning have also been reported in numerous studies
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in which animals received intraperitoneal injections of disulfoton (Bombinski and DuBois 1958; 
Brodeur and DuBois 1963, 1964; Costa and Murphy 1982, 1983a, 1986; Costa et al. 1981, 1982a, 
1986, 1990; Foley and McPhillips 1973; LeFever and Green 1975; Llorens et al. 1993; McDonald et 
al. 1988; McPhillips 1969a; McPhillips and Dar 1967; Perrine and McPhillips 1970; Schwab et al. 
1981; Smith et al. 1968; Stavinoha et al. 1969; Westfall et al. 1974). 
Animal studies suggest that disulfoton causes neurobehavioral changes; however, most of these 
changes do not appear to be adverse. Unexpected faster maze running times and fewer errors were 
made by rats fed disulfoton for 90 days, despite a significant depression in brain cholinesterase (Clark 
and Pearson 1973). Furthermore, an unexpected increase in exploratory behavior was observed in 
mice fed disulfoton (Clark et al. 1971). Disulfoton did not result in impaired memory (assessed by 
shock treatment sensitivity and passive avoidance retention) in mice made tolerant by intraperitoneal 
injections of disulfoton for 14 days (Costa and Murphy 1982). However, McDonald et al. (1988) 
hypothesized that a decrease in muscarinic receptor densities in brain tissues of disulfoton-tolerant rats 
was the reason for the observed impairment of spatial memory after intraperitoneal injection with 
disulfoton for 14 days. In rats given daily intraperitoneal injections of disulfoton for 30 days, reduced 
motor activity occurred at 2.0 mg/kg/day, but tolerance to this effect did not develop (Llorens et al. 
1993). Disulfoton had no effect on acquisition or retention of passive avoidance, but impaired 
performance in a spatial memory water maze occurred at 2.0 mg/kg/day. This deficit in cognitive 
performance occurred at a time when tolerance to overt signs of cholinergic toxicity developed. 
Data from the few available case reports and the numerous animal studies strongly suggest that 
disulfoton exposure may cause mild to severe neurological effects in humans. Although disulfoton-
associated memory loss has not been reported in humans, there should be concern that occupational 
exposure and exposure at hazardous waste sites may interfere with the performance of cognitive and 
complex tasks. 
Reproductive Effects. No studies were located regarding reproductive effects in humans after 
exposure to disulfoton. No effect on male fertility was found in mice treated orally in a dominant 
lethal study (Herbold 1980). A 3-generation study demonstrated that a disulfoton diet providing 
0.5 mg/kg/day resulted in slightly reduced litter sizes in the third generation of rats (Taylor 1965a). In 
a study where males or females were fed disulfoton prior to and/or during mating, the failure of two of 
five females to become pregnant indicated that reproductive function in males as well as females may 
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have been severely affected (Ryan et al. 1970). A more extensive multigeneration feeding study in 
rats found decreased reproductive performance, evidenced by a decreased percentage of females placed 
for mating and decreased percentage of sperm-positive F0, and F1 parental females, decreased maternal 
weight of F0 and F1 dams during gestation and lactation, decreased litter counts, decreased viability 
and lactation indices, increased dead births and percentage of dead births in both generations, and 
decreases in F2b litter counts and litter weights (Hixson and Hathaway 1986). Histological examination 
of male and female reproductive organs generally did not reveal any treatment-related lesions in rats 
(Carpy et al. 1975; Hayes 1985; Klotzsche 1972; Shiotsuka 1989; Thyssen 1980), mice (Hayes 1983; 
Rivett et al. 1972), dogs (Hoffman et al. 1975), or rabbits (Flucke 1986) exposed to disulfoton by any 
route. The only exception was uterine cystic hyperplasia in female rats fed the high dietary 
concentration of disulfoton for 2 years (Hayes 1985). Reproductive function was not assessed in these 
studies. Based on the reproductive studies in animals, the possibility for reproductive effects in 
humans exposed to disulfoton cannot be ruled out. 
Developmental Effects. No studies were located regarding developmental effects in humans after 
exposure to disulfoton. Incomplete ossification of the parietal bones and the stemebrae, but no tissue 
malformations were observed in the offspring of rats fed disulfoton during gestation (Lamb and 
Hixson 1983). Erythrocyte acetylcholinesterase depression, cloudy swelling and fatty infiltration of the 
liver, mild nephropathy, and juvenile hypoplasia of the testes were found in F3b litters in a threegeneration 
feeding study (Taylor 1965a). Brain cholinesterase depression was also observed in the 
fetuses of rat dams fed disulfoton (Ryan et al. 1970) and in the F1a pups of male and female rats in a 
dietary reproduction study (Hixson and Hathaway 1986). Intraperitoneal injection of pregnant mice 
with disulfoton on gestation day 11 resulted in 71.4% fetal mortality and decreased litter size (Uzokwu 
1974). No malformations were seen. Nevertheless, rabbit fetal survival, growth, and development was 
not affected by oral exposure of the dams to disulfoton during gestation (Tesh et al. 1982). Based on 
the animal data, the potential for disulfoton to cause fetotoxic and developmental effects in humans 
cannot be ruled out. 
Genotoxic Effects. No studies were located regarding genotoxicity of disulfoton in humans after 
inhalation, oral, or dermal exposure or in animals after inhalation or dermal exposure. The results of 
in viva studies are summarized in Table 2-4. Disulfoton did not induce micronuclei in the erythrocytes 
of mice treated orally at 6 or 12 mg/kg/day for 2 days (Herbold 1981) or orally or intraperitoneally at 
2, 4, or 8 mg/kg disulfoton (EPA 1984a; Sandhu et al. 1985). Disulfoton was also negative in a 
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dominant lethal test in mice given a single oral dose of 5 mg/kg (Herbold 1980). Furthermore, 
disulfoton did not induce sex-linked recessive lethal mutations in Drosophila melunogaster (EPA 
1981a; Sandhu et al. 1985; Waters et al. 1981, 1982). 
Disulfoton has been tested in numerous types of in vitro assays, mainly with negative results (see 
Table 2-5). Disulfoton was negative in most assays for reverse mutation in most strains of Salmonella 
typhimurium with or without metabolic activation (EPA 1980a; Inukai and Iyatomi 1976; Moriya et al. 
1983; Sandhu et al. 1985; Waters et al. 1981, 1982); but positive results were obtained in LT-2 strains 
(Hanna and Dyer 1975) and in one assay with strain TA1535 (Moriya et al. 1983; Shirasu et al. 1982, 
1984) of S. typhimurium without activation. Results of reverse mutation assays in Escherichia coli 
were equivocal; positive results without activation in WP2 strains were reported in one study (Hanna 
and Dyer 1975), but negative results in WP2 uvrA with and without activation were found in another 
study (EPA 1980a, 1984a; Sandhu et al. 1985; Waters et al. 1981, 1982). Disulfoton was negative in 
assays of differential toxicity in S. typhimurium, E. coli, and Bacillus subtilis with or without 
activation (EPA 1980a; Herbold 1983; Inukai and Iyatomi 1976; Sandhu et al. 1985; Waters et al. 
1981, 1982). Negative results were obtained in assays for reverse mutation, gene conversion, mitotic 
crossing over and recombinants, and for primary DNA damage in eukaryotic yeast, Succhuromyces 
cerevisiue, with and without activation (Brusick 1981; EPA 1984a; Jagannath 1981; Sandhu et al. 
1985; Waters et al. 1981, 1982). However, positive results without activation were obtained in assays 
for chiasma frequency (genetic recombinants), mitotic index, chromosomal aberrations, and pollen 
fertility in barley (Hordeurn vulgaris) (Murty et al. 1983; Panda 1983; Singh et al. 1977). Some 
positive and some negative results have been obtained in cultured mammalian cells. Positive or 
weakly positive results were obtained for sister chromatid exchanges in Chinese hamster ovary cells 
with metabolic activation in two assays (EPA 1984a; Sandhu et al. 1985; Waters et al. 1981, 1982), 
but negative results were found in another study (Chen et al. 1981, 1982). Conversely, disulfoton 
induced sister chromatid exchanges in Chinese hamster ovary cells without metabolic activation, but 
not with metabolic activation, in another study (Putnam 1987). Disulfoton was negative for HGPRT 
mutations in Chinese hamster ovary cells with and without activation (Yang 1988). Positive results 
without activation were obtained for forward mutations in mouse lymphoma cells, for unscheduled 
DNA synthesis in human lung fibroblasts (EPA 1984a; Sandhu et al. 1985; Waters et al. 1981, 1982), 
and for growth inhibition and increased protein synthesis in human HeLa cells (Litterst et al. 1969). 
However, negative results were found for chromosomal aberrations in human hematopoietic cell lines 
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While many of the studies on genotoxicity of disulfoton were negative, the positive results indicate a 
potential for mutagenic and clastogenic effects in humans exposed to disulfoton. 
Cancer. No studies were located regarding cancer in humans after exposure to disulfoton. 
Carcinogenic effects were not observed in rats (Carpy et al. 1975; Hayes 1985), mice (Hayes 1983), or 
dogs (Hoffman et al. 1975) fed disulfoton for 1.5-2.0 years. There is no reason to believe that 
disulfoton is carcinogenic. 
2.5 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They 
have been classified as markers of exposure, markers of effect, and markers of susceptibility 
(NAS/NRC 1989). 
A biomarker of exposure is a xenobiotic substance or its metabolite(s), or the product of an interaction 
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a 
compartment of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally 
the substance itself or substance-specific metabolites in readily obtainable body fluid(s) or excreta. 
However, several factors can confound the use and interpretation of biomarkers of exposure. The 
body burden of a substance may be the result of exposures from more than one source. The substance 
being measured may be a metabolite of another xenobiotic substance (e.g., high urinary levels of 
phenol can result from exposure to several different aromatic compounds). Depending on the 
properties of the substance (e.g., biologic half-life) and environmental conditions (e.g., duration and 
route of exposure), the substance and all of its metabolites may have left the body by the time samples 
can be taken. It may be difficult to identify individuals exposed to hazardous substances that are 
commonly found in body tissues and fluids (e.g., essential mineral nutrients such as copper, zinc, and 
selenium). Biomarkers of exposure to disulfoton are discussed in Section 2.5.1. Biomarkers of effect 
are defined as any measurable biochemical, physiologic, or other alteration within an organism that, 
depending on magnitude, can be recognized as an established or potential health impairment or disease 
(NAUNRC 1989). This definition encompasses biochemical or cellular signals of tissue dysfunction 
(e.g., increased liver enzyme activity or pathologic changes in female genital epithelial cells), as well 
as physiologic signs of dysfunction such as increased blood pressure or decreased lung capacity. Note 
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that these markers are not often substance specific. They also may not be directly adverse, but can 
indicate potential health impairment (e.g., DNA adducts). Biomarkers of effects caused by disulfoton 
are discussed in Section 2.5.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism3s 
ability to respond to the challenge of exposure to a specific xenobiotic substance. It can be an 
intrinsic genetic or other characteristic or a preexisting disease that results in an increase in absorbed 
dose, a decrease in the biologically effective dose, or a target tissue response. If biomarkers of 
susceptibility exist, they are discussed in Section 2.7, Populations That Are Unusually Susceptible. 
2.5.1 Biomarkers Used to Identify or Quantify Exposure to Disulfoton 
Disulfoton and its metabolites have been measured in various tissues and body fluids (blood, urine, 
feces, liver, kidney, and body fat) from humans or animals exposed to disulfoton (Brokopp et al. 1981; 
Hattori et al. 1982; Puhl and Fredrickson 1975; Yashiki et al. 1990). Because disulfoton is quickly 
metabolized, it is rarely detected in the blood or plasma of exposed individuals, but detection of the 
insecticide in blood provides conclusive evidence of previous exposure. At ≈2-3 hours after a man 
accidentally ingested disulfoton, 0.093 nmol/g (4.92 ng/g) of disulfoton and 4.92 nmol/g of total 
metabolites were detected in his blood (Yashiki et al. 1990). In another study, 1.45 nmol/g of 
disulfoton was detected in the blood of a man found dead at least 24 hours after he had ingested 
disulfoton (Hattori et al. 1982). In both cases, the original dose was unknown; therefore, a correlation 
between disulfoton exposure and blood concentration cannot be made. 
The presence of disulfoton and/or its metabolites in the liver appears to be a sensitive indicator of 
disulfoton exposure, despite the limited data. Supporting evidence from animal studies indicates that 
disulfoton exposure will result in detectable levels in the liver (Bull 1965; Puhl and Fredrickson 1975). 
However, monitoring of liver levels would require biopsy, which is not practical. 
The presence of disulfoton and/or its metabolites in urine is usually a reliable biomarker of disulfoton 
exposure. Specimens of urine collected from 64 locations across the United States, comprising the 
sample areas of the Second Health and Nutrition Examination Survey (NHANES II), reported 
detection (detection limit 0.02 ppm) of DEP and DETP at a frequency of 6-7% and DEDPT at a 
frequency of <1% of those tested (Murphy et al. 1983). Although no human data were located on the 
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relationship between the concentration of urinary metabolites and the exposure dose, data from several 
animal studies demonstrate that 28.6-98% of the dose was accounted for in the urine 2-10 days 
postexposure (Bull 1965; Lee et al. 1985; Puhl and Fredrickson 1975). An unknown amount of 
disulfoton sulfoxide and/or demeton S-sulfone was detected in the urine from a person exposed to an 
unknown amount of disulfoton (Yashiki et al. 1990). Results from a human occupational study of 
pesticide formulators who had worked with disulfoton for 25 weeks showed that the metabolites DEP 
(0.01-4.4 ppm), DETP (0.01-1.57), DEDPT (<0.01-0.05 ppm), and DEPTh (<0.01-0.55 ppm) were 
detected in the urine (Brokopp et al. 1981). The mean preformulation urinary levels were 0.05 ppm 
DEP, 0.04 ppm DETP, 0.01 ppm DEDPT, and 0.008 ppm DEPTh. Threshold levels of these 
metabolites, defined as two standard deviations above the mean, were 0.13 ppm DEP, 0.12 ppm 
DETP, 0.06 ppm DEDPT, and 0.06 ppm DEPTh. Although the excretion of DEP varied considerably 
among the individuals, this metabolite was more commonly detected above the threshold level among 
these employees. The dialkyl phosphate metabolites are not only very sensitive indicators of 
disulfoton exposure, but their presence strongly suggests previous exposure to a diethyl 
organophosphate ester. One animal study demonstrated that a greater percentage of the disulfoton 
dose was eliminated as DEP (Bull 1965). This provides limited but supporting evidence that DEP is a 
more sensitive urinary biomarker than the other metabolites discussed. 
A combination of neurological signs is usually a biomarker of organophosphate exposure. 
Neurological signs such as pupil miosis, muscular tremors, and increased salivation have been 
observed in humans accidentally exposed to disulfoton (Yashiki et al. 1990) and in animals given 
disulfoton (Schwab et al. 1981). 
Inhibition of erythrocyte acetylcholinesterase activity or serum cholinesterase activity with or without 
concomitant neurological signs is usually a good indicator of organophosphate exposure. In addition, 
T-lymphocyte acetylcholinesterase activity was found to be rapidly and greatly depressed in rats during 
a 14-day daily exposure to disulfoton, but rapidly recovered after exposure (Fitzgerald and Costa 
1993). Therefore, T-lymphocyte acetylcholinesterase activity could be used as a biomarker of 
exposure to organophosphorus pesticides during exposure, but not once exposure has ceased. The 
acetylcholinesterase activity recovered more slowly in erythrocytes than in lymphocytes, indicating the 
erythrocyte activity is a better biomarker of exposure once exposure has ceased. However, the severity 
of the signs and symptoms and the degree of cholinesterase depression are not always correlated. 
Standards for serum cholinesterase activity (175-440 IU) have been established for humans (Yashiki et 
DISULFOTON 116 
2. HEALTH EFFECTS 
al. 1990), but there is a wide normal range due to the variation in the human population. A man had 
depressed blood cholinesterase activity (<10 IU for 5 days and <40 IU for 8 days after exposure) as 
well as cholinergic signs of toxicity following accidental ingestion of disulfoton (Yashiki et al. 1990). 
As demonstrated in this case, cholinesterase activity can remain depressed for at least a week after 
neurological signs have disappeared; therefore, other parameters (e.g., urine metabolites) may help with 
the diagnosis. Cholinesterase depression was not observed in 11 employees exposed to disulfoton for 
≤2.5 weeks (Brokopp et al. 1981). The presence of urinary metabolites of disulfoton was the only 
biomarker of disulfoton exposure. Employees occupationally exposed to disulfoton for 9 weeks had 
marked depression of the erythrocyte acetylcholinesterase activity, but no neurological signs (Wolfe et 
al. 1978). Urinary metabolites were not reported; therefore, cholinesterase depression was the only 
biomarker of exposure. Because organophosphates other than disulfoton and carbamates can depress 
cholinesterase activity (Osweiler et al. 198.5) cholinesterase activity is not specific for disulfoton 
exposure. Furthermore, liver dysfunction, pregnancy, malnutrition, neoplasia, infection, and certain 
drugs such as codeine and morphine may lower plasma pseudocholinesterase activity, while 
hemoglobinopathies such as sickle cell disease and thalassemia and other anemias may lower 
erythrocyte cholinesterase activity (Goldfrank et al. 1990). 
Urine catecholamines may also serve as biomarkers of disulfoton exposure. No human data are 
available to support this, but limited animal data provide some evidence of this. Disulfoton exposure 
caused a 173% and 313% increase in urinary noradrenaline and adrenaline levels in female rats, 
respectively, within 72 hours of exposure (Brzezinski 1969). The major metabolite of catecholamine 
metabolism, HMMA, was also detected in the urine from rats given acute doses of disulfoton 
(Wysocka-Paruszewska 1971). Because organophosphates other than disulfoton can cause an 
accumulation of acetylcholine at nerve synapses, these chemical compounds may also cause a release 
of catecholamines from the adrenals and the nervous system. In addition, increased blood and urine 
catecholamines can be associated with overstimulation of the adrenal medulla and/or the sympathetic 
neurons by excitement/stress or sympathomimetic drugs, and other chemical compounds such as 
reserpine, carbon tetrachloride, carbon disulfide, DDT, and monoamine oxidase inhibitors (MAO) 
inhibitors (Brzezinski 1969). For these reasons, a change in catecholamine levels is not a specific 
indicator of disulfoton exposure. 
Disulfoton induced the liver MFO system in animals (Stevens et al. 1973). In the same study, 
exposure to disulfoton orally for 3 days also increased ethylmorphine N-demethylase and NADPH 
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oxidase activities, but had no effect on NADPH cytochrome c reductase. Thus, the induction of the 
MFO system required repeated dosing with relatively high doses. Furthermore, these changes are not 
specific for disulfoton exposure, and these subtle liver effects require invasive techniques in humans to 
obtain liver tissue for performance of these enzyme assays. 
2.5.2 Biomarkers Used to Characterize Effects Caused by Disulfoton 
Disulfoton exposure results in cholinergic signs such as salivation, diarrhea, pupil constriction, muscle 
tremors, and weight loss. Ataxia, convulsions, coma, respiratory distress, and death are common signs 
associated with a more severe toxicosis. Nervous tissue is evidently the most sensitive target organ. 
Because cholinesterase inhibition is a very sensitive biomarker for other chemicals, it is not always 
conclusive evidence of disulfoton exposure. However, depression of cholinesterase activity can alert a 
physician to the possibility of more serious neurological effects. Erythrocyte acetylcholinesterase 
activity more accurately reflects the degree of synaptic cholinesterase inhibition in nervous tissue, 
while serum cholinesterase activity may be associated with other sites (Goldfrank et al. 1990). In 
addition, a recent study showed that after rats received oral doses of disulfoton for 14 days, 
acetylcholinesterase levels in circulating lymphocytes correlated better with brain acetylcholinesterase 
activity than did erythrocyte cell cholinesterase activities during exposure (Fitzgerald and Costa 1993). 
However, recovery of the activity in lymphocytes was faster than the recovery of activity in the brain, 
which correlated better with the activity in erythrocytes. Animal studies have also demonstrated that 
brain acetylcholinesterase depression is a sensitive indicator of neurological effects (Carpy et al. 1975; 
Costa et al. 1984; Schwab and Murphy 1981; Schwab et al. 1981, 1983); however, the measurement of 
brain acetylcholinesterase in humans is too invasive to be practical. 
Serum β-glucuronidase activity was increased in a dose-related manner when disulfoton was given 
intraperitoneally to rats (Kikuchi et al. 1981). In the same study, this effect was not observed in mice, 
rabbits, or guinea pigs. This enzyme appears to be a useful biomarker of hepatic function in rats 
exposed to disulfoton, but may not be a useful biomarker in humans. 
Increased levels of urinary catecholamines may also be associated with accumulation of acetylcholine 
that resulted from acetylcholinesterase inhibition by disulfoton. No human data were located to 
support this, but limited animal data provide some evidence. Disulfoton exposure caused a 173% and 
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313% increase in urinary noradrenaline and adrenaline levels in rats, respectively, within 72 hours 
(Brzezinski 1969). The major metabolite of catecholamine metabolism, HMMA, was also detected in 
the urine from rats given acute doses of disulfoton (Wysocka-Paruszewska 1971). 
Additional information regarding biomarkers for effects can be found in OTA (1990) and 
CDC/ATSDR (1990). A more detailed discussion of the health effects caused by disulfoton can be 
found in Section 2.2 of Chapter 2. 
2.6 INTERACTIONS WITH OTHER SUBSTANCES 
Disulfoton can function as an inhibitor of MFO when given in one or two doses and can potentiate the 
toxicity of similarly related compounds. Disulfoton exhibits Type I binding, that is, binding to the 
oxidized form of cytochrome P-450, and when given as a single dose, competitively inhibits the 
metabolism of other Type I substrates (Stevens et al. 1973). However, it was also reported that 
disulfoton was a noncompetitive inhibitor of rat and mouse ethylmorphine N-demethylase (Stevens and 
Green 1974; Stevens et al. 1972a). When given as a single dose, disulfoton also appears to inhibit 
NADPH cytochrome c reductase (Stevens et al. 1973). Disulfoton was reported to inhibit hexobarbital 
metabolism, thereby prolonging hexobarbital sleeping time in mice (Stevens et al. 1972a). This effect 
was not due to inhibition of cholinesterase nor was it due to an altered sensitivity of the brain to 
barbiturates, but it was associated with inhibition of hepatic MFO metabolism. These investigators 
also determined that disulfoton depressed microsomal metabolism of aniline as well as ethylmorphine 
in the mouse. A significant decrease in N-demethylase activity of aminopyrine and hydroxylase 
activity of acetanilide was observed in animals pretreated orally with disulfoton for 2 successive days, 
compared to the control group (Fawade and Pawar 1978). Disulfoton also caused decreased levels of 
cytochrome P-450 and cytochrome b, and an increase in NADPH-linked and ascorbate-promoted lipid 
peroxidation. 
In contrast to the inhibitory effects of acute exposure, repeated dosing with disulfoton induces the 
cytochrome P-450 MFO system (Stevens et al. 1973). Disulfoton (1/2 LD50) given orally to mice for 
3 days resulted in increased activities of ethylmorphine N-demethylase and NADPH oxidase activities, 
but not the activity of NADPH cytochrome c reductase, the rate of reduction of cytochrome P-450, or 
the content of cytochrome P-450. The 5-day treatment regimen resulted in increased activities of 
ethylmorphine N-demethylase and NADPH oxidase activities, as well as increased cytochrome P-450 
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content. Apparently, the duration of exposure determines the effect of disulfoton on the various 
components of the MFO system. In another study, treatment of mice orally with disulfoton (1/2 LD50) 
for 5 days followed by administration of hexobarbital resulted in an increase in hexobarbital 
hydroxylase activity (Stevens et al. 1972b). Therefore, disulfoton-treated mice had shorter 
hexobarbital sleeping times. Microsomes from disulfoton-treated mice also had increased activity of 
aniline hydroxylase when aniline was added to the incubation mixture. Lower doses of disulfoton for 
similar time periods of exposure did not result in significant hepatic enzyme induction. The results 
from these studies suggest that depending on the duration of exposure, disulfoton may increase or 
decrease the severity of toxicity associated with chemicals that are similarly metabolized. 
The toxicity of disulfoton may be altered by pretreatment with inducers or inhibitors of the hepatic 
microsomal drug metabolizing system. Phenobarbital causes enzyme repression of flavin-containing 
monooxygenase, but it also causes induction of cytochrome P-450 activity (Sipes and Gandolfi 1986). 
Therefore, pretreatment with phenobarbital will not result in flavin monooxygenase-mediated activation 
of disulfoton to its active metabolite. Cytochrome P-450 can activate disulfoton to its toxic 
metabolites as well as detoxify disulfoton by oxidative dearylation and dealkylation to less toxic 
metabolites (Ecobichon 1990). However, pretreatment with phenobarbital induced cytochrome P-450 
enzymes that functioned more as detoxification enzymes than as activation enzymes (DuBois and 
Kinoshita 1968; Pawar and Fawade 1978). Although phenobarbital affects both enzyme systems 
differently, the net result is protection from the toxicity of disulfoton. One hundred percent protection 
against the toxicity of disulfoton was achieved both in mice and rats pretreated with phenobarbital and 
then given disulfoton orally at the LD85 dose level (Pawar and Fawade 1978). Pretreatment with 
another enzyme inducer, 3-methylcholanthrene, resulted in only 73% protection against disulfoton 
toxicity in both rats and mice. The authors proposed that the different levels of protection were due to 
the induction of two different interconvertible forms of cytochrome P-450. Rats pretreated with 
phenobarbital were less susceptible to the toxicity of disulfoton (DuBois and Kinoshita 1968). In this 
study, the LD50 value for the pretreated group (16.3 mg/kg) was greater than that for the control group 
(6.7 mg/kg), suggesting that phenobarbital pretreatment reduced the toxic effects of disulfoton by way 
of hepatic microsomal enzyme induction. A 3-day phenobarbital pretreatment also resulted in 
increased microsomal protein content and increased aminopyrine N-demethylase activity, but decreased 
acetanilide hydroxylase activity, in mice given disulfoton for 3 more days (Fawade and Pawar 1980). 
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Pretreatment with the Type I substrate, ethylmorphine, resulted in 100% mortality in both rats and 
mice, and aminopyrine pretreatment resulted in 100% and 64% mortality in rats and mice, 
respectively, exposed to disulfoton (Pawar and Fawade 1978). Nickel chloride, cobalt chloride, or 
cycloheximide decreased the levels of cytochrome b,, cytochrome c reductase, and total heme in rats 
(Fawade and Pawar 1983). These electron transport components were further decreased in rats 
pretreated with these inhibitors and given a single dose of disulfoton. Data from this study suggests 
an additive effect, since disulfoton also decreases the activities of these components. Evidence of an 
additive effect between disulfoton and these metabolic inhibitors was suggested by the decrease in 
ethylmorphine N-demethylase and acetanilide hydroxylase activities when rats were given an inhibitor 
followed by disulfoton. In another experiment, these inhibitors decreased the activity of 
delta-aminolevulinic acid synthetase, but this decrease was reversed when disulfoton was administered. 
Although some steroids have been reported to reduce the toxic effects of some insecticides, the steroid 
ethylestrenol decreased the rate of recovery of depressed cholinesterase activity in disulfoton-pretreated 
rats (Robinson et al. 1978). The exact mechanism of this interaction was not determined. 
Ethylestrenol alone caused a small decrease in cholinesterase activity, and, therefore, resulted in an 
additive effect. Rats excreted less adrenaline and more noradrenaline when given simultaneous 
treatments of atropine and disulfoton compared with rats given disulfoton alone (Brzezinski 1973). 
The mechanism of action of disulfoton on catecholamine levels may depend on acetylcholine 
accumulation. In the presence of atropine, the acetylcholine effect on these receptors increases the 
ability of atropine to liberate catecholamines. 
Cross-tolerance between disulfoton and another organophosphate, chlorpyrifos, was observed in mice 
(Costa and Murphy 1983b). Because of this cross-tolerance, a benefit is derived as a result of this 
interaction. In the same study, propoxur-tolerant mice were tolerant to disulfoton but not vice versa. 
Propoxur (a carbamate) is metabolized by carboxylesterases, and these enzymes are inhibited in 
disulfoton-tolerant animals; disulfoton-tolerant animals are more susceptible to propoxur and/or 
carbamate insecticides than are nonpretreated animals. In another study, disulfoton-tolerant rats were 
tolerant to the cholinergic effects of octamethyl pyrophosphoramide (OMPA) but not parathion 
(McPhillips 1969a, 1969b). The authors were unable to explain why the insecticides OMPA and 
parathion caused different effects. 
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2.7 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to disulfoton than will most 
persons exposed to the same level of disulfoton in the environment. Reasons include genetic make-up, 
developmental stage, age, health and nutritional status (including dietary habits that may increase 
susceptibility, such as inconsistent diets or nutritional deficiencies), and substance exposure history 
(including smoking). These parameters result in decreased function of the detoxification and excretory 
processes (mainly hepatic, renal, and respiratory) or the pre-existing compromised function of target 
organs (including effects or clearance rates and any resulting end product metabolites). For these 
reasons we expect the elderly with declining organ function and the youngest of the population with 
immature and developing organs will generally be more vulnerable to toxic substances than healthy 
adults. Populations who are at greater risk due to their unusually high exposure are discussed in 
Section 5.6, Populations With Potentially High Exposure. 
No data were located that identify subpopulations of humans more susceptible to the toxic effects of 
disulfoton. Animal studies demonstrate that there are sex, age, and liver function differences in the 
susceptibility of animals to disulfoton toxicosis. Data from LC50 and LD50 studies suggest that female 
rats and mice are more sensitive than male rats and mice to disulfoton after inhalation (Thyssen 1978), 
oral (Bombinski and DuBois 1958; Crawford and Anderson 1974; Gaines 1969; Mihail 1978; Pawar 
and Fawade 1978), dermal (Gaines 1969; Mihail 1978), or intraperitoneal (Bombinski and DuBois 
1958) exposure. Erythrocyte and brain cholinesterase activity was more depressed in female rats than 
in male rats (Klotzsche 1972; Ryan et al. 1970; Thyssen 1980). While absolute and relative brain 
weights generally increased in male rats exposed to disulfoton, the trend was reversed in female rats 
(Carpy et al. 1975). In the same study, liver, spleen, kidney, and pituitary weights were increased in 
male rats and decreased in female rats. The toxicological significance of these observations is 
unknown. Results from toxicokinetic studies showed that male rats eliminated disulfoton faster than 
female rats (Lee et al. 1985; Puhl and Fredrickson 1975). This apparent difference in the toxic 
responses of the sexes may have been due to differences in absorption, retention, metabolism, or a 
combination of factors. 
Animal studies suggest that younger animals are more susceptible to disulfoton toxicosis than older 
animals. The intraperitoneal LD50 of disulfoton was lower in weanling rats than in adult rats (Brodeur 
and DuBois 1963). These investigators proposed that the relatively slow rate of metabolic 
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detoxification and/or incomplete development of detoxification enzymes in weanlings accounted for 
the difference in the effects. Calves were more sensitive to disulfoton than yearling cattle, as indicated 
by an increase in severe clinical signs and a greater depression of cholinesterase activity in calves 
(McCarty et al. 1969). 
Data suggest that animals pretreated with disulfoton or hepatic enzyme inducers were less susceptible 
to disulfoton toxicosis than those subpopulations that were not pretreated. Disulfoton-tolerant animal 
populations are generally less sensitive to subsequent disulfoton exposure than are nontolerant animals 
(Costa et al. 1984; Schwab and Murphy 1981; Schwab et al. 1981, 1983). In addition, animals 
pretreated with chemicals that induce MFO (e.g., phenobarbital) were less susceptible to disulfoton 
toxicosis (DuBois and Kinoshita 1968; Pawar and Fawade 1978). 
2.8 METHODS FOR REDUCING TOXIC EFFECTS 
This section will describe clinical practice and experimental research concerning methods for reducing 
toxic effects of exposure to disulfoton. However, because some of the treatments discussed may be 
experimental and unproven, this section should not be used as a guide for treatment of exposure to 
disulfoton. When specific exposures have occurred, poison control centers and medical toxicologists 
should be consulted for medical advice. 
2.8.1 Reducing Peak Absorption Following Exposure 
If disulfoton is inhaled, the victim should be removed to a fresh air environment. Artificial respiration 
and the use of oxygen has been recommended (Sittig 1991). Not much can be done to reduce 
absorption of disulfoton from the respiratory tract. If disulfoton is ingested, the stomach should be 
emptied by inducing emesis or by gastric lavage (Haddad and Winchester 1990). If the patient is 
unconscious, means to prevent aspiration are recommended prior to gastric lavage. Because most 
organophosphates contain hydrocarbon solvents, which are severe aspiration hazards, the use of 
emetics may be contraindicated (Ellenhom and Barceloux 1988). Activated charcoal and a cathartic 
should then be given to adsorb any of the remaining disulfoton. Repeated treatment with activated 
charcoal may be useful to prevent reabsorption following enterohepatic circulation. In the event of 
dermal exposure, contaminated clothing should be removed and the victim should be bathed with soap 
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and water in an attempt to decontaminate the skin. The eyes should be rinsed with water or 
physiological saline if disulfoton entered the eye. 
2.8.2 Reducing Body Burden 
No information is available regarding methods for specifically reducing the body burden of disulfoton. 
Diuresis, dialysis, and hemoperfusion have been used to reduce the body burden of other 
organophosphates in humans and animals (Ellenhorn and Barceloux 1988). Because disulfoton is 
rapidly metabolized to its active metabolites which bind to ubiquitous cholinesterases in nervous tissue, 
these methods may not be effective unless started immediately after exposure. However, repeated 
administration of activated charcoal/cathartics may prevent possible enterohepatic recirculation of 
disulfoton or its metabolites. Administration of oximes, such as 2-PAM, may also increase the 
excretion of disulfoton metabolites, since oximes accelerate the hydrolysis of phosphorylated 
cholinesterase (Ellenhorn and Barceloux 1988; Goldfrank et al. 1990; Haddad and Winchester 1990; 
Morgan 1982). However, “aging” of the phosphorylated enzyme may occur after l-2 days (Ecobichon 
1990). Because 2-PAM is unable to reverse cholinesterase inhibition once “aging” has started, 2-PAM 
should be administered as soon as possible after exposure or any time following exposure when 
clinical signs or symptoms are present. 
2.8.3 Interfering with the Mechanism of Action for Toxic Effects 
The mechanism of action of disulfoton depends on active metabolites of disulfoton binding to 
acetylcholinesterase and causing an accumulation of acetylcholine at the synapse that results in 
muscarinic (e.g., salivation) and nicotinic (e.g., muscle tremors) effects. Atropine sulfate has been 
used as a therapeutic agent to reduce the severity of disulfoton toxicosis by binding to muscarinic 
receptors, thus blocking the muscarinic and central nervous system manifestations (Goldfrank et al. 
1990). Atropine also reduces excessive bronchial secretions that can result in bronchopneumonia. 
This drug was also used successfully to treat a patient with severe signs of disulfoton toxicosis 
(Yashiki et al. 1990). Pretreatment of rats with atropine protected them against an intraperitoneal LD50 
dose (Bombinski and DuBois 1958). Oxime derivatives (e.g., 2-PAM), accelerate the hydrolysis of 
phosphorylated cholinesterase and hence accelerate regeneration of the active cholinesterase (Ellenhorn 
and Barceloux 1988; Goldfrank et al. 1990; Haddad and Winchester 1990; Morgan 1982). The oximes 
usually reduce both the muscarinic and nicotinic effects of poisoning when administered within 
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36 hours after organophosphate exposure (Goldfrank et al. 1990; Morgan 1982). However, “aging” of 
the phosphorylated enzyme may occur after l-2 days (Ecobichon 1990). Because 2-PAM is unable to 
reverse cholinesterase inhibition once “aging” has started, 2-PAM should be administered as soon as 
possible after exposure. Atropine and 2-PAM synergistically alleviate the manifestations of 
cholinesterase inhibition when co-administered (Goldfrank et al. 1990). While atropine blocks the 
muscarinic effects, 2-PAM regenerates cholinesterase enzymes in sympathetic, parasympathetic, and 
central nervous system sites. 
2.9 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with 
the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of disulfoton is available. Where adequate information is 
not available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to 
assure the initiation of a program of research designed to determine the health effects (and techniques 
for developing methods to determine such health effects) of disulfoton. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will 
be evaluated and prioritized, and a substance-specific research agenda will be proposed. 
2.9.1 Existing Information on Health Effects of Disulfoton 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
disulfoton are summarized in Figure 2-4. The purpose of this figure is to illustrate the existing 
information concerning the health effects of disulfoton. Each dot in the figure indicates that one or 
more studies provide information associated with that particular effect. The dot does not imply 
anything about the quality of the study or studies. Gaps in this figure should not be interpreted as 
“data needs.” A data need, as defined in ATSDR’s Decision Guide for Identifying Substance-Specific 
Data Needs Related to Toxicological Profiles (ATSDR 1989) is substance-specific information 
necessary to conduct comprehensive public health assessments. Generally, ATSDR defines a data gap 
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more broadly as any substance-specific information missing from the scientific literature. 
As seen from Figure 2-4, data exist regarding neurological effects in humans after inhalation exposure 
to disulfoton. The data for neurological effects were derived from medical evaluations of workers at a 
pesticide-fertilizer mixing operation. Neurological effects consisted of >22.8% depression in 
erythrocyte cholinesterase activity after 9 weeks of exposure to disulfoton. Other severe neurological 
effects were not reported. Systemic and neurological effects were observed in humans after accidental 
or intentional ingestion of disulfoton. Respiratory and renal effects, more associated with postmortem 
changes, were reported in a man who died after ingesting disulfoton. Neurological effects consisted of 
miosis, increased salivation, masseteric spasms, and monoplegia. Epidemiological studies suggest that 
disulfoton causes myopia in children. Neurological effects were observed in humans after dermal 
exposure to disulfoton for acute or intermediate durations. Neurological effects after acute exposure 
included weakness, fatigue, and depressed cholinesterase activity. Intermediate dermal exposure 
resulted only in erythrocyte cholinesterase depression. 
Death and neurological effects were observed in animals after acute- and intermediate-duration 
inhalation exposure to disulfoton. Intermediate-duration inhalation studies that investigated systemic 
end points, effects in lymphoreticular organs, and effects in reproductive organs were conducted in 
rats. Effects consisted of cholinergic signs of disulfoton toxicity, depressed erythrocyte and brain 
cholinesterase activity, inflammation in respiratory organs, increased adrenal weight, hematological 
effects, and bone marrow changes. Death, systemic effects of acute-, intermediate-, and chronicduration 
exposure, lymphoreticular, neurological, developmental, reproductive, genotoxic, and 
carcinogenic effects were investigated in animals after oral exposure to disulfoton. Systemic effects 
consisted of respiratory, gastrointestinal, hematological, musculoskeletal, hepatic, renal, endocrine, 
dermal, ocular, and body weight effects. Ocular effects consisted of myopia development in dogs and 
cornea1 neovascularization in rats after chronic exposure to disulfoton. Neurological effects consisted 
of cholinergic signs of disulfoton toxicity, depressed erythrocyte and brain acetylcholinesterase activity, 
and pathology of the optic nerve and retina. Reproductive effects were observed in male and female 
rats, and fetotoxicity was reported in several developmental studies. Mostly negative results were 
obtained for genotoxicity, and negative results were found in carcinogenicity studies. Death and 
cholinergic toxicity were the only reliable effects reported in animal studies regarding acute dermal 
exposure to disulfoton. Rabbits that died showed gross effects in the lungs, stomach, liver, kidney, 
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and spleen upon necropsy. An intermediate-duration dermal study examined all systemic end points, 
effects in lymphoreticular and reproductive organs, and neurological effects. 
2.9.2 Identification of Data Needs 
Acute-Duration Exposure. No studies were located regarding systemic effects in humans after 
inhalation or dermal exposure to disulfoton for acute durations. Acute oral ingestion by a man 
resulted in death, and respiratory and renal damage were found at autopsy performed at least 24 hours 
after death (Hattori et al. 1982). No studies were located regarding systemic effects in animals after 
inhalation exposure for acute durations. Information regarding systemic effects after dermal exposure 
is limited to reports of breathing difficulties in rats (Mihail 1978), and degenerative changes in heart, 
liver, kidney, and skin of rats, rabbits, and cats (Kundiev and Rappoport 1967). However, these 
studies were not very reliable. In addition, gross effects in the lungs, stomach, liver, kidney, and 
spleen were observed on necropsy of rabbits that died from cholinergic toxicity after a few dermal 
doses in a 3-week study (Flucke 1986). Acute inhalation lethality data are available for rats and mice 
(Doull 1957; DuBois 1971; Thyssen 1978, 1980); acute oral LD50 values are available for rats 
(Bombinski and DuBois 1958; Crawford and Anderson 1974; Gaines 1969; Mihail 1978; Pawar and 
Fawade 1978), mice (Mihail 1978; Pawar and Fawade 1978; Stevens et al. 1972a), and guinea pigs; 
(Bombinski and DuBois 1958; Crawford and Anderson 1973); acute dermal lethality data are available 
for rabbits (Flucke 1986); and dermal LD50 values are available for rats (DuBois 1957; Gaines 1969; 
Mihail 1969). Acute oral studies in animals have identified the liver as a possible target organ, 
evidenced by induction or inhibition of liver enzymes (Stevens et al. 1972a, 1972b, 1973) and lipid 
peroxidation (Fawade and Pawar 1978). Weight loss in animals also resulted from acute oral exposure 
to disulfoton (Costa et al. 1984, 1986; Schwab and Murphy 1981; Schwab et al. 1981, 1983). An 
acute inhalation MRL of 0.006 mg/ m3 was derived based on a NOAEL for acetylcholinesterase 
inhibition in rats (Thyssen 1978). An acute oral MRL of 0.001 mg/kg/day was derived from animal 
data for acetylcholinesterase inhibition in rat dams exposed during gestation (Lamb and Hixson 1983). 
Acute-duration inhalation, oral, and dermal animal studies that perform comprehensive histological 
examination and look for other sensitive effects using several exposure concentrations or doses will 
provide dose-response data on possible end points other than neurological effects. Attempts to identify 
other target organs in animals after acute exposure will increase the weight of evidence that 
neurological effects (cholinesterase inhibition) are the most sensitive end points. This information is 
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important because there are populations surrounding hazardous waste sites that might be exposed to 
disulfoton for brief periods of time. 
Intermediate-Duration Exposure. No studies were located regarding systemic effects in humans 
after inhalation, oral, or dermal exposure to disulfoton for intermediate durations. Intermediateduration 
inhalation studies in rats using several exposure concentrations and that included clinical 
chemistry, urinalysis, hematology, and comprehensive gross and histological examinations have been 
conducted (Shiotsuka 1989; Thyssen 1980). Inflammation in respiratory tissues, increased adrenal 
weight, decreased spleen weight, decreased lymphocytes, body weight gain reductions, bone marrow 
changes, and neurological effects were identified. An intermediate-duration inhalation MRL of 
2x10-4  mg/ m3 was derived based on a NOAEL for cholinergic effects and acetylcholinesterase 
inhibition in rats (Thyssen 1980). Intermediate-duration oral studies that used several dietary 
concentrations and conducted clinical chemistry, urinalysis, hematology, and performed comprehensive 
gross and histological examination in rats (Klotzsche 1972) and mice (Rivett et al. 1972) have been 
conducted. The liver was identified as a possible target organ, evidenced by a slight increase in liver 
weight in female mice (Rivett et al. 1972). Body weight gain reduction, in addition to neurological 
effects, also resulted from intermediate oral exposure in animals (Hixson and Hathaway 1986; 
Robinson et al. 1978; Schwab and Murphy 1981; Stavinoha et al. 1969). An intermediate-duration 
oral MRL of 9x10-5 mg/kg/day was derived based on a NOAEL for acetylcholinesterase inhibition in 
rat pups (Hixson and Hathaway 1986). A 3-week dermal study that used several dose levels and 
conducted clinical chemistry, urinalysis, hematology, and performed comprehensive gross and 
histological examination has been conducted on rabbits (Flucke 1986). No effects other than 
erythrocyte cholinesterase inhibition were found at 1.6 mg/kg/day, but the next higher dose of 
6.5 mg/kg/day resulted in 100% deaths. A dermal study that uses doses between these extremes might 
provide dose-response information on systemic end points. Additional intermediate-duration animal 
studies by the oral and inhalation routes of exposure using doses intermediate between NOAEL values 
for effects other than cholinesterase inhibition and doses associated with death and severe neurotoxicity 
may be helpful for identifying thresholds for systemic effects. This information is important because 
there are populations surrounding hazardous waste sites that might be exposed to disulfoton for 
intermediate periods of time. 
Chronic-Duration Exposure and Cancer. No studies were located regarding systemic effects in 
humans or animals after inhalation or dermal exposure to disulfoton for chronic durations. Results 
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from an epidemiological study suggest that oral exposure to disulfoton caused myopia in children 
(Ishikawa and Miyata 1980). Clinical evidence of myopia in dogs (Ishikawa and Miyata 1980; Suzuki 
and Ishikawa 1974) and histopathology of the ciliary muscles in the eyes of dogs (Ishikawa and 
Miyata 1980) were observed after chronic oral exposure. Another 2-year oral study was conducted in 
dogs, in which clinical chemistry, hematology, and gross and comprehensive histological examinations, 
including ophthalmology were performed; no effects for any systemic end points, including ocular, 
were found (Hoffman et al. 1975). The doses in this study were about 5 times lower than the doses 
that caused myopia and effects in the ciliary muscles. In addition to the 2-year oral studies in dogs, 
chronic oral studies have been conducted in rats (Carpy et al. 1975; Hayes 1985) and mice (Hayes 
1983). These studies also used several dose levels and conducted clinical chemistry, hematology, 
urinalysis and gross and comprehensive histology. No systemic end points were found in the mice. 
One study in rats identified the liver and the kidney as possible target organs, suggested by an increase 
in liver and kidney weights in male rats (Carpy et al. 1975). The other study in rats found 
granulomatous and suppurative inflammation in the lungs, which may have been due to aspiration of 
the food particles; mucosal hyperplasia and chronic inflammation of the forestomach, skeletal muscle 
atrophy (due to debilitation); pancreatic atrophy; dermal lesions; and decreased body weight gain 
(Hayes 1985). In addition, ocular effects consisting of cystic degeneration of the Harderian gland and 
cornea1 neovascularization were observed. The chronic oral dietary studies in rats (Carpy et al. 1975; 
Hayes 1985), mice (Hayes 1983), and dogs (Hoffman et al. 1975) established LOAEL and NOAEL 
values for acetylcholinesterase inhibition. A chronic inhalation MRL was not derived because no 
studies were located. A chronic oral MRL of 6x10-5  mg/kg/day was derived based on a LOAEL for 
erythrocyte and brain cholinesterase inhibition in female rats in the study by Hayes (1985). Welldesigned 
chronic-duration inhalation and dermal studies in rats and mice, in which several dose levels 
are used and comprehensive end points are examined, might identify systemic target organs for these 
routes and establish dose-response relationships. Although cholinesterase inhibition is the most 
sensitive end point, additional chronic dietary studies in mice and dogs could be conducted that use 
doses to establish LOAEL and NOAEL values for end points other than cholinesterase inhibition, that 
is for systemic target organs. This information is important because there are populations surrounding 
hazardous waste sites that might be exposed to disulfoton for long periods of time. 
No studies were located regarding cancer in humans after inhalation, oral, or dermal exposure to 
disulfoton or in animals after inhalation or dermal exposure. A 13-week inhalation study in rats 
reported that comprehensive histological examination of organs and tissues revealed no treatment­
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related neoplastic lesions (Shiotsuka 1989); however, a chronic-duration inhalation study would be 
more appropriate to assess possible carcinogenicity. Carcinogenicity was not observed in rats (Carpy 
et al. 1975; Hayes 1985), mice (Hayes 1983) or dogs (Hoffman et al. 1975) that had been fed a diet 
of disulfoton for 1.5-2.0 years. Although there is little reason to suspect that disulfoton is 
carcinogenic, chronic inhalation, oral, or dermal studies should include comprehensive histology to 
confirm that disulfoton is not carcinogenic. 
Genotoxicity. Disulfoton has been tested in numerous types of assays for genotoxicity. Disulfoton 
was positive for unscheduled DNA synthesis in human lung fibroblasts (EPA 1984a; Sandhu et al. 
1985) and for growth inhibition in human HeLa cells (Litterst et al. 1969). Disulfoton was negative in 
assays for chromosomal aberrations in human hematopoietic cell lines (Huang 1973) and for alterations 
in DNA or RNA synthesis in human HeLa cells (Litterst et al. 1969). Disulfoton did not induce 
micronuclei in mice exposed orally or intraperitoneally (EPA 1984a; Herbold 1981; Sandhu et al. 
1985), dominant lethality in mice exposed orally (Herbold 1980), or sex-linked recessive lethal 
mutation in D. melunogaster (EPA 1981a; Waters et al. 1981). Mostly negative results were obtained 
in in vitro tests in bacteria and yeast (Brusick 1981; EPA 1980a, 1984a; Herbold 1983; Jagannath 
1981; Moriya et al. 1983; Sandhu et al. 1985; Waters et al. 1981, 1982), but a few positive results 
were obtained in some strains of S. typhimurium and E. coli (Hanna and Dyer 1975; Moriya et al. 
1983; Shirasu et al. 1982, 1984). Disulfoton also produced positive results in several assays in barley 
(Murty et al. 1983; Panda 1983; Singh et al. 1977). Some positive and some negative results have 
been obtained in cultured mammalian cells. Positive results were found for sister chromatid exchange 
in Chinese hamster ovary cells in some studies (EPA 1984a; Putnam 1987; Sandhu et al. 1985; Waters 
et al. 1981, 1982), but negative results were obtained in another study (Chen et al. 1981, 1982). 
Negative results were also obtained for HGPRT mutations in Chinese hamster ovary cells (Yang 
1988). Disulfoton was positive for forward mutation in mouse lymphoma cells (EPA 1984a; Sandhu 
et al. 1985; Waters et al. 1981, 1982). Although most assays were negative, the few positive results 
suggest a genotoxic potential. However, it is doubtful that additional testing would add meaningful 
data. 
Reproductive Toxicity. No studies were located regarding reproductive effects in humans after 
inhalation, oral, or dermal exposure to disulfoton. Disulfoton did not affect male fertility in mice in an 
oral dominant lethal study (Herbold 1980). Slightly reduced litter sizes in third generations were the 
findings of a three-generation oral reproductive study in rats (Taylor 1965a). When males and females 
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were exposed to disulfoton for 60 days prior to and/or during mating, 2 of 5 females failed to become 
pregnant (Ryan et al. 1970). Although complete gross anatomical and histopathological examinations 
were lacking, the data do suggest that the male and/or female reproductive system may be affected. A 
more extensive multigeneration feeding study in rats found decreased reproductive performance of 
males and females; decreased maternal weight of F0 and F1 dams during gestation and lactation; 
decreased litter counts, viability index; and lactation index; increased dead births and percentage of 
dead births in both generations; and decreases in F2b litter counts and litter weights (Hixson and 
Hathaway 1986). However, negative histopathological results were generally obtained from the 
examination of male and female reproductive systems in rats exposed by inhalation for 3 or 13 weeks 
(Shiotsuka 1989; Thyssen 1980); in rabbits treated dermally for 3 weeks (Flucke 1986); in rats 
(Klotzsche 1972) or mice (Rivett et al. 1972) fed disulfoton for 90 days; or in rats (Carpy et al. 1975; 
Hayes 1985), mice (Hayes 1983), or dogs (Hoffman et al. 1975) fed disulfoton for ≈2 years, with the 
exception of uterine cystic hyperplasia in female rats fed the high dietary concentration of disulfoton 
for 2 years (Hayes 1985). Studies on reproductive function in animals exposed by the inhalation or 
dermal routes will help clarify whether disulfoton affects reproduction by these routes as well as the 
oral route. 
Developmental Toxicity. No studies were located regarding developmental effects in humans 
after inhalation, oral, or dermal exposure to disulfoton or in animals after inhalation or dermal 
exposure. Developmental effects have been found in animals after acute- and intermediate-duration 
oral exposure to disulfoton. Plasma and erythrocyte cholinesterase depression and increased incidences 
of incomplete ossified parietal bones and sternebrae were observed in fetuses from rats fed disulfoton 
on days 6-15 of gestation (Lamb and Hixson 1983). Bone and soft tissue malformations were not 
observed. Effects in fetuses or pups, such as depressed brain cholinesterase activity (Hixson and 
Hathaway 1986; Ryan et al. 1970), renal and hepatic pathology, and juvenile hypoplasia of testes 
(Taylor 1965a) were also observed in reproductive studies. However, disulfoton did not cause any 
fetotoxic effects in the fetuses from pregnant rabbits treated orally with disulfoton during gestation 
(Tesh et al. 1982). Additional developmental studies involving inhalation or dermal exposure of 
animals to disulfoton might indicate whether fetotoxic effects are route-dependent. 
lmmunotoxicity and Lymphoreticular Effects. No studies were located regarding 
immunological effects in humans after inhalation, oral, or dermal exposure to disulfoton. In two acute 
animal studies (Costa et al. 1990; Fitzgerald and Costa 1993), repeated intraperitoneal or oral doses of 
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disulfoton caused a down-regulation of cholinergic muscarinic receptors in lymphocytes. Although the 
effect on lymphocytes is regarded as a neurological effect, secondary effects due to neuroimmuno 
interactions are possible and warrant further investigation. After inhalation exposure of rats, 
inflammatory changes throughout the respiratory tract (associated with bone marrow changes and low 
percentages of lymphocytes and high percentages of polymorphonuclear leukocytes) and decreased 
spleen weight were observed (Thyssen 1980). In a chronic dietary study in rats, increased incidence of 
plasma cell hyperplasia in the mandibular lymph nodes and a significantly increased incidence of 
splenic lymphoid follicle depletion were observed (Hayes 1985). In other inhalation (Shiotsuka 1989), 
dietary (Carpy et al. 1975; Hayes 1983; Hoffman et al. 1975; Klotzsche 1972; Rivett et al. 1972), and 
dermal (Flucke 1986) studies in animals exposed to disulfoton, histological examination of 
lymphoreticular organs revealed no treatment-related lesions. However, immunological data collected 
from animals exposed to disulfoton by all three routes for acute, intermediate, or chronic durations 
might indicate whether disulfoton affects the immune system. A battery of immune function tests 
would clarify whether disulfoton is an immunotoxicant. 
Neurotoxicity. Exposure to disulfoton by the inhalation, oral, or dermal routes has resulted in 
neurological effects in humans. Disulfoton can cause erythrocyte cholinesterase depression in humans 
after inhalation exposure without other overt neurological effects (Wolfe et al. 1978). The more overt 
neurological effects have been observed in humans after oral exposure to disulfoton (Hattori et al. 
1982; Yashiki et al. 1990). The clinical signs consisted of muscle tremors and incoordination, 
increased salivation, pupil miosis, and even death. Weakness and fatigue (Savage et al. 1971) and 
depressed erythrocyte acetylcholinesterase activity (Wolfe et al. 1978) were observed in humans after 
dermal exposure to disulfoton. No significant depression in brain, serum, or submaxillary gland 
cholinesterase activity and no overt signs of neurotoxicity were observed in rats after acute inhalation 
(5-10 days) exposure (DuBois and Kinoshita 1971). Inhalation, oral, and dermal exposures of animals 
to disulfoton resulted in signs of cholinergic toxicity (Costa et al. 1984; Doull 1957; Flucke 1986; 
Mihail 1978; Schwab and Murphy 1981; Schwab et al. 1981, 1983; Shiotsuka 1989; Thyssen 1980). 
These cholinergic signs were similar to those observed in humans and are associated with inhibition of 
acetylcholinesterase. Inhibition of brain, erythrocyte, and other tissue acetylcholinesterase activities 
(Carpy et al. 1975; Christenson and Wahle 1993; Clark and Pearson 1973; Doull and Vaughn 1958; 
Flucke 1986; Hayes 1983, 1985; Hikita et al. 1973; Hixson and Hathaway 1986; Hoffman et al. 1975; 
Klotzsche 1972; Robinson et al. 1978; Ryan et al. 1970; Schwab and Murphy 1981; Schwab et al. 
1981; Sheets 1993a, 1993b; Shiotsuka 1989; Thyssen 1978, 1980) have been observed in animals in 
DISULFOTON 133 
2. HEALTH EFFECTS 
numerous studies regardless of the route, duration, or animal species. The acute and intermediate 
inhalation MRLs and the acute, intermediate, and chronic oral MRLs are based on cholinesterase 
inhibition. Tolerance was also observed in animals exposed to disulfoton for ≥5-10 days (Costa et al. 
1984; Schwab and Murphy 1981; Schwab et al. 1981, 1983). Neurobehavioral changes were observed 
in rats (Clark and Pearson 1973) and mice (Clark et al. 1971) exposed orally for intermediate 
durations. Necrosis and atrophy of the optic nerve and retina in dogs (Uga et al. 1977) were observed 
after oral exposure. Based on the results of the human and animal studies, neurological effects (subtle 
and/or overt) may occur regardless of the route of exposure. Additional animal studies do not seem to 
be warranted at this time. 
Epidemiological and Human Dosimetry Studies. Epidemiological studies are limited. A 
coincidental increase in the incidence of myopia was observed in young children thought to be orally 
exposed to disulfoton (Ishikawa and Miyata 1980). Although there is clinical and histopathological 
evidence from animal studies to support the association between myopia and disulfoton exposure, other 
neurological effects (i.e., depressed acetylcholinesterase activity) were not reported. Employees 
exposed to disulfoton by inhalation and dermal routes (Brokopp et al. 1981; Wolfe et al. 1978) did not 
show overt signs of toxicity, but disulfoton exposure was confirmed in part by depressed 
cholinesterase activity and/or urinary metabolite identification. These studies are limited because it is 
not clear whether inhalation or dermal exposure contributed the most to the observed effects. Future 
human epidemiological studies should look for subtle neurological indicators of exposure (i.e., 
erythrocyte or lymphocyte acetyl cholinesterase depression) in addition to the ocular effects already 
described. The data would be useful for establishing cause/effect relationships and for future 
monitoring of individuals living near hazardous waste sites. 
Biomarkers of Exposure and Effect 
Exposure. Disulfoton and its metabolites have been detected in the blood and the urine of humans 
exposed to disulfoton either accidentally or in the workplace (Brokopp et al. 1981; Hattori et al. 1982; 
Wolfe et al. 1978; Yashiki et al. 1990). Whereas, disulfoton and its metabolites were detected in the 
blood of humans who ingested unknown quantities of disulfoton (Hattori et al. 1982; Yashiki et al. 
1990), urinary metabolites were a better indicator of occupational exposure to the pesticide (Brokopp 
et al. 1981; Wolfe et al. 1978). Although no animal studies reported the detection of disulfoton or its 
metabolites in blood, data from animal studies demonstrated that urinary metabolites were a reliable 
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indicator of disulfoton exposure (Bull 1965; Lee et al. 1985; Puhl and Fredrickson 1975). These 
animal studies also demonstrated that DEP was a more sensitive urinary biomarker than other 
metabolites. DEPs are specific for diethyl organophosphates such as disulfoton. A combination of 
neurological signs is usually a biomarker of disulfoton exposure, as demonstrated in humans (Yashiki 
et al. 1990) and animals (Schwab et al. 1981). Inhibition of serum cholinesterase and/or erythrocyte 
acetylcholinesterase are usually reliable biomarkers of exposure in humans (Wolfe et al. 1978; Yashiki 
et al. 1990). Since blood cholinesterase depression was not observed, but urinary metabolites were 
detected in exposed employees (Brokopp et al. 1981), urinary metabolites may be a more sensitive 
biomarker of disulfoton exposure. Urinary metabolites are generally eliminated within 2 weeks after 
the last exposure and are not usually detected beyond this period. However, cholinesterase depression 
may be a better biomarker, because the enzyme may remain inhibited for >2 weeks. A recent study 
showed that T-lymphocyte acetylcholinesterase activity was rapidly and greatly depressed in rats 
during a 14-day exposure to disulfoton, but rapidly recovered after exposure (Fitzgerald and Costa 
1993). Therefore, T-lymphocyte acetylcholinesterase levels could be used as a biomarker of exposure 
to organophosphorus pesticides during exposure, and could be investigated for use in biomonitoring 
worker exposure. Animal studies indicate that nonspecific biomarkers of disulfoton exposure may 
include increased urinary levels of catecholamines (Brzezinski 1969) or their metabolite HMMA 
(Wysocka-Paruszewska 1971) and increased MFO enzymes (Stevens et al. 1973). No human data 
were located to support these findings. Although available biomarkers of exposure for disulfoton are 
nonspecific, it is doubtful that further research will identify a more useful and specific biomarker. 
Effect. Disulfoton exposure in humans or animals causes characteristic cholinergic effects such as 
increased salivation, diarrhea, muscle tremors, and pupillary miosis (Costa et al. 1984; Schwab et al. 
1981, 1983; Yashiki et al. 1990). These effects are also associated with exposure to other 
organophosphates and are, therefore, not specific to disulfoton. Inhibition of erythrocyte 
acetylcholinesterase can alert the physician to the possibility of more serious neurological effects. In 
rats, acetylcholinesterase levels in circulating lymphocytes correlated better with brain 
acetylcholinesterase activity than did erythrocyte cell cholinesterase activities during exposure, but not 
during recovery after exposure (Fitzgerald and Costa 1993). Thus, lymphocyte acetylcholinesterase 
activity may be a better biomarker of effect than erythrocyte acetylcholinesterase activity during 
exposure, but erythrocyte acetylcholinesterase probably remains the better sentinel for brain 
acetylcholinesterase activity after exposure has ceased. However, other organophosphates and also 
carbamates can cause this neurological effect. Although animal studies have demonstrated that brain 
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acetylcholinesterase inhibition is a sensitive indicator of a neurological effect (Carpy et al. 1975), this 
measurement is not practical in humans. Increased β-glucuronidase activity (Kikuchi et al. 1981) and 
increased urinary catecholamine levels (Brzezinski 1969) observed in animals may be useful 
nonspecific biomarkers of effects in humans. There does not appear to be a need for additional 
biomarkers of effect. 
Absorption, Distribution, Metabolism, and Excretion. No studies were located regarding the 
absorption, distribution, metabolism, and excretion of disulfoton by humans or animals after inhalation 
or dermal exposure. Limited data exist regarding the absorption, distribution, and excretion after oral 
exposure to disulfoton. Data on levels of disulfoton and metabolites excreted in urine and expired air 
suggest that some almost complete absorption of an administered dose of disulfoton over 3-10 days 
(Lee et al. 1985; Puhl and Fredrickson 1975). The data are limited regarding the relative rate and 
extent of absorption. Animal data suggest that disulfoton and/or its metabolites are rapidly distributed 
to the liver, kidney, fat, skin, muscle, and brain, with peak levels occurring within 6 hours (Puhl and 
Fredrickson 1975). Elimination of disulfoton and metabolites occurs primarily in the urine, with >90% 
excreted in the urine in 3-10 days (Lee et al. 1985; Puhl and Fredrickson 1975). Evidence further 
suggests that male rats eliminate disulfoton at a faster rate than females. This difference may be due 
to differences in absorption, metabolism, retention, excretion, or a combination of factors. The 
metabolic pathways of disulfoton are relatively well understood based on data from animal studies 
(Bull 1965; Lee et al. 1985; March et al. 1957; Puhl and Fredrickson 1975). Similar metabolites have 
been detected in the urine and tissues from humans exposed to disulfoton (Brokopp et al. 1981; 
Yashiki et al. 1990). One study suggests that a greater percentage of disulfoton sulfoxide is oxidized 
to demeton S-sulfoxide, rather than disulfoton sulfone to form demeton S-sulfone (Bull 1965). 
Additional studies in animals, designed to measure the rate and extent of absorption, distribution, and 
excretion of disulfoton after inhalation or dermal exposure would be useful for predicting the 
toxicokinetics of disulfoton in humans at an occupational or hazardous waste site. 
Comparative Toxicokinetics. The primary target organ for disulfoton in animals and humans is 
the nervous system. Other organs, such as the liver, are hardly affected. Since there have been no 
toxicokinetic studies in animals or humans exposed by inhalation or dermal routes, it is impossible to 
compare animals and humans by these two routes of exposure. Data from occupational studies suggest 
that disulfoton was absorbed via inhalation and/or dermal routes of exposure (Brokopp et al. 1981; 
Wolfe et al. 1978); however, the data from these studies on the rate and extent of absorption are 
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limited. No animal studies were available for comparison. Although the rate and extent of absorption 
was unknown, disulfoton was readily absorbed by two men as demonstrated in two separate studies 
(Hattori et al. 1982; Yashiki et al. 1990). In animals, toxicokinetic data are available only in rats 
exposed by the oral route (Lee et al. 1985; Puhl and Fredrickson 1975). No studies were located 
regarding the distribution of disulfoton following inhalation or dermal exposure in humans or animals. 
Although no studies were located regarding the distribution of disulfoton following oral exposure in 
humans, data from animal studies were located. Disulfoton and its metabolites were detected in the 
liver, kidney, adipose tissue, muscle, skin, and brain (Puhl and Fredrickson 1975). Data from human 
(Brokopp et al. 1981; Wolfe et al. 1978; Yashiki et al. 1990), rat (Bull 1965; Lee et al. 1985; Puhl and 
Fredrickson 1975), and mouse (March et al. 1957) studies indicate that similar metabolic pathways 
operate in humans and rodents. No studies were located regarding the rate or extent of excretion of 
disulfoton in humans or animals after inhalation or dermal exposure. Although no studies were 
located regarding the rate or extent of excretion of disulfoton after oral exposure in humans, limited 
data for animal studies were located. Data from the only animal study located suggested that most of 
the disulfoton was eliminated within 3-10 days of exposure and that male rats eliminated disulfoton at 
a faster rate than females (Lee et al. 1985; Puhl and Fredrickson 1975). With intraperitoneal 
administration, rats eliminated 28% of the original dose within 48 hours (Bull 1965), and mice 
eliminated 30-60% of the original dose within 96 hours (March et al. 1957). There appears to be 
insufficient toxicokinetic data to use as a basis for comparison of animals and humans. Additional 
studies comparing the rate and extent of absorption, distribution, and elimination in several different 
animal species after inhalation, oral, and dermal exposure to disulfoton could be useful. 
Methods for Reducing Toxic Effects. No data were located regarding the mechanism of 
absorption via the respiratory tract, gastrointestinal tract, or the skin. Besides moving the exposed 
individual to a fresh air environment and/or administering oxygen, very little can be done if disulfoton 
is inhaled (Sittig 1991). Induction of emesis, gastric lavage, and administration of a saline cathartic 
immediately after oral exposure help reduce absorption. Since diuresis, dialysis, and hemoperfusion 
have been used to reduce the body burden of other organophosphates (Ellenhorn and Barceloux 1988), 
it seems reasonable that these methods may also be used to treat disulfoton intoxication. Repeated 
administration of activated charcoal and cathartics may prevent possible enterohepatic recirculation of 
the parent compound and its metabolites. The treatment protocol also includes interfering with the 
known mechanism of action of disulfoton. Atropine is used to block the muscarinic effects of 
disulfoton (Goldfrank et al. 1990; Yashiki et al. 1990), and an oxime (e.g., 2-PAM) is given to 
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accelerate the hydrolysis of phosphorylated cholinesterase, which accelerates regeneration of the active 
cholinesterase (Ellenhorn and Barceloux 1988; Goldfrank et al. 1990; Haddad and Winchester 1990; 
Morgan 1982). There are numerous treatment protocols that successfully use some or all of the 
methods described. Therefore, further studies regarding the reduction of toxic effects for disulfoton 
exposure may not be warranted. 
2.9.3 Ongoing Studies 
A study by S.C. Soderholm of the University of Rochester is in progress to relate the deposition 
efficiency of volatile aerosols of disulfoton in humans to physical properties of the airborne system, 
including exposure concentration, saturation vapor concentration, particle size, and blood/gas partition 
coefficient (CRISP Database 1994). Disposition efficiency will be determined from laboratory 
experiments and computer modelling. The results of computer models will be compared to measure 
disposition efficiencies of disulfoton aerosols in humans. With this information, the inhaled dose in 
humans can be estimated. 
Studies on particular organophosphates are currently being conducted by EPA to substantiate the 
findings that these organophosphates, including disulfoton, are associated with the development of 
myopia in humans, as reported in Japanese populations (Dementi 1994). 
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3.1 CHEMICAL IDENTITY 
Information regarding the chemical identity of disulfoton is located in Table 3-l. 
3.2 PHYSICAL AND CHEMICAL PROPERTIES 
Disulfoton is a systemic insecticide/acaricide that belongs to the organophosphate class of pesticides. 
Pure disulfoton is a colorless oil with low volatility and water solubility, but is readily soluble in most 
organic solvents (Worthing 1987). Information regarding the physical and chemical properties of 





4. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
4.1 PRODUCTION 
Disulfoton is produced commercially by a reaction of the sodium salt of O,O’-diethylhydrogen 
phoshorodithioate with 2-chloroethylthioethyl ether (VonRumker et al. 1974). Disulfoton is produced 
in the United States by a subsidiary of Bayer AG, Germany. Chemagro of Kansas City, Missouri, a 
subsidiary of Bayer AG, produced an estimated 5 million pounds of disulfoton in 1972 (VonRumker et 
al. 1974). Disulfoton production has declined in recent years as a result of restricted use due to its 
toxicity (EPA 1984b). In 1986, Mobay Corp., Kansas City, Missouri, produced over 2.1 million 
pounds of disulfoton in the United States (Goodrich et al. ld!Jl). Since the annual use of disulfoton in 
the United States from 1989 to 1991 was 3.06 million pounds (Gianessi and Puffer 1992), the 
production volume during this period must have exceeded 3.1 million pounds. In 1994, Miles Inc., 
Agriculture Division, Kansas City, Missouri, a subsidiary of Bayer AG of Germany, produced 
disulfoton; however, information on current production volume is not available (SRI 1994). 
4.2 IMPORT/EXPORT 
In 1972, disulfoton was not imported into the United States, and the exports of disulfoton from the 
United States to other countries were negligible (VonRumker et al. 1974). Import/export data for 
disulfoton in recent years were not located; however, since the recent yearly consumption of disulfoton 
in the United States is substantially lower than the estimated yearly production capacity of 7 million 
pounds at the Kansas City plant (VonRumker et al. 1974), it is unlikely that disulfoton is being 
imported. 
4.3 USE 
Disulfoton is a systemic organophosphate insecticide/acaricide (i.e., it is absorbed and translocated by 
treated plants) effective for controlling a variety of harmful insects that attack many field and 
vegetable crops. As emulsifiable concentrates and in granular or pelleted/tableted forms, disulfoton is 
used to treat seeds and is applied to soils or plants. Disulfoton is also available in a ready-to-use 
liquid formulations (EPA 1984b). Disulfoton is used to protect small grains, sugar cane, sorghum, 
corn, cotton, Cole, root, seed, forage, and other field crops; some vegetable, fruit (strawberry, 
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pineapple), and nut crops; and forest plantings, ornamental and potted plants (EPA 1984b; VonRumker 
et al. 1974). Agricultural uses account for most of its consumption; small quantities are used on home 
and garden plants and for other purposes, such as mosquito abatement (VonRumker et al. 1974; 
Warnick and Eldredge 1972). Use of disulfoton has declined since the early 1970s. In 1972, 
4.9 million pounds of disulfoton were used for agricultural purposes, and only 0.1 million pounds were 
used in homes and gardens (VonRumker et al. 1974). Based on state usage data from 33 states for 
1982, California use data for 1981, and the EPA Office of Pesticide Programs national survey of 
pesticide usage by urban applicators and nurseries, Gianessi (1986) estimated that 2.1 million pounds 
of disulfoton were used annually in agriculture during 1981 and 1982. The estimated annual 
agricultural use of disulfoton was 2.1 million pounds in 1986 (Goodrich et al. 1991) and 3.1 million 
pounds in 1989-1991 (Gianessi and Puffer 1992). The use of disulfoton in the production of corn, 
wheat, potatoes, and cotton accounted for the largest annual use during 1989-1991 (Gianessi and 
Puffer 1992). 
4.4 DISPOSAL 
The two preferable methods for disposing of wastes containing disulfoton are incineration and alkaline 
hydrolysis (HSDB 1994). For disposal of low-viscosity wastes (permitting atomization in the 
combustion chamber) containing disulfoton, liquid injection incineration at 650-1,600 ºC and a 
residence time of 0.1-2 seconds are recommended. For the disposal of viscous and solid wastes, 
rotary kiln incineration at 820-1,600 ºC and a residence time of seconds to hours, or fluidized bed 
incineration at 450-980 ºC with a residence time of seconds or longer are recommended. The effluent 
gases from the incineration units should pass through scrubbers or other air pollution control devices 
(HSDB 1994). Alkaline hydrolysis leads to the complete degradation of disulfoton to non-toxic end 
products (alkaline salts of O,O-dimethylphosphorothioic acid and ethylthioethyl mercaptan). Disulfoton 
is resistant to hydrolysis in acid media (Sittig 1980). Acid hydrolysis produces essentially the same 
end products; however, the reaction rate is much slower (IRPTC 1985). Fifty percent hydrolysis at 
70 ºC requires 60 hours at pH 5, but only 7.2 hours at pH 9 (Sittig 1980). In the alkaline hydrolysis 
method, the waste should be subjected to hydrolysis with 6% potassium hydroxide in isopropanol 
under reflux for 30 minutes (IRPTC 1985) or 5% sodium hydroxide in ethanol for 3 hours (for 
2%,10%, and 50% granular formulations) (Dillon 1981). The hydrolyzed product should be adsorbed 
on vermiculite, then incinerated or disposed of in a landfill (IRPTC 1985). 
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The EPA has proposed incineration as the best demonstrated available technology (BDAT) for treating 
organophosphorus nonwaste waters (waste containing >l% by weight total suspended solids and >l% 
by weight total organic carbon). EPA has demonstrated that rotatory kiln incineration at 1,000°C was 
satisfactory for attaining the proposed treatment standard of a maximum 0.1 mg/kg disulfoton in 
treated nonwaste waters (Berlow and Cunningham 1989). 
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5.1 OVERVIEW 
Disulfoton enters the environment primarily during its use as an insecticide/acaricide in crops and 
vegetables, and in homes and gardens. Other important pathways for disulfoton’s entry into the 
environment are the disposal of liquid disulfoton wastes into soil evaporation pits, ditches, ponds 
(Winterlin et al. 1989), and hazardous waste sites. Thus, soil is the environmental medium most likely 
to be contaminated with disulfoton. The processes that may transport disulfoton from soil to other 
environmental media include leaching to groundwater, runoff to surface water, and absorption by 
plants (Holden 1986; Mostaghimi et al. 1993; Nash 1974; Plumb 1991; Sanbom et al. 1977; Spalding 
and Snow 1989). Biodegradation, abiotic hydrolysis and, to a lesser extent, sensitized oxidation are 
principally responsible for the loss of disulfoton from water (Cape1 et al. 1988; Mossman et al. 1988; 
Wanner et al. 1989). In a chemical spill in the Rhine River where an initial disulfoton concentration 
of 5 µ/L was observed, the estimated biodegradation half-life of disulfoton in 10 ºC river water was 
7-41 days (Wanner et al. 1989). The measured whole-body bioconcentration factor for disulfoton in 
carp was 450, but disulfoton residues disappeared rapidly from the fish when they were placed in 
uncontaminated water (Takase and Oyama 1985). Biodegradation and photosensitized oxidation play 
major roles in the loss of disulfoton from soil (Gohre and Miller 1986; Wanner et al. 1989; Zepp et al. 
1981). The estimated half-life of disulfoton in soil ranges from 3.5 to ≤290 days (Chapman et al. 
1993, 1994a; Garg and Sethi 1980; GreenhaIgh 1978; Harris et al. 1988; Jury et al. 1987a; Menzie 
1972). 
Disulfoton was detected at a maximum of 4.7 ng/m3 in 1 of 123 ambient air samples from 
10 locations in the United States (Carey and Kutz 1985). Disulfoton was qualitatively detected in 
groundwater samples from 1 of 479 hazardous waste sites (Plumb 1991) and in runoff water in an 
agricultural watershed at concentrations ranging from trace to 0.4 µg /L (Spalding and Snow 1989). 
Disulfoton was also detected in groundwater samples from the Nomini Creek Watershed in Virginia at 
a mean and maximum concentration of 0.39 µg/L and 2.87 µg /L respectively (Mostaghimi et al. 1993). 
A core soil sample taken from a waste evaporation pit at a depth of 90 cm contained disulfoton at a 
concentration of 44 mg/kg (Winterlin et al. 1989). The mean concentration of disulfoton in the bottom 
soil of an agricultural tail water pit used to collect irrigation runoff was 13.4 µg /kg. 
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The Food and Drug Administration (FDA) estimated the average dietary intake of disulfoton from 
1986-1991 for a 14- to 16-year-old male in the United States at 0.2 ng/kg body weight/day, a quantity 
over 1,000 times lower than the Food and Agricultural Organization of the United Nations/World 
Health Organization’s (FAO/WHO) acceptable daily intake (ADI) of 300 ng/kg body weight/day (EPA 
1993b; FAO/WHO 1991; Winter 1992; Yess 1991). 
Workers in industries that manufacture and formulate disulfoton, farm workers who enter treated fields 
after the insecticide has been applied and, in particular, applicators of the insecticide are at a higher 
risk of exposure than the general population. Among the general population, people who use the 
insecticide in homes and garden applications are at a higher risk of exposure, as are people who live 
near hazardous waste sites containing disulfoton. 
Disulfoton has been identified in 7 of the 1,408 hazardous waste sites on the NPL (HazDat 1994). 
The frequency of these sites within the United States can be seen in Figure 5-1. 
5.2 RELEASES TO THE ENVIRONMENT 
5.2.1 Air 
Disulfoton may enter the atmosphere during its production and its use as an insecticide/acaricide. Air 
emissions from disulfoton production have been reported to be 0.5 kg per 1,000 kg (one metric ton) 
(Sittig 1980). Assuming a minimum production volume of 3.1 million pounds (1.4 million kg) per 
year, based on Gianessi and Puffer (1992) use estimates for 1989 through 1991, approximately 
1,500 pounds (700 kg) are emitted to the atmosphere from production annually. Disulfoton is 
primarily released to the atmosphere during application of the granular insecticide by ground broadcast 
or aerial application (CPCR 1992). Disulfoton also enters the atmosphere when the emulsifiable 
insecticide is sprayed on crops and soil (CPCR 1992), and when the insecticide is aerially applied as a 
fog for controlling mosquitos (Racke 1992; Warnick and Eldredge 1972). Although not as significant 
a source, unintentional releases of disulfoton into the atmosphere include volatilization of applied 
insecticide from soil and plant surfaces, and accidental spills. 
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5.2.2 Water 
Other than aerial application over swamps for mosquito abatement, disulfoton is not known to be used 
over water. Potential sources of release into surface water include discharge of waste water from 
disulfoton manufacturing, formulation, and packaging facilities (HSDB 1994). Leaching and runoff 
from treated fields, pesticide disposal pits, or hazardous waste sites may contaminate both groundwater 
and surface water with disulfoton. Entry into water can also occur from accidental spills. Small 
amounts of volatilized disulfoton may be removed from the atmosphere as a result of wet deposition 
and may enter surface water (Racke 1992). 
5.2.3 Soil 
Disulfoton is released to agricultural, home, and garden soil during direct soil or foliar treatment with 
the insecticide and from disposal of disulfoton-containing wastes in hazardous waste sites (HSDB 
1994). Much of the foliar-applied disulfoton or its metabolites eventually reach the soil (Racke 1992). 
Soil in waste disposal sites may include manufacturing wastes containing disulfoton. A primary 
method for disposing of liquid pesticide wastes has been dumping liquid materials into soil 
evaporation pits, ditches, and ponds. Topsoil from such discharge areas can be expected to be 
contaminated with pesticides, as the soil from one such discharge pit contained disulfoton (Winterlin et 
al. 1989). Soil from tail water pits used for collecting irrigation runoff may also be a source of 
disulfoton if the soil has been treated with this insecticide (Kadoum and Mock 1978). Small amounts 
of disulfoton may enter soil by deposition of aerial disulfoton on land (Racke 1992). Entry may also 
occur from spills during storage, transport, or equipment loading and cleaning, although contemporary 
management practices significantly reduce the quantities of disulfoton accidentally released during its 
use (Racke 1992). 
5.3 ENVIRONMENTAL FATE 
5.3.1 Transport and Partitioning 
There is a paucity of experimental data regarding the transport and partitioning of disulfoton in air. 
Given the vapor pressure of 1.8x10-4 mm Hg at 20 ºC (Melnikov 1971), disulfoton should exist almost 
entirely in the vapor phase in the atmosphere (Eisenreich et al. 1981). Because of low particle 
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diameter, the removal rate by dry deposition is low for compounds that exist in the vapor phase in the 
atmosphere (Schroeder et al. 1987); therefore, depending on its reactivity characteristics, vapor-phase 
disulfoton may travel long distances in the air. The solubility of 25 mg/L (Sanborn et al. 1977) 
ensures that at least partial removal of atmospheric disulfoton will occur by wet deposition. 
The transport of disulfoton from water to air can occur due to volatilization. Compounds with a 
Henry’s law constant (H) of <10m-5 atm-m3/mol volatilize slowly from water (Thomas 1990). 
Therefore, disulfoton, with an H value of 2.17x10-6 atm- m3/mol (Domine et al. 1992), will volatilize 
slowly from water. The rate of volatilization increases as the water temperature and ambient air flow 
rate increases and decreases as the rate of adsorption on sediment and suspended solids increases 
(Dragan and Carpov 1987). The estimated gas-exchange half-life for disulfoton volatilization from the 
Rhine River at an average depth of 5 meters at 11 ºC was 900 days (Wanner et al. 1989). The 
estimated volatilization half-life of an aqueous suspension of microcapsules containing disulfoton at 
20 ºC with still air was >90 days (Dragan and Carpov 1987). 
Adsorption to particulate matter will transport disulfoton from water to suspended solids and sediment 
in water. The estimated organic carbon-adjusted soil sorption coefficient (Koc) for disulfoton varies 
between 600 and 1,603 (Jury et al. 1987a; Rao and Davidson 1982; Wauchope et al. 1992). This 
range of Koc values suggests that disulfoton in water adsorbs moderately to suspended solids and 
sediments (Swann et al. 1983), and this process may transport considerable amounts of disulfoton from 
water to particulate matter. 
Based on structure activity relationships, certain regression equations have been developed to estimate 
disulfoton’s bioconcentration factor (BCF) from its water solubility and Koc values. Based on these 
regression equations, the estimated BCF for disulfoton in aquatic organisms is 100-l 10 (Kenaga 
1980). A microcosm, simulating paddy fields containing water, sweet potato, tobacco cutworm 
(Spodoptera litura), algae (Spirogyra crassa), red snail (Indoplanorbis exustus), Daphnia, mosquito 
larvae (Culex pipiens), and guppies (Labistes reticulatus), was used to assess disulfoton accumulation 
in aquatic organisms over a 33-day period (Tomizawa 1980). Whole-body BCF values of 9 and 2,487 
were reported for snails and guppies, respectively. The bioconcentration of disulfoton and its 
oxidation products (sulfoxide and sulfone) in carp (Cyprinus carpio) was investigated in a continuousflow 
water system for ≤56 days (Takase and Oyama 1985). The whole-body BCF values in carp were 
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≈450 for disulfoton, <l for the sulfoxide, and <6 for the sulfone. Disulfoton disappeared rapidly from 
fish tissues when the fish were transferred to uncontaminated fresh water. 
The transport processes that may move disulfoton from soil to other media are volatilization, leaching, 
runoff, and absorption by plants. Volatilization of disulfoton from wet soil may be greater than from 
relatively dry soil (Gohre and Miller 1986). Like other pesticides, disulfoton in soil partitions between 
soil-sorbed and soil-water phases (Racke 1992). This latter phase may be responsible for the 
volatilization of disulfoton from soil; however, due to the low Henry’s law constant value, the rate of 
disulfoton volatilization from the soil-water phase to the atmosphere would be low. 
The reported Koc values of 600-1,603 suggest that the adsorption of disulfoton to soil is moderately 
strong and that the rate of leaching may be minor in most soils. Batch-type adsorption tests and soil 
column studies showed that the disulfoton adsorption rate in soil increases as the clay content of the 
soil increases (King and McCarty 1968; McCarty and King 1966). Disulfoton leaching through Hugo 
sandy loam soil was initially rapid, but very little further leaching was observed with an increase in 
eluent volume (McCarty and King 1966). For example, 27.5% of disulfoton applied to a 6-inch soil 
column eluted with a total of 4 feet of buffered water (pH 7), but only 29% eluted with a total of 
110 feet of buffered water. Other investigators concluded from soil column and soil thin-layer 
chromatography studies that disulfoton is only very slightly to moderately mobile in soil (Harris 1969; 
Helling et al. 1974; Thornton et al. 1976). Mobility may decrease with an increase in soil pH and 
organic content (Thornton et al. 1976). The oxidation products of disulfoton (sulfone and sulfoxide) 
are less mobile in soils than the parent compound (EPA 1989b). Due to increased polarity, the 
mobility of the oxidation products is expected to depend on the soil’s cation exchange properties; 
mobility would decrease as the soil’s cation exchange potential increases. Disulfoton has been 
detected infrequently and at low concentrations in groundwater from agricultural soil (Holden 1986; 
Mostaghimi et al. 1993) and in groundwater from disposal sites (Plumb 1991). These observations 
suggest that small amounts of disulfoton can leach through certain soils into groundwater. 
Disulfoton is also transported through soils or from soil to surface water (streams or rivers) via runoff. 
Pesticides with water solubilities >10 mg/L move mainly.in solution phase in runoff water (Racke 
1992). Disulfoton, with a water solubility of 25 mg/L (Sanbom et al. 1977), is expected to be found 
mainly in runoff water. In a runoff event from agricultural soil in Nebraska, low levels of disulfoton 
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were detected both in the dissolved state and in eroding soil particles in the sorbed state (Spalding and 
Snow 1989). 
Disulfoton is absorbed from soil by the root systems of plants and is translocated to the plant top 
(Nash 1974). Plants metabolize disulfoton to its sulfone, sulfoxide, and oxons (Szeto et al. 1983a, 
1983b). The concentrations of disulfoton and its metabolites in plant tops depend on the applied 
dosage in soil and the type of plants. The level of parent compound and its metabolites reaches a 
maximum concentration in plants within days or weeks and then tends to decrease (Nash 1974; Szeto 
et al. 1983a, 1983b). When disulfoton was applied to a soil at levels of 0.5 and 4.0 kg active 
ingredient per hectare in asparagus field plots, the levels of sulfone, sulfoxide, and oxons in asparagus 
ferns increased steadily to maximums of 14 and 61 mg/kg (fresh weight) in 70-85 days and then 
declined to 0.4 and 17.1 mg/kg in 147 days; no parent compound was detected at any time after 
14 days following application (Szeto et al. 1983a). Similarly, the metabolites of disulfoton were 
detected in lettuce grown in a treated field (Szeto et al. 1983b). The residual levels of disulfoton and 
its metabolites in vegetables grown on treated soil were highest in carrots, intermediate in Chinese 
cabbage, and lowest in turnips (Sanbom et al. 1977). Recently, Chapman et al. (1994b) studied the 
effects of multiple soil applications of disulfoton (one treatment each year for 3 years) on enhanced 
microbial degradation in soil and subsequent uptake by seed potatoes and foliage. Disulfoton was the 
major insecticidal component detected in soil, a minor component of seed potatoes, and was not 
detected (<0.02 ppm) in potato foliage during all three treatment years. Disulfoton sulfoxide and 
sulfone were the major insecticidal degradation products detected in the seed potatoes and foliage. 
In the first year, the maximum concentrations of sulfoxide and sulfone in soil, seed potatoes, and 
foliage were approximately 2, 2, and 6 times, respectively, the concentrations of those metabolites 
measured in the second and third year treatments. These results demonstrated that enhanced microbial 
degradation of relatively minor insecticidal compounds in the soil can significantly affect insecticide 
levels in the plant (when these degradation products are the major insecticidal component 
accumulated). As the sulfoxide and the sulfone metabolites are the major toxicants in the foliage of 
potato plants grown in disulfoton-treated soil, this reduction in toxicant residues over time can be 
expected to reduce insecticide efficacy. 
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5.3.2 Transformation and Degradation 
5.3.2.1 Air 
One of the important reactions for most organic pollutants in the atmosphere is with hydroxyl radicals. 
Using an estimation method (Atkinson 1988), the estimated rate constant for the vapor-phase reaction 
of disulfoton with hydroxyl radicals is 13.2x10-11 cm3/molecule-sec. Based on this value and 
assuming an average atmospheric hydroxyl radical concentration of 5x105 radicals/cm3 (Atkinson 
1988), the estimated half-life of disulfoton in the atmosphere due to this reaction is 3 hours. 
Therefore, disulfoton is short-lived in the atmosphere. Disulfoton is not susceptible to direct 
photolysis in sunlight (Gohre and Miller 1986). As with soil and water (Gohre and Miller 1986; Zepp 
et al. 1981), it is possible that disulfoton reacts with singlet oxygen in the atmosphere. The 
importance of this reaction for the transformation of disulfoton cannot be assessed because a reaction 
rate is unavailable. 
5.3.2.2 Water 
The three processes responsible for the transformation and degradation of disulfoton in water are 
abiotic hydrolysis, photosensitized oxidation, and biodegradation. Disulfoton is most stable towards 
hydrolysis in the pH range l-5 (Muhlmann and Schrader 1957). The experimentally estimated rate 
constants for the hydrolysis of disulfoton at 70 ºC were 1.16x10-2/hour, 1.56x10-2/hour, 
2.50x10-2/hour, 3.22x10-2/hour, and 9.61x10-2/hour at pH of 5, 6, 7, 8, and 9, respectively (Muhlmann 
and Schrader 1957). The corresponding estimated half-lives are 60, 44, 27.6, 21.5, and 7.2 hours. 
The estimated hydrolysis half-life of disulfoton at 70 ºC and pH 6.9 in ethanol-aqueous buffer solution 
(20:80) was 32 hours (Ruzicka et al. 1967). Other investigators reported the hydrolysis half-life of 
disulfoton under more realistic environmental conditions. For example, estimated hydrolysis half-lives 
were 103 days at 25 ºC and pH 7 (Ellington et al. 1988) and 170 days at 11 ºC and pH 7.9 (Wanner 
et al. 1989). Hydrolysis products of disulfoton are diethylthiophosphoric acid and 2-ethylmercaptothio 
ether (Muhlmann and Schrader 1957). 
Direct photolysis of disulfoton is negligible, since it does not significantly absorb sunlight (Wanner et 
al. 1989). Disulfoton is more likely to react with singlet molecular oxygen (1O2) produced from the 
reaction of certain photochemically excited dissolved organic matters (e.g., humic and fulvic 
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substances) with molecular oxygen in water (Zepp et al. 1981). The estimated near-surface half-life 
for photosensitized oxidation of disulfoton by sunlight available during midwinter in the southern 
United States was 3 hours (Zepp and Baughman 1978). Due to light attenuation with increasing water 
depth, the half-life of disulfoton due to the oxidation reaction is expected to increase with increasing 
water depth. Estimated half-lives due to photosensitized oxidation are 1,000 days at a depth of 
5 meters for a winter day and 100 days for a summer day (Wanner et al. 1989). The products of 
photosensitized oxidation are disulfoton sulfone and disulfoton sulfoxide (Mitchell et al. 1968). 
Hydroxyl radicals in natural water also oxidize disulfoton. When a 13 umol solution of disulfoton was 
exposed to October sunlight (Davis, California) in the presence of 100 umol hydrogen peroxide, 49% 
of the insecticide disappeared in 10.2 days due to reaction with hydroxyl radicals (Draper and Crosby 
1984). The rate of this reaction will be slower in natural surface water where the concentration of 
available hydroxyl radicals is lower than that available from the photolysis of 100 pmol hydrogen 
peroxide (levels ≤30 pmol hydrogen peroxide are generated in eutrophic water) (Draper and Crosby 
1984). 
Following an accidental discharge of stored chemicals including disulfoton, the estimated 
biodegradation half-life of disulfoton in Rhine River water was between 7 and 41 days at 10 ºC 
(Wanner et al. 1989). Therefore, biodegradation of disulfoton is expected to be important in water, 
and the rate will depend on the initial concentration. A theoretical model predicted that over 12 days 
biodegradation and photolysis would account for an 80% mass loss of disulfoton in the Rhine River 
after an accident spill incident (Mossman et al. 1988); however, the removal of disulfoton by chemical 
processes was much slower than by biodegradation (Cape1 et al. 1988). 
5.3.2.3 Sediment and Soil 
Disulfoton in soil and sediment may undergo degradation and transformation by hydrolysis, 
photoinduced oxidation, and biotic processes. The hydrolysis of disulfoton may occur in the 
soil/sediment-water phase, as opposed to the soil/sediment-sorbed phase. As a result, the rate of 
hydrolysis is expected to be comparable to that in water. Based on slow hydrolysis rates observed in 
water (see Section 5.3.2.2), hydrolysis of disulfoton in soil is not expected to be significant. A group 
of investigators reported the oxidation of disulfoton on soil surfaces by singlet oxygen produced from 
sunlight irradiation (Gohre and Miller 1986; Hebert and Miller 1990; Miller et al. 1989). The initial 
loss of disulfoton on soil surfaces by photooxidation is quite rapid and slows down as the reaction 
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proceeds. Thus, attributing the loss to a first-order rate process and assigning a half-life to this process 
is misleading (Miller et al. 1989). Although the most rapid oxidation occurred in soil with the lowest 
organic carbon, half of the original concentrations of disulfoton in four different soil samples was lost 
in ≈3 days (Gohre and Miller 1986). The rate substantially decreased over the course of irradiation. 
The photooxidation of disulfoton occurred appreciably deeper than optical depths (depths for sunlight 
penetration in soil) of 0.2-0.3 mm (Hebert and Miller 1990). In aerated and moisture-unsaturated soil, 
the photooxidation can proceed up to a soil depth of 2 mm (Hebert and Miller 1990). The primary 
photooxidation product was the sulfoxide with trace amounts of the sulfone (Gohre and Miller 1986). 
In laboratory tests, several fungi and cultures of actinomycetes isolated from garden soil readily 
degraded disulfoton (Bhaskaran et al. 1973). In flooded soil under anaerobic conditions, the reduction 
of disulfoton sulfoxide to disulfoton was due to biological conversion (Tomizawa 1975). The 
reduction of sulfone to either sulfoxide or sulfide (i.e., disulfoton) was not observed under the same 
conditions. Since the bacterial populations in sediments and soils are higher than in typical surface 
waters (Mossman et al. 1988), biodegradation is expected to play a major role in the loss of disulfoton 
in soil and sediment, as occurred in the disulfoton spill in the Rhine River (Cape1 et al. 1988; Wanner 
et al. 1989). 
Several investigators have reported the rate of overall loss of disulfoton from soil due to all biotic and 
abiotic processes. The estimated half-life of disulfoton in soil ranged from 3.5 to 14 days (Chapman 
et al. 1993; Garg and Sethi 1980; Greenhalgh 1978; Harris et al. 1988; Jury et al. 1987a; McCarty and 
King 1966; Rao et al. 1985; Shaw 1975), although half-life values of 17 days and 42 days were 
reported for loam and Plainfield sand respectively (Chapman et al. 1994a). A half-life value of 
≤290 days was also reported for soil (soil type unspecified) (Menzie 1972). The estimated persistence 
of disulfoton in soil varied between 28 and >64 days (Belanger and Hamilton 1979; Clapp et al. 1976; 
Jury et al. 1987b; Keamey et al. 1969). Soil type and soil temperature influenced the degradation rate 
of disulfoton. Disulfoton degraded almost twice as fast over the first 12 weeks post-application in 
loam as compared to Plainfield sand; however, the authors believe that lower temperatures may have 
contributed to the slower disappearance of disulfoton in the Plainfield sand study (Chapman et al. 
1994a). Since the compound degraded faster during winter in Evesboro loamy sand soil than during 
summer in Chillum silt loam soil, the authors (Menzer et al. 1970) concluded that soil type was 
predominantly responsible, rather than temperature. 
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The presence of light and higher soil pH (pH 8 versus 5) also accelerated degradation of disulfoton in 
soil (Shaw 1975). The only metabolites isolated from disulfoton degradation in soil were the sulfoxide 
and sulfone (Chapman et al. 1994a, 1994b); only minute amounts of oxons were found (Clapp et al. 
1976; Greenhalgh 1978; Shaw 197.5; Szeto et al. 1983a). Diethyl phosphorothioate was identified as 
the major metabolite in the aqueous fraction of soil (Shaw 1975). Disulfoton and disulfoton sulfoxide 
degraded in ≤32 days in soil, while disulfoton sulfone persisted for >64 days (Clapp et al. 1976; 
Greenhalgh 1978). 
5.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT 
5.4.1 Air 
Disulfoton was detected at maximum and mean concentrations of 4.7 and 0.1 ng/ m3 in only 1 of 
123 ambient air samples collected from 10 locations in the United States in 1980 (Carey and Kutz 
1985; Kutz 1983; Kutz and Carey 1986). No other air monitoring data were located. 
5.4.2 Water 
Disulfoton was detected in 7 groundwater samples from 28 California counties at a maximum of 
6 µg /L from May 1979 to April 1984 (Cohen 1986; Hallberg 1989; Holden 1986). In an earlier 
survey of 48 municipal and 6 private groundwater supply systems in California, no disulfoton was 
detected at a minimum detection limit of 5 µg /L (Maddy et al. 1982). Disulfoton was not detected 
(detection limit of 1 µg /L) in over 1,508 samples from 358 groundwater wells in Wisconsin during 
1980-1984 (Holden 1986; Krill and Sunzogni 1986). As of 1983, disulfoton was not detected 
(detection limit not given) in three samples of groundwater from Suffolk County, New York (Holden 
1986). Disulfoton was detected in a 1985 survey of groundwater in the Nomini Creek Watershed in 
Virginia. The mean and maximum concentrations detected were 0.39 ppb and 2.87 ppb respectively. 
The frequency of detection of disulfoton in this watershed was 2.6% (Mostaghimi et al. 1993). 
Disulfoton was qualitatively detected (detection limit of 0.1 µg /L) in three groundwater samples from 
1 of 479 hazardous waste disposal sites in the United States (Plumb 1991). 
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Recently, levels of disulfoton in an agricultural watershed were monitored during a spring runoff event 
in Shell Creek, an eastern tributary of the Platte River in Nebraska. The concentrations of disulfoton 
in this agricultural watershed ranged from trace to 0.4 µg /L (Spalding and Snow 1989). 
During 1981-1985, disulfoton and other pesticides were monitored at three watersheds adjacent to 
agricultural production areas: the mouths of the Grand River, the Saugeen River, and the Thames 
River, Ontario, Canada (Frank and Logan 1988). At a detection limit of <0.1 µg /L, no disulfoton was 
detected in the river water samples. Disulfoton was also not detected (detection limit of 0.003 µg /L) 
in samples of water collected from Lakes Superior and Huron, including Georgian Bay, in 1974 
(Glooschenko et al. 1976). 
5.4.3 Sediment and Soil 
The primary method for the disposal of liquid pesticide wastes in California in the past has involved 
soil evaporation pits, ditches, and ponds (Winterlin et al. 1989). A core soil sample taken from one 
such pit in northern California contained 44 mg/kg disulfoton at a depth of 90 cm (Winterlin et al. 
1989). Disulfoton was detected in six of seven bottom soil samples from tail water pits used to collect 
irrigation runoff in Haskell County, Kansas, in 1974. The maximum and mean concentrations of 
disulfoton in these samples were 32.7 and 13.42 µg /kg respectively (Kadoum and Mock 1978). At a 
detection limit of 0.01 mg/kg, disulfoton was not detected in sediment samples collected from Lakes 
Superior and Huron, including Georgian Bay, in 1974 (Glooschenko et al. 1976). 
5.4.4 Other Environmental Media 
Disulfoton was detected in 1 of 360 food composites collected from different locations in the United 
States in fiscal year 1969. The positive sample was a composite of leafy vegetables collected from 
Boston, Massachusetts, that contained 2 µg /kg of disulfoton (Comeliussen 1970). From this data, the 
estimated daily adult human intake of disulfoton was <l µg /day in 1969 (Duggan and Comeliussen 
1972). During fiscal year 1976, the FDA identified disulfoton in one sample each of cereal 
byproducts and leaf and stem vegetables, and in four samples of oilseed byproducts (Duggan et al. 
1983). Disulfoton was also detected in one sample of whole grains for animal use and four 
miscellaneous animal feed samples (Duggan et al. 1983). The FDA’s monitoring program for 
domestic and imported food commodities during fiscal years 1978-1982 detected disulfoton in 
DISULFOTON 159 
5. POTENTIAL FOR HUMAN EXPOSURE 
unspecified foods at unspecified concentrations (Yess et al. 1991). During 1982-1986, the FDA Los 
Angeles District Laboratory analyzed 19,851 samples of domestic and imported food and feed 
commodities (Luke et al. 1988). Disulfoton sulfone was detected in 45 samples of 6,391 domestic 
agricultural commodities and in 1 sample of 12,044 imported agricultural commodities at 
concentrations ranging from 0.05-1.0 mg/kg. In domestic foods, disulfoton sulfone was detected in 
broccoli, cabbage, Boston lettuce, butter lettuce, green leaf lettuce, iceberg lettuce, red leaf lettuce, 
romaine lettuce, potatoes, and spinach; it was also detected in imported tomatillos (Hundley et al. 
1988). Disulfoton was not detected in 14,492 domestic and imported food samples analyzed as part of 
the FDA pesticide monitoring program for 1986-1987 (FDA 1988). Disulfoton was not detected in 
various domestic food commodities by state regulatory monitoring activities during fiscal year 
1988-1989 (Minyard et al. 1991). In a pesticide residue screening program conducted in 1989-1991 
in San Antonio, Texas, on 6,970 produce samples, disulfoton was detected (0.1 ppm detection limit) in 
two produce samples (one sample of broccoli and one sample of cabbage) (Schattenburg and Hsu 
1992). As part of the FDA’s Pesticide Monitoring Program for domestic and imported foods, 
disulfoton residues have been detected in unspecified foods at unspecified concentrations during 
1988-1989, 1989-1990, 199&1991, and 1991-1992 (FDA 1990, 1991, 1992, 1993). 
Processing raw food reduced disulfoton levels in some potato products (Kleinschmidt 1971). Total 
residues were reduced by 35% with lye peeling. Lye peeling plus the first water blanching reduced 
the total disulfoton residue on a dry weight basis by 58, 74 and 61% for french fries, dehydrated 
potato cubes and dehydrated mashed potatoes, respectively. 
In a study of pesticide residue contamination of processed milk-based and soy-based infant formula, 
disulfoton was not detected (detection limit <0.02 µg /g [ppm]) (Gelardi and Mountford 1993). The 
EPA Office of Water has recommended that disulfoton residues be monitored by states in their fish 
and shellfish contaminant monitoring programs in watersheds where this pesticide is currently used 
extensively in agriculture (EPA 1993a). While no fish or shellfish consumption advisories are 
currently in effect for disulfoton, this contaminant has not been widely monitored in national fish 
contaminant monitoring programs (e.g., the EPA National Study of Chemical Residues in Fish or the 
U.S. Fish and Wildlife Service National Contaminant Biomonitoring Program) (EPA 1993a). 
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5.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE 
The general population is exposed to disulfoton by inhaling air and ingesting drinking water and food 
containing disulfoton. Toxicokinetic data show that disulfoton is readily and extensively absorbed by 
the gastrointestinal tract (see Section 2.4). The urinary metabolites of disulfoton are DEP, DETP, 
DEDPT, and DEPTh (see Section 2.3). Although the occurrence of these phosphate esters in human 
urine may not result specifically from exposure to disulfoton, detection of these metabolites in human 
urine indicates the possibility of exposure to disulfoton or several other organophosphate insecticides. 
Specimens of urine collected at 64 locations across the United States, comprising the sample areas in 
NHANES II, reported detection (detection limit 20 µg /L or ppb) of DEP and DETP at a frequency of 
6-7% and DEDPT at a frequency of <1% of those tested (Murphy et al. 1983). Other than during 
home and garden insecticide application, exposure of the general public to disulfoton from skin contact 
with consumer products is not expected. Those among the general population who use the insecticide 
for homes and gardens are potentially at higher risk of exposure to disulfoton. It has been estimated 
that application to rose plants and other omamentals constitute by far the largest home and garden use 
of disulfoton (Whitmore et al. 1992). 
Disulfoton has been very infrequently detected in ambient air (0.8% of air samples from 10 cities) and 
at very low concentrations (mean of 0.1 ng/ m3 in detectable samples) (see Section 5.4.1). Therefore, 
the exposure of the general population to disulfoton from inhaling ambient air is probably 
insignificant. Disulfoton has never been detected in drinking water (see Section 5.4.2), possibly 
because of it occurs at very low concentrations and has only infrequently been detected in groundwater 
(Cohen 1986; Hallberg 1989; Holden 1986; Mostaghimi et al. 1993; Plumb 1991). Therefore, general 
population exposure to disulfoton from consumption of drinking water is negligible. 
Disulfoton has been detected in some foods (see Section 5.4.4); thus, consumers can be exposed to 
disulfoton by ingesting contaminated food. The FDA has estimated daily food intakes of disulfoton 
for different age/sex groups in the United States for fiscal years 1982-1984 as follows: 
6-11 months = 0.6; 2 years = 1.1; 14-16-year-old females = 0.4; 14-16-year-old males = 0.3; 
25-30-year-old females = 0.3; 25-30-year-old males = 0.3; 60-65-year-old females = 0.5; and 
60-65-year-old males= 0.6 (ng/kg body weight/day) (Gunderson 1988). The reported corresponding 
values for combined disulfoton and its metabolites (e.g., sulfone, sulfoxide, etc.) are 2.2, 4.8, 2.3, 1.8, 
2.4, 2.2, 2.9, and 3.0 (ng/kg body weight/day) (Gunderson 1988). The FDA reported the following 
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dietary intakes of disulfoton for different age/sex groups in fiscal year 1990: 6-11 months, <0.1; 
14-16-year-old males, 0.2; and 60-6.5year-old females, 0.3 (ng/kg body weight/day) (FDA 1991, 
Winter 1992; Yess 1991). Most recently, the FDA reported the following dietary intakes of disulfoton 
(total) for different age/sex groups averaged over 1986-1991: 6-11 months, 0.1; 2 years, 0.3; 
14-16-year-old males, 0.2; 14-16-year-old females, 0.2; 25-30-year-old females, 0.4; 25-30-year-old 
males, 0.3; 60-65year-old females, 0.4; and 60-65-year-old males, 0.3 (ng/kg body weight/day) (FDA 
1993). These 1982-1984, 1990, and 1986-1991 intakes estimated from the FDA Total Diet Study 
Program show a declining trend in the estimated daily food intakes of disulfoton over the past 
10 years. All of the FDA estimated daily food intakes for the various sex and age groups are more 
than 1,000 times lower than the FAO/WHO Acceptable Daily Intake (ADI) value of 2,000 ng/kg body 
weight/day and an EPA revised reference dose of 40 ng/kg body weight/day ((FAO/WHO 1991; FDA 
1991, 1993; Winter 1992; Yess 1991). 
Workers involved in the manufacture, formulation, handling, or application of disulfoton, or those 
involved in the disposal of disulfoton-contaminated wastes are likely to be exposed to higher 
concentrations by dermal contact and inhalation than the general population. When granular disulfoton 
was applied at 0.75 active ingredient per acre to a field by air, the estimated inhalation exposure to 
disulfoton was 0.02 mg/8-hour day for the pilot and 0.03 mg/8-hour day for the ground staff (Myram 
and Forrest 1969). The estimated inhalation exposure to disulfoton for workers using ground machines 
was 0.33 mg/8-hour day (Myram and Forrest 1969). 
No information was found in the National Occupational Exposure Survey (NOES) conducted by 
NIOSH from 1981 to 1983 on the number of workers and the number of facilities where workers 
could be potentially exposed to disulfoton in the United States (NOES 1990). NIOSH (1992) 
recommends that the exposure level to skin not exceed 0.1 mg/ m3 for a l0-hour time weighted average 
workday. 
5.6 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
Other than individuals who are occupationally exposed to disulfoton during its production, formulation, 
packaging, distribution, use, or disposal, populations exposed to higher than background concentrations 
of disulfoton in ambient air include those living near chemical manufacturing or processing sites, 
individuals living on farms or in the vicinity of agricultural areas where disulfoton is extensively used, 
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and individuals living near hazardous waste sites. Individuals living near these sites may also be 
exposed to potentially higher concentrations of disulfoton or its metabolites in their drinking water if 
they obtain tap water from wells near these sources. Children may receive higher disulfoton doses 
from dermal exposures if they play on freshly treated soils. In addition, children may receive 
potentially higher oral doses from ingestion of disulfoton contaminated soils from their hands while 
playing in contaminated areas. 
5.7 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with 
the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of disulfoton is available. Where adequate information is 
not available, ATSDR, in conjunction with the NTP, is required to assure the initiation of a program 
of research designed to determine the health effects (and techniques for developing methods to 
determine such health effects) of disulfoton. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will 
be evaluated and prioritized, and a substance-specific research agenda will be proposed. 
5.7.1 Identification of Data Needs 
Physical and Chemical Properties. As seen in Table 3-2, the relevant physical and chemical 
properties of disulfoton are known (Bowman and Sans 1983; Domine et al. 1992; HSDB 1994; 
Kenaga and Goring 1980; Melnikov 1971; Merck 1989; Sanbom et al. 1977; Worthing 1987) and 
predicting the environmental fate and transport of disulfoton based on Kow, Koc, and H is possible. 
Production, Import/Export, Use, Release, and Disposal. Knowledge of production and use 
data for a chemical is important in predicting its potential for environmental contamination and human 
exposure. Since disulfoton is produced by only one manufacturer (SRI 1994), to maintain 
confidentiality, its recent production volume is not known. Similarly, data concerning the import and 
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export volumes for disulfoton in recent years are not available. Estimates of its yearly use in the 
United States are available (Gianessi 1986; Gianessi and Puffer 1992; Goodrich et a1.1991; 
VonRumker et al. 1974). No information in the available literature was located that indicates 
disulfoton’s use in any consumer products other than edible crops and vegetables during and after their 
planting (EPA 1984b; VonRumker et al. 1974). Disulfoton enters the environment primarily during its 
use as an agricultural insecticide/acaricide on a variety of field and vegetable crops and in its use in 
home and garden applications. Disulfoton wastes have been disposed of in soil evaporation pits, 
ditches, and ponds (Winterlin et al. 1989) and in hazardous waste sites. Thus, soils are most likely to 
be contaminated with this pesticide. Although some information regarding the disposal of wastes 
containing disulfoton is available (Berlow and Cunningham 1989; HSDB 1994; IRPTC 1985; Sittig 
1980), more detailed information on the method used for the disposal of aqueous wastes would be 
helpful. The standards promulgated by the EPA for the disposal of wastes containing disulfoton are 
available (Berlow and Cunningham 1989). 
According to the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. 
Section 11023, industries are required to submit chemical release and off-site transfer information to 
the EPA. The Toxics Release Inventory (TRI), which contains this information for 1988-1992, 
became available in May of 1994. This database will be updated yearly and should provide a list of 
industrial facilities and emissions. However, no TRI data were located for disulfoton because this 
chemical is not required to be reported by chemical producers (EPA 199313). 
Environmental Fate. Information regarding the fate of disulfoton in the air was not located in the 
literature. Although the available data indicate that the concentration of disulfoton in air will be low 
(Carey and Kutz 1985), more information would help predict the distance of its aerial transport. The 
fate of disulfoton in water is better studied (Wanner et al. 1989). Although it has been estimated that 
sorption onto particulates and settling into the sediment may not be important for disulfoton in Rhine 
River water, more information regarding the relative importance of sorption for disulfoton’ s removal 
from water to sediment would be helpful (Wanner et al. 1989). There is conflicting evidence in the 
literature (Harris 1969; Helling et al. 1974; King and McCarty 1968; McCarty and King 1966) 
regarding disulfoton’s mobility in soil. Disulfoton is degraded in soil by hydrolysis, photoinduced 
oxidation, and biodegradation (Bhaskaran et a1.1973; Cape1 et al. 1988; Chapman et al. 1993, 1994b; 
Gohre and Miller 1986; Hebert and Miller 1990; Miller et al. 1989; Tomizawa 1975; Wanner at al. 
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1989). Additional information on degradation of disulfoton in water and air and the fate of the 
degradation products in soil would be helpful. 
Bioavailability from Environmental Media. Available information regarding the rate of 
disulfoton absorption following inhalation, oral, or dermal contact has been discussed in the 
Toxicokinetics section (see Section 2.3). Although no data on disulfoton’s bioavailability from 
contaminated air are available, the bioavailability from inhalation exposure is expected to be high 
because disulfoton is likely to be present in the vapor phase (Eisenreich et al. 1981) and not in the 
particulate phase in the adsorbed state. Similarly, no data on the bioavailability of disulfoton from 
water and soil or plant material are available; however, disulfoton adsorbs rather strongly to soil 
(Harris 1969; Helling et al. 1974; Wauchope et al. 1992). Since the part that remains adsorbed to soil 
or sediments may, at most, be partially bioavailable, disulfoton is expected to have reduced 
bioavailability from soil and water. Data on the bioavailability of disulfoton from actual 
environmental media need further development. 
Food Chain Bioaccumulation. Disulfoton bioconcentrates to a moderate extent in fish (Takase 
and Oyama 1985; Tomizawa 1980); however, measured bioconcentration factor (BCF) values are not 
available for a large number of edible invertebrate and fish species. EPA (1993a) has recently 
recommended that states monitor disulfoton in fish and shellfish in watersheds where it is extensively 
used, and additional information on disulfoton residues may be available in the future. There is also a 
lack of data in the literature regarding the biomagnification potential of disulfoton through aquatic 
food chains. Available data on terrestrial food chains indicate that disulfoton is translocated from the 
root to aerial parts of the plants, where it is quickly metabolized to sulfone and sulfoxide (Nash 1974; 
Szeto et al. 1983a, 1983b). Data regarding the biomagnification potential of disulfoton in terrestrial 
and aquatic food chains would be desirable. These data would be helpful in assessing the potential for 
human exposure as a result of ingestion of contaminated food. 
Exposure Levels in Environmental Media. Although some data on the levels of disulfoton in 
ambient air are available (Carey and Kutz 1985), these data are neither current nor general enough to 
estimate inhalation exposure to disulfoton for the general population in the United States. No data on 
the level of disulfoton in drinking water were located in the literature, although disulfoton has been 
detected in groundwater (Cohen 1986; Hallberg 1989; Holden 1986; Mostaghimi et al. 1993). More 
recent data regarding the levels of disulfoton in ambient air, in drinking water, and in soil are needed. 
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Data on disulfoton levels in food and recent estimates of human intake of disulfoton from foods are 
available (Duggan et al. 1983; FDA 1990, 1991, 1992, 1993; Gelardi and Mountford 1993; Gunderson 
1988; Luke et al. 1988; Schattenburg and Hsu 1992; Yess 1991). 
Reliable monitoring data for the levels of disulfoton in contaminated media at hazardous waste sites 
are needed so that the information obtained on levels of disulfoton in the environment can be used in 
combination with the known body burden of disulfoton to assess the potential risk of adverse health 
effects in populations living in the vicinity of hazardous waste sites. 
Exposure Levels in Humans. No data on disulfoton levels in various human tissues and body 
fluids of a control population, populations near hazardous waste sites, or occupationally exposed 
groups in the United States are available. The levels of disulfoton metabolites (DEP [0.05 ppm], 
DETP [0.04 ppm], DEPTh [0.005 ppm], dimethyl phosphate [0.04 ppm], dimethyl thiophosphate 
[0.180 ppm], and dimethyl phosphorothiolate [0.004 ppm]) in the urine of disulfoton formulators have 
been measured (Brokopp et al. 1981). Data on the levels of disulfoton and its metabolites in body 
tissues and fluids are needed to estimate the extent of exposure to disulfoton. 
This information is necessary for assessing the need to conduct health studies on these populations. 
Exposure Registries. No exposure registries for disulfoton were located. This substance is not 
currently one of the compounds for which a subregistry has been established in the National Exposure 
Registry. The substance will be considered in the future when chemical selection is made for 
subregistries to be established. The information that is amassed in the National Exposure Registry 
facilitates the epidemiological research needed to assess adverse health outcomes that may be related 
to exposure to this substance. 
5.7.2 Ongoing Studies 
A search of federal research programs in progress indicates a few projects that would fill some of the 
existing data gaps. Drs. Singmaster and Acin-Diaz of the University of Puerto Rico are developing 
methods for determining disulfoton residue levels in food commodities and for disulfoton disposal. 
Dr. Brady of the University of Georgia is conducting a study to determine disulfoton’s dissipation on 
peach fruit, on foliage, in soil, in tank mixes, and in building interiors. 
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The purpose of this chapter is to describe the analytical methods that are available for detecting, and/or 
measuring, and/or monitoring disulfoton, its metabolites, and other biomarkers of exposure and effect 
to disulfoton. The intent is not to provide an exhaustive list of analytical methods. Rather, the 
intention is to identify well-established methods that are used as the standard methods of analysis. 
Many of the analytical methods used for environmental samples are the methods approved by federal 
agencies and organizations such as EPA and the National Institute for Occupational Safety and Health 
(NIOSH). Other methods presented in this chapter are those that are approved by groups such as the 
Association of Official Analytical Chemists (AOAC) and the American Public Health Association 
(APHA). Additionally, analytical methods are included that modify previously used methods to obtain 
lower detection limits, and/or to improve accuracy and precision. 
6.1 BIOLOGICAL SAMPLES 
Several methods are available for analyzing disulfoton in biological media; some of the commonly 
used methods are reported in Table 6-l. A variety of detectors may be used for the gas 
chromatographic analysis of disulfoton, but flame photometric detectors are superior because of low 
background interference and good reproducibility (Holstege et al. 1991). Mass spectrometric detectors 
show high specificity (Kawasaki et al. 1992) and may also be used to confirm detection by other 
methods. 
The stability of disulfoton must be considered at all stages of sample storage and analysis. 
Organophosphorus insecticides, including disulfoton, react with natural esterases in human tissue and 
may reduce the level of free organophosphates (Singh et al. 1986). Besides the esterases, 
phosphorylphosphatase in natural tissue hydrolyzes and inactivates organophosphorus compounds 
(Singh et al. 1986). As a result, the amount of organophosphates in blood and excreted in urine will 
be considerably less than the amount expected from its concentration at the time of exposure (Hattori 
et al. 1982; Singh et al. 1986). 
As discussed in Section 2.5.1, the detection of certain thiophosphate esters in human urine may 
indicate exposure to disulfoton and/or other organophosphate insecticides. Several methods are 
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available for the quantitation of organophosphorus metabolites from urine (Bradway et al. 1981; 
Daughton et al. 1976; Lores and Bradway 1977; Shafik et al. 1973). 
6.2 ENVIRONMENTAL SAMPLES 
Analytical methods for determining disulfoton in environmental samples are reported in Table 6-2. 
The steps included in the methods are solvent extraction, purification and fractionation, and gas 
chromatographic analysis. Other analytical techniques, including capillary gas chromatography with 
mass selective detection (Stan 1989), high-performance liquid chromatography with either mass 
spectrometric (MS) or MS-MS detection (Betowski and Jones 1988), have been used to determine 
disulfoton in environmental samples. 
Precautions should be taken to avoid disulfoton loss from stored water, soil, sediment, crop, and 
vegetable samples (Belisle and Swineford 1988; Miller et al. 1981; Munch and Frebis 1992; Szeto and 
Brown 1982). Disulfoton, disulfoton sulfone, and disulfoton sulfoxide were not recovered from spiked 
well water stored 14 days; however, sample extracts were stable for 14 days (84-92% recovery) 
(Munch and Frebis 1992). In most environmental samples, disulfoton will be present along with its 
environmental transformation products, disulfoton sulfone, disulfoton sulfoxide, disulfoton oxon, 
disulfoton oxon sulfone, and disulfoton oxon sulfoxide (Szeto and Brown 1982). Disulfoton and its 
oxon are very unstable, and they oxidize rapidly to the corresponding sulfoxides. The sulfoxides are 
relatively stable, but they oxidize slowly to their sulfones, which are most stable (Szeto and Brown 
1982). Several methods for determining the metabolites of disulfoton in environmental samples are 
included in Table 6-2. 
Few methods were located for determination of disulfoton in air. Ambient air monitoring data were 
reported for samples collected by ethylene glycol impinger samplers with subsequent gas 
chromatographic analysis; however, no performance data were reported (Kutz et al. 1976). A method 
for determination of organophosphorus pesticides, including disulfoton, in workplace air involves 
collection using a combined filter/XAD-2 sorbent sampler and gas chromatography/flame photometric 
(FPD) detection (Kennedy et al. 1994). Recovery is very good (>90%) and samples are stable for 30 
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Overall recoveries are good (>80%) and detection limits are in the low to sub-parts-per-billion (ppb) 
range for determination of disulfoton in water (Borburgh and Hammers 1992; Bourgeois et al. 1993; 
EPA 1986a, 1988c). Methods for soil and sediment also provide good recovery (>80%) and detection 
limits are in the ppb range (Belisle and Swineford 1988; Szeto and Brown 1982). Methods for 
determination of disulfoton in food matrices generally provide acceptable recovery (≥75%) and 
detection limits in ppb range (Hsu et al. 1991; Liao et al. 1991; Szeto and Brown 1982). 
6.3 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with 
the Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of disulfoton is available. Where adequate information is 
not available, ATSDR, in conjunction with the NTP, is required to assure the initiation of a program 
of research designed to deterrnine the health effects (and techniques for developing methods to 
determine such health effects) of disulfoton. 
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled. In the future, the identified data needs will 
be evaluated and prioritized, and a substance-specific research agenda will be proposed. 
6.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect. Analytical methods are 
available to determine the concentrations of disulfoton and its metabolites in blood, urine, and other 
body tissue and fluids (Bowman and Beroza 1969; Brokopp et al. 1981; Hattori et al. 1982; Holstege 
et al. 1991; Singh et al. 1986; Yashiki et al. 1990). The accuracy of the methods in terms of percent 
recovery has been determined. A reasonably low detection limit can be obtained when flame 
photometric detection is used to determine disulfoton (Bowman and Beroza 1969; Holstege et al. 
1991). When blood samples were spiked with 0.3 µg /g (ppm) of disulfoton, phosphorodithioate 
sulfone, and phosphorothiolate sulfone, and quantitated by gas-chromatography-flame photometric 
detection (GC/FPD) method, the recovery of disulfoton and two of its metabolites were in the range of 
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101.0-104.6% (Yashiki et al. 1990). In spiked urine samples, the detection limits of four metabolites 
of disulfoton (DEP, DETP, DEDPT, and DEPTh) were 0.01 ppm by a GC/FPD method (Brokopp et 
al. 1983). Due to the unavailability of data regarding disulfoton concentrations in tissues and body 
fluids of the background population, it is not known if the available analytical methods will be 
sensitive enough to determine these concentrations. Analytical methods are available for the detection 
of 4-hydroxy-3-methoxymandelic (HMMA), the major metabolite of catecholamine metabolism and a 
possible biomarker to characterize effects by disulfoton (Wysocka-Paruszewska 1971). It would be 
helpful to determine if the available analytical methods can measure disulfoton levels in body tissues 
and fluids of the background population. This will permit assessment of the severity of exposure of a 
highly exposed population. 
Methods for Determining Parent Compounds and Degradation Products in 
Environmental Media. Several methods are available for determining disulfoton and its 
degradation products in environmental samples such as contaminated water, food, and soil (Edge11 et 
al. 1991; EPA 1988c; Grant et al. 1969; Ruzicka et al. 1968; Szeto and Brown 1982; Zweig and 
Devine 1969). The specificity and accuracy of the methods are generally well established (see 
Table 6-2). In spiked water samples, the mean recoveries of disulfoton, disulfoton sulfone, and 
disulfoton sulfoxide were in the range of 86.5-104.0% (Edge11 et al. 1991). The recoveries of 
disulfoton and its metabolites in soil and asparagus tissue ranged from 83.5% to 110% (Szeto and 
Brown 1982). Consumption of contaminated food is probably the most important route of disulfoton 
exposure for the general population. Disulfoton has been found at much lower concentrations than the 
AD1 value (Winter 1992; Yess 1991). Developing sensitive methods for determining disulfoton in 
ambient air and for establishing background levels of disulfoton in environmental samples would be 
desirable. 
6.3.2 Ongoing Studies 
Drs. Singmaster and Acin-Diaz of the University of Puerto Rico are developing methods for 
determining disulfoton residue levels in food commodities. No other ongoing studies regarding the 
determination of disulfoton and its metabolite and degradation products in biological or environmental 
media were found. 
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International, national, and state regulations and guidelines for disulfoton are listed in Table 7- 1. 
An acute-duration inhalation MRL for disulfoton of 0.006 mg/ m3 was derived. The MRL is based on 
a NOAEL of 0.5 mg/ m3 for lethargy and decreased cholinesterase activity in rats exposed for 
4 hours/day, 5 days/week (Thyssen 1978). 
An intermediate-duration inhalation MRL for disulfoton of 2x10-4 mg/ m3 was derived. The MRL is 
based on a NOAEL of 0.02 mg/ m3 for decreased cholinesterase activity in rats exposed for 
6 hours/day, 5 days/week for 3 weeks (Thyssen 1980). 
An acute-duration oral MRL for disulfoton of 0.001 mg/kg/day was derived. The MRL is based on a 
NOAEL value of 0.1 mg/kg/day for decreased cholinesterase activity in rats treated by gavage on 
gestation days 6-15 (Lamb and Hixson 1983). 
An intermediate-duration oral MRL for disulfoton of 9x10-5 mg/kg/day was derived. The MRL is 
based on a NOAEL value of 0.009 mg/kg/day for decreased cholinesterase activity in rat pups in a 
multigeneration feeding study in rats (Hixson and Hathaway 1986). 
A chronic-duration oral MRL for disulfoton of 6 x10-5 mg/kg/day was derived. The MRL is based on a 
LOAEL value of 0.06 mg/kg/day for decreased cholinesterase activity in female rats in a chronic 
feeding study (Hayes 1985). 
EPA has verified a chronic oral reference dose (RfD) for disulfoton of 4 x10-5 mg/kg/day (IRIS 1994). 
The RfD is based on the LOAEL of 0.04 mg/kg/day for cholinesterase inhibition in rats treated with 
disulfoton in the diet for 2 years (Hayes 1985). 
The chronic-duration oral MRL for disulfoton is 6 x10-5 mg/kg/day, and the EPA chronic oral RfD is 
4 x10-5 mg/kg/day (IRIS 1994). Both of these values are based on the same study (Hayes 1985) and 
the identical end point. Even though the MRL and the RfD are essentially the same, they have minor 
differences due to the manner in which the exposure doses were calculated. The LOAEL of 
0.04 mg/kg/day used by EPA was calculated by multiplying the analytical dietary concentration of 
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0.8 ppm (nominal concentration of 1 ppm) by the reference rat food consumption factor of 0.05. 
However, Hayes (1985) provided an equivalent dose of 0.08 mg/kg/day for the nominal concentration 
of 1 ppm, based on actual food consumption and body weight data. The LOAEL of 0.06 mg/kg/day 
used in deriving the chronic oral MRL was obtained by multiplying the 0.08 mg/kg/day dose, 
corresponding to the nominal concentration of 1 ppm, by the analytical concentration of 0.8 ppm. 
Disulfoton is on the list of chemicals appearing in “The Emergency Planning and Community Rightto-
Know Act of 1986” (EPCRA) (EPA 1988d). Section 313 of Title III of EPCRA requires owners 
and operators of certain facilities that manufacture, import, process, or otherwise use the chemicals on 
this list to report annually their release of those chemicals to any environmental media. 
An Occupational Safety and Health Administration (OSHA) permissible exposure limit (PEL) for 
disulfoton does not exist. A U.S. Court of Appeals decision rescinded the 1989 PELs promulgated by 
OSHA (OSHA 1989), which included a PEL for disulfoton. Only PELs in place prior to the 1989 are 
now allowed. Disulfoton had no PEL prior to 1989; therefore, it currently has no PEL. 
Disulfoton is regulated by the Clean Water Effluent Guidelines as state in Title 40, Sections 400-475, 
of the Code of Federal Regulations. The point source category for which disulfoton has a specific 
Regulatory Limitation is the organic pesticide chemicals industry (EPA 1978a). 
Under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), disulfoton is classified for 
restrictive use (EPA 1978b). 
Under the Resource Conservation and Recovery Act (RCRA), disulfoton is listed as a hazardous waste 
when it is a discarded commercial chemical product, off-specification species (e.g., a product that does 
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Acute Exposure - Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Adsorption Coefficient (Koc) - The ratio of the amount of a chemical adsorbed per unit weight of 
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd) - The amount of a chemical adsorbed by a sediment or soil (i.e., the solid 
phase) divided by the amount of chemical in the solution phase, which is in equilibrium with the solid 
phase, at a fixed solid/solution ratio. It is generally expressed in micrograms of chemical sorbed per 
gram of soil or sediment. 
Bioconcentration Factor (BCF) - The quotient of the concentration of a chemical in aquatic 
organisms at a specific time or during a discrete time period of exposure divided by the concentration 
in the surrounding water at the same time or during the same period. 
Cancer Effect Level (CEL) - The lowest dose of chemical in a study, or group of studies, that 
produces significant increases in the incidence of cancer (or tumors) between the exposed population 
and its appropriate control. 
Carcinogen - A chemical capable of inducing cancer. 
Ceiling Value - A concentration of a substance that should not be exceeded, even instantaneously. 
Chronic Exposure - Exposure to a chemical for 365 days or more, as specified in the Toxicological 
Profiles. 
Developmental Toxicity - The occurrence of adverse effects on the developing organism that may 
result from exposure to a chemical prior to conception (either parent), during prenatal development, or 
postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any 
point in the life span of the organism. 
Embryotoxicity and Fetotoxicity - Any toxic effect on the conceptus as a result of prenatal 
exposure to a chemical; the distinguishing feature between the two terms is the stage of development 
during which the insult occurred. The terms, as used here, include malformations and variations, 
altered growth, and in utero death. 
EPA Health Advisory - An estimate of acceptable drinking water levels for a chemical substance 
based on health effects information. A health advisory is not a legally enforceable federal standard, 
but serves as technical guidance to assist federal, state, and local officials. 
Immediately Dangerous to Life or Health (IDLH) - The maximum environmental concentration of 
a contaminant from which one could escape within 30 min without any escape-impairing symptoms or 
irreversible health effects. 




Immunologic Toxicity - The occurrence of adverse effects on the immune system that may result 
from exposure to environmental agents such as chemicals. 
In vitro - Isolated from the living organism and artificially maintained, as in a test tube. 
In vivo - Occurring within the living organism. 
Lethal Concentration(LO)(LC LO) - The lowest concentration of a chemical in air which has been 
reported to have caused death in humans or animals. 
Lethal Concentration(50) (LC50) - A calculated concentration of a chemical in air to which exposure 
for a specific length of time is expected to cause death in 50% of a defined experimental animal 
population. 
Lethal Dose(LO) (LD LO) - The lowest dose of a chemical introduced by a route other than inhalation 
that is expected to have caused death in humans or animals. 
Lethal Dose(50) ( LD50) - The dose of a chemical which has been calculated to cause death in 50% of 
a defined experimental animal population. 
Lethal Time(50)  ( LT50) - A calculated period of time within which a specific concentration of a 
chemical is expected to cause death in 50% of a defined experimental animal population. 
Lowest-Observed-Adverse-Effect Level (LOAEL) - The lowest dose of chemical in a study, or 
group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control. 
Malformations - Permanent structural changes that may adversely affect survival, development, or 
function. 
Minimal Risk Level - An estimate of daily human exposure to a dose of a chemical that is likely to 
be without an appreciable risk of adverse noncancerous effects over a specified duration of exposure. 
Mutagen - A substance that causes mutations. A mutation is a change in the genetic material in a 
body cell. Mutations can lead to birth defects, miscarriages, or cancer. 
Neurotoxicity - The occurrence of adverse effects on the nervous system following exposure to 
chemical. 
No-Observed-Adverse-Effect Level (NOAEL) - The dose of chemical at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen 
between the exposed population and its appropriate control. Effects may be produced at this dose, but 
they are not considered to be adverse. 
Octanol-Water Partition Coefficient (Kow) - The equilibrium ratio of the concentrations of a 
chemical in n-octanol and water, in dilute solution. 
Permissible Exposure Limit (PEL) - An allowable exposure level in workplace air averaged over 
an 8-hour shift. 
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q1* - The upper-bound estimate of the low-dose slope of the dose-response curve as determined by 
the multistage procedure. The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually µg/L for water, mg/kg/day for food, and 
µg/m3 for air). 
Reference Dose (RfD) - An estimate (with uncertainty spanning perhaps an order of magnitude) of 
the daily exposure of the human population to a potential hazard that is likely to be without risk of 
deleterious effects during a lifetime. The RfD is operationally derived from the NOAEL (from animal 
and human studies) by a consistent application of uncertainty factors that reflect various types of data 
used to estimate RfDs and an additional modifying factor, which is based on a professional judgment 
of the entire database on the chemical. The RfDs are not applicable to nonthreshold effects such as 
cancer. 
Reportable Quantity (RQ) - The quantity of a hazardous substance that is considered reportable 
under CERCLA. Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an 
amount established by regulation either under CERCLA or under Sect. 311 of the Clean Water Act. 
Quantities are measured over a 24-hour period. 
Reproductive Toxicity - The occurrence of adverse effects on the reproductive system that may 
result from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the 
related endocrine system. The manifestation of such toxicity may be noted as alterations in sexual 
behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the 
integrity of this system. 
Short-Term Exposure Limit (STEL) - The maximum concentration to which workers can be 
exposed for up to 15 min continually. No more than four excursions are allowed per day, and there 
must be at least 60 min between exposure periods. The daily TLV-TWA may not be exceeded. 
Target Organ Toxicity - This term covers a broad range of adverse effects on target organs or 
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Teratogen - A chemical that causes structural defects that affect the development of an organism. 
Threshold Limit Value (TLV) - A concentration of a substance to which most workers can be 
exposed without adverse effect. The TLV may be expressed as a TWA, as a STEL, or as a CL. 
Time-Weighted Average (TWA) - An allowable exposure concentration averaged over a normal 8­
hour workday or 40-hour workweek. 
Toxic Dose (TD50) - A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population. 
Uncertainty Factor (UF) - A factor used in operationally deriving the RfD from experimental data. 
UFs are intended to account for (1) the variation in sensitivity among the members of the human 
population, (2) the uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in 
extrapolating from data obtained in a study that is of less than lifetime exposure, and (4) the 






Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language. Its intended 
audience is the general public especially people living in the vicinity of a hazardous waste site or 
chemical release. If the Public Health Statement were removed from the rest of the document, it 
would still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence 
that will direct the reader to chapters in the profile that will provide more information on the given 
topic. 
Chapter 2 
Tables and Figures for Levels of Significant Exposure (LSE) 
Tables (2-1, 2-2, and 2-3) and figures (2-l and 2-2) are used to summarize health effects and illustrate 
graphically levels of exposure associated with those effects. These levels cover health effects observed 
at increasing dose concentrations and durations, differences in response by species, minimal risk levels 
(MRLs) to humans for noncancer end points, and EPA’s estimated range associated with an 
upper-bound individual lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. Use the LSE tables and 
figures for a quick review of the health effects and to locate data for a specific exposure scenario. The 
LSE tables and figures should always be used in conjunction with the text. All entries in these tables 
and figures represent studies that provide reliable, quantitative estimates of 
No-Observed-Adverse-Effect Levels (NOAELs), Lowest-Observed-Adverse-Effect Levels (LOAELs), 
or Cancer Effect Levels (CELs). 
The legends presented below demonstrate the application of these tables and figures. Representative 
examples of LSE Table 2-l and Figure 2-l are shown. The numbers in the left column of the legends 
correspond to the numbers in the example table and figure. 
LEGEND 
See LSE Table 2-1 
( 1 ) Route of Exposure One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. When 
sufficient data exists, three LSE tables and two LSE figures are presented in the document. The 
three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, and 
dermal (LSE Table 2-1, 2-2, and 2-3, respectively). LSE figures are limited to the inhalation 
(LSE Figure 2-l) and oral (LSE Figure 2-2) routes. Not all substances will have data on each 





(2)	  Exposure Period Three exposure periods - acute (less than 15 days), intermediate (15-364 days), 
and chronic (365 days or more) are presented within each relevant route of exposure. In this 
example, an inhalation study of intermediate exposure duration is reported. For quick reference 
to health effects occurring from a known length of exposure, locate the applicable exposure 
period within the LSE table and figure. 
(3) 	Health Effect The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer. 
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer. 
Systemic effects are further defined in the “System” column of the LSE table (see key number 
18). 
(4)  	Key to Figure Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure. In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the 2 “18r” data points in Figure 2-l). 
(5) 	Species The test species, whether animal or human, are identified in this column. Section 2.4, 
“Relevance to Public Health,” covers the relevance of animal data to human toxicity and Section 
2.3, “Toxicokinetics,” contains any available information on comparative toxicokinetics. 
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
(6)	  Exposure Frequency/Duration The duration of the study and the weekly and daily exposure 
regimen are provided in this column. This permits comparison of NOAELs and LOAELs from 
different studies. In this case (key number 18), rats were exposed to 1,1,2,2-tetrachloroethane 
via inhalation for 6 hours per day, 5 days per week, for 3 weeks. For a more complete review 
of the dosing regimen refer to the appropriate sections of the text or the original reference paper, 
i.e., Nitschke et al. 1981. 
(7) 	System This column further defines the systemic effects. These systems include: respiratory, 
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and dermal/ocular. 
“Other” refers to any systemic effect (e.g., a decrease in body weight) not covered in these 
systems. In the example of key number 18, 1 systemic effect (respiratory) was investigated. 
(8) 	 NOAEL A No-Observed-Adverse-Effect Level (NOAEL) is the highest exposure level at which 
no harmful effects were seen in the organ system studied. Key number 18 reports a NOAEL of 
3 ppm for the respiratory system which was used to derive an intermediate exposure, inhalation 
MRL of 0.005 ppm (see footnote “b”). 
(9) 	 LOAEL A Lowest-Observed-Adverse-Effect Level (LOAEL) is the lowest dose used in the 
study that caused a harmful health effect. LOAELs have been classified into “Less Serious” and 
“Serious” effects. These distinctions help readers identify the levels of exposure at which 
adverse health effects first appear and the gradation of effects with increasing dose. A brief 
description of the specific endpoint used to quantify the adverse effect accompanies the LOAEL. 
The respiratory effect reported in key number 18 (hyperplasia) is a Less serious LOAEL of 10 
ppm. MRLs are not derived from Serious LOAELs. 
(10) Reference The complete reference citation is given in chapter 8 of the profile. 
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(11) CEL A Cancer Effect Level (CEL) is the lowest exposure level associated with the onset of 
carcinogenesis in experimental or epidemiologic studies. CELs are always considered serious 
effects. The LSE tables and figures do not contain NOAELs for cancer, but the text may report 
doses not causing measurable cancer increases. 
(12) Footnotes Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes. Footnote “b” indicates the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm. 
LEGEND 
See Figure 2-1 
LSE figures graphically illustrate the data presented in the corresponding LSE tables. Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
(13) Exposure Period The same exposure periods appear as in the LSE table. In this example, health 
effects observed within the intermediate and chronic exposure periods are illustrated. 
(14) Health Effect These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table. 
(15) Levels of Exposure concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures. Exposure concentration or dose is measured on the log 
scale “y” axis. Inhalation exposure is reported in mg/ m3 or ppm and oral exposure is reported in 
mg/kg/day . 
(16) NOAEL In this example, 18r NOAEL is the critical endpoint for which an intermediate 
inhalation exposure MRL is based. As you can see from the LSE figure key, the open-circle 
symbol indicates to a NOAEL for the test species-rat. The key number 18 corresponds to the 
entry in the LSE table. The dashed descending arrow indicates the extrapolation from the 
exposure level of 3 ppm (see entry 18 in the Table) to the MRL of 0.005 ppm (see footnote “b” 
in the LSE table). 
(17) CEL Key number 38r is 1 of 3 studies for which Cancer Effect Levels were derived. The 
diamond symbol refers to a Cancer Effect Level for the test species-mouse. The number 38 
corresponds to the entry in the LSE table. 
(18) Estimated Upper-Bound Human Cancer Risk Levels This is the range associated with the 
upper-bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000. These risk levels are 
derived from the EPA’s Human Health Assessment Group’s upper-bound estimates of the slope 
of the cancer dose response curve at low dose levels (ql*). 





Chapter 2 (Section 2.4) 
Relevance to Public Health 
The Relevance to Public Health section provides a health effects summary based on evaluations of 
existing toxicologic, epidemiologic, and toxicokinetic information. This summary is designed to 
present interpretive, weight-of-evidence discussions for human health end points by addressing the 
following questions. 
1. What effects are known to occur in humans? 
2. What effects observed in animals are likely to be of concern to humans? 
3. What exposure conditions are likely to be of concern to humans, especially around hazardous
    waste sites? 
The section covers end points in the same order they appear within the Discussion of Health Effects
 
by Route of Exposure section, by route (inhalation, oral, dermal) and within route by effect. Human
 
data are presented first, then animal data. Both are organized by duration (acute, intermediate,
 
chronic). In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.)
 
are also considered in this section. If data are located in the scientific literature, a table of
 
genotoxicity information is included.
 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
 
existing toxicokinetic, genotoxic, and carcinogenic data. ATSDR does not currently assess cancer
 
potency or perform cancer risk assessments. Minimal risk levels (MRLs) for noncancer end points (if
 
derived) and the end points from which they were derived are indicated and discussed.
 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to
 
public health are identified in the Data Needs section.
 
Interpretation of Minimal Risk Levels 
Where sufficient toxicologic information is available, we have derived minimal risk levels (MRLs) for 
inhalation and oral routes of entry at each duration of exposure (acute, intermediate, and chronic). 
These MRLs are not meant to support regulatory action; but to acquaint health professionals with 
exposure levels at which adverse health effects are not expected to occur in humans. They should 
help physicians and public health officials determine the safety of a community living near a chemical 
emission, given the concentration of a contaminant in air or the estimated daily dose in water. MRLs 
are based largely on toxicological studies in animals and on reports of human occupational exposure. 
MRL users should be familiar with the toxicologic information on which the number is based. 
Chapter 2.4, “Relevance to Public Health,” contains basic information known about the substance. 
Other sections such as 2.6, “Interactions with Other Substances,” and 2.7, “Populations that are 
Unusually Susceptible” provide important supplemental information. 
MRL users should also understand the MRL derivation methodology. MRLs are derived using a 
modified version of the risk assessment methodology the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses for lifetime exposure (RfDs). 
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To derive an MRL, ATSDR generally selects the most sensitive endpoint which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration. ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is 
available for all potential systemic, neurological, and developmental effects. If this information and 
reliable quantitative data on the chosen endpoint are available, ATSDR derives an MRL using the 
most sensitive species (when information from multiple species is available) with the highest NOAEL 
that does not exceed any adverse effect levels. When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty 
factor (UF) of 10 must be employed. Additional uncertainty factors of 10 must be used both for 
human variability to protect sensitive subpopulations (people who are most susceptible to the health 
effects caused by the substance) and for interspecies variability (extrapolation from animals to 
humans). In deriving an MRL, these individual uncertainty factors are multiplied together. The 
product is then divided into the inhalation concentration or oral dosage selected from the study. 
Uncertainty factors used in developing a substance-specific MRL are provided in the footnotes of the 
LSE Tables. 





